上海醫藥集團股份有限公司

Shanghai Pharmaceuticals Holding Co., Ltd.*

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02607)

SHANGHAI PHARMA
CORPORATE SOCIAL RESPONSIBILITY REPORT

DEFINITIONS

In this report, unless the context otherwise requires, the following terms shall have the following meanings:

"Shanghai Pharmaceutical Group", "Shangh Pharmaceuticals Holding", "Shanghai Pharmaceuticals", "the Company" or "We"	Shanghai Pharmaceuticals Holding Co., Ltd.
SPHAPHAR	Shanghai Pharma Co., Ltd.
SPH Keyuan	SPH Keyuan Xinhai Pharmaceutical Co., Ltd.
SPH Sine	Shanghai SPH Sine Pharmaceutical Laboratories Co., Ltd.
SPH No. 1 Biochemical and Pharmaceutical	SPH No. 1 Biochemical & Pharmaceutical Co., Ltd.
SPH Traditional Chinese Medicine	Shanghai Traditional Chinese Medicine Co., Ltd.
SPH Changzhou Pharmaceutical	SPH Changzhou Pharmaceutical Co., Ltd.
SPH New Asiatic	SPH New Asia Pharmaceutical Co., Ltd.
SPH Zhongxi	Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd.
SPH Sales	Shanghai Pharma Sales Co., Ltd.
SPH Techpool	Techpool Bio-pharma Co., Ltd.
SPH Qingchunbao Pharmaceutical	Chiatai Qingchunbao Pharmaceutical Co., Ltd.
SPH Growful	SPH Qingdao Growful Pharmaceutical Co., Ltd.
SPH Research Institute	Central Research Institute of Shanghai Pharmaceuticals Holding Co., Ltd.
SPH Herbapex	Liaoning SPH Herbapex Pharmaceutical (Group) Co., Ltd.
Huqingyutang Pharmaceutical	Hangzhou Huqingyutang Pharmaceutical Co., Ltd.
SPH Zhonghua	Shanghai Zhonghua Pharmaceutical Co., Ltd.
SPH Xiamen Traditional Chinese Medicine	Xiamen TCM Factory Co., Ltd.
SPH Dong Ying	SPH Dong Ying (Jiangsu) Pharmaceutical Co., Ltd.
SPH Medical Instruments	Shanghai Medical Instruments Co., Ltd.
SPH Material Supply and Marketing	SPH Materials Supply and Sales Co., Ltd.
SPH Sunway Biotech	Shanghai Sunway Biotech Co., Ltd.
SPH Ruier	Shanghai SPH Ruier Pharmaceutical Co., Ltd.

A Shares	domestic shares of the Company, which are listed on the Shanghai Stock Exchange and traded in RMB
H Shares	overseas shares of the Company, which are listed on the Hong Kong Stock Exchange and traded in Hong Kong dollars
RMB	Renminbi, the lawful currency of the PRC


Persist and Strive
to Improve People's Healthy Living Quality

Contents

Our Responsibility,
Our Commitment

2020

009

013

ABOUT THIS REPORT

Scope

The duration of this report is from January 1, 2020 to December 31,2020. Unless otherwise stated, the data and cases mentioned in this Report are derived from Shanghai Pharmaceuticals Holding Co., Ltd. and its subsidiaries.

Standards for preparation

This report makes reference to the Sustainability Reporting Guidelines of the Global Reporting Initiative (GRI), "Notice on Strengthening the Social Responsibility Commitment of Listed Companies and Promulgating the "Guidelines on Environmental Information Disclosure of Companies Listed on Shanghai Stock Exchange" "promulgated by the Shanghai Stock Exchange, the "Guidelines on Preparation of Corporate Social Responsibility Reporting" and the "Environmental, Social and Governance Reporting Guide", as set out in Appendix 27 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited, and its Main Amendments. In 2019, the Company fully complied with the principles and terms set out in the aforesaid regulations and guidelines.

Content selection

This report makes reference to the principles of GRI's substance, sustainable background, stakeholders' engagement and integrity, and fully takes into account the Company's development strategy and business development initiatives.

Indicator selection

This report primarily takes into consideration the relevance, substance and availability of all specific indicators related to performance disclosure of key issues. We will continue to adjust and optimize the disclosure indicators in future reports.

Form of promulgation

This report is published online. The online version can be downloaded from the Shanghai Stock Exchange website (www.sse.com.cn) and the Company website (www.sphchina.com).

For further information on the Company's business, please refer to the 2020 annual report of Shanghai Pharmaceuticals.

Contact us

Contact us: 86 21 63730908
Email: pharm@sphchina.com

Message from the Chairman

> In 2020, Shanghai Pharmaceuticals officially entered the list of Fortune Global 500 and the global top 50 pharmaceutical companies, marking a new milestone in the Company's development history;
>
> In 2020, in the face of the epidemic, Shanghai Pharmaceuticals took the lead and responsibility, adhered to the conviction of life first, focused on fighting the epidemic, shared the burden with the state, and did our best for the health of the people.

Going far at a steady pace. In the past year, Shanghai Pharmaceuticals adhered to its responsibility and mission, and reaffirmed its development direction. In 2020, overcoming the adverse impacts of the epidemic, Shanghai Pharmaceuticals maintained a sustained and stable growth in its operating results. Its industry position steadily improved, and the momentum of synergy value trended upwards. With a more cohesive, innovative, progressive, and healthier attitude, we have truly responded to the expectations and trust from society, the public, partners, and employees, giving more people a sense of achievement, security, accomplishment and happiness. In 2020, Shanghai Pharmaceuticals clearly defined its strategic positioning, stimulated innovation momentum, strengthened integrated management and control, and actively responded to the uncertainty of external changes with the certainty of internal development, achieving remarkable performance - In 2020, it was selected into the Fortune Global 500 for the first time and made the list of Global 50 Pharmaceutical Companies. In 2020, Shanghai Pharmaceuticals recorded an operating income of RMB191.909 billion, representing an increase of 2.86% on a YOY basis. Net profit attributable to the shareholders of the listed company was RMB4.496 billion, representing an increase of 10.17% on a YOY basis.

Dedicated to innovation. As a leading domestic pharmaceutical company, Shanghai Pharmaceuticals has never stopped its quest for R&D and innovation. It continuously increases R&D investment, actively gains access to high-end R&D resources at home and abroad, cooperates with major research institutes and R&D institutions at home and abroad, and actively promotes the construction of a series of R&D, pilot, clinical, and industrialization innovation platforms. It cooperated with the Molecular Cell Center of Excellence of the Chinese Academy of Sciences, Shanghai Jiao Tong University School of Medicine, Ruijin Hospital, the Tenth Hospital, and the Pediatric Center on innovation projects to promote the deep integration of industry, schools, institutes and hospitals. The SPH Biomedicine Industrial Base officially started construction to build a leading biomedical innovation industry cluster in China...At the same time, Shanghai Pharmaceuticals pays great attention to the management of drug life cycle. Through quality system construction, quality risk control, optimization of production layout and manufacturing resources, and lean Six Sigma management, we ensure the safe, effective and stable supply of Shanghai Pharmaceuticals' drugs.

Benefiting society. Benefiting from China's continuous opening-up and development potential, as the largest service provider of imported drugs and vaccines in China, Shanghai Pharmaceuticals assumes the responsibility of meeting the needs of Chinese patients, actively seeks cooperation with multinational pharmaceutical companies, and accelerates the introduction of global innovative drugs, so that Chinese patients can have access high-quality medicines within the country. At the same time, Shanghai Pharmaceuticals strives to build a medical and pharmaceutical innovation service platform, with continuously expanding extension services of hospital supply chain becoming an important force in modern hospital management. It explores new forms of cooperation in more fields to improve the accessibility and convenience of patients' medication relying on the combination of Internet + medicine. It facilitates the reform in medical security system and jointly builds a new model of seeking medical treating and using drugs to reduces the burden of patients for medication and meet the people's medication needs.

Upholding original aspiration. The growth of Shanghai Pharmaceuticals is inseparable from the support of the government, society and the public. It is our constant mission and pursuit to give back to society. Regarding targeted poverty alleviation, Shanghai Pharmaceuticals actively facilitates the construction of medical care, education, and infrastructure in poverty-stricken areas. Our "sincere care+ concrete action" came into fruition in 2020, helping the Midu County of Dali, a poverty alleviation area, to officially extricate itself from the list of poverty-stricken counties. Regarding community services, Shanghai Pharmaceuticals has always spared no effort. In addition to promoting publicity and services for community health, we contribute to the health of special groups.

In 2020, the COVID-19 epidemic ravaged the world. From the onset of the epidemic, Shanghai Pharmaceuticals immediately mobilized the entire group, from party members to grassroots employees, from treatment equipment, anti-epidemic drugs to rescue supplies, to support the front-line fight against the epidemic, fully demonstrating the speed, wisdom and responsibility of a responsible pharmaceutical company in the face of disasters.

Exceeding the limitation. In 2021, we believe that only with steady measures, groundbreaking courage, unrelenting dream, pragmatic actions, immutable aspiration, and incessant transcendence can we seize opportunities, fulfill our mission, and realize our dream. At the important historical moment of the beginning of the "14th Five-Year Plan", standing at the new starting point of Shanghai Pharmaceuticals, let us work together to boost the power of Shanghai Pharmaceuticals, serve the national strategy, regional development and the people's livelihood and well-being, and continue to march forward together on the road of pursuing dreams in the new era...

Shanghai Pharmaceuticals Holding Co., Ltd. Chairman:

Overview of the Company

The main businesses of Shanghai Pharmaceuticals cover pharmaceutical R&D and manufacturing, distribution and retail. The Company keeps focusing on the core links of the industrial chain and conducts simultaneous development of endogenous development and extension. It is one of the few listed pharmaceutical players holding a leading position in the industry and commerce in China.

The Company will continuously provide the mass patients with safe and efficient treatment drugs including chemical drugs, biological products, modern TCM and healthcare products, etc., focusing on 7 therapeutic area covering anti-neoplastics, heart and cerebral vessels, psychoneural, anti-infection, autoimmunity, digestion metabolism and respiratory system. The Company aims at the clinical need, actively developing high-end generic drugs and innovative drugs, and developing drugs for rare diseases at the same time, so as to continue to construct a product line in consistence with the clinical need and possessing technological advantages. With respect to innovative drugs, the Company increased the innovative investment and optimized the product layout through independent R&D and external cooperation, focusing on the development of the new-generation products in immune cells treatment, gene therapy and micro-ecology, etc.

With respect to chemical drugs, the Company is dedicated to developing new drugs from common generic drugs to difficult generic drugs, competitive generic drugs and improved drugs. With respect to traditional Chinese medicine, the Company focuses on continuous secondary development of major varieties, deeply explores clinical value of products and actively develops a batch of modern major traditional Chinese medicine products. In 2020, our large major varieties achieved a great growth, with the number of products exceeding RMB100 million increasing to 42. Major breakthroughs have been made in our R&D work: innovative drug pipeline has made more stage progress; "SPH3127" initiated Phase III clinical trial; the new drug for acute stroke "LT3001 for injection" , the new generation of recombinant herpes oncolytic virus T3011, the new anti-tumor small molecule drug "SPH4336 tablets", and the new anti-tumor drug c-Met selective inhibitor "SPH3348" initiated Phase I clinical trials; the anti-rheumatoid arthritis indication of I008 ("Lei Teng Shu") initiated phase II clinical trials. The Company's generic drug consistency evaluation work has also made good progress. In 2020, a total of 16 varieties and 18 product specifications passed the consistency evaluation.

The Company keeps promoting the external R&D cooperation. It signed a strategic cooperation framework agreement with Shanghai Jiao Tong University School of Medicine to build an incubation platform of "Shanghai Pharmaceuticals –Innovation Achievements of Shanghai Jiao Tong University School of Medicine" to promote the accelerated development of R&D and industrialization of cutting-edge innovation projects. The Company cooperated with the Molecular Cell Center of Excellence of the Chinese Academy of Sciences to jointly build the "Molecular Cell Center of Excellence of the Chinese Academy of Sciences-Shanghai Pharmaceuticals" incubation platform for innovation achievements to promote the incubation and conversion of the original scientific research results and cutting-edge innovative technologies of the Molecular Cell Center of Excellence. The Company cooperated with National Children's Medical Center and Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine to introduce CAR-T technology that has a certain research foundation in clinical practice. The Company participated in the A round of financing of Chengdu Wesker Biopharmaceutical

Co., Ltd. as a lead investor to enter the vaccine research and development field.

Our distribution network covers 31 provinces, municipalities and autonomous regions in China, among which 24 provinces, municipalities and autonomous regions are directly controlled by the holding subsidiary. Distribution service covers more than 32,000 medical institutions. The Company also cooperates with numerous transnational pharmaceutical players across the globe and is committed to building efficient, agile and intelligent supply chain management system. The Company excels other domestic peers in SPD, third-party logistics service, DTP, one-stop services for imported drugs, informationized management of drug stores, clinical support service and other innovative business models. The Company leads the Pharmacy retail industry in retail size, covering 16 provinces, municipalities directly under the Central Government and autonomous regions in China and the number of chain brand retail pharmacies exceeding 2,000. SPHC proactively explores the new model of "Internet + Pharmaceutical" and endeavors to building a new retail eco-system for prescription pharmaceutical centering on the transfer of electronic prescriptions, providing patients with professional, safe, efficient and convenient services for purchase of prescribed drugs and comprehensive long-term health management. In 2020, SPHC completed B round financing with an aim to bring in advantageous industry resources and development funds， facilitating the integration of industry-related new retail assets and upgrade the pharmaceutical business technology platform, and accelerating the Company's growth into the future industry leader.

In 2020, China's healthcare industry continued to deepen structural reforms with intensive promulgation and implementation of policies and regulations. A series of policies and measures including pilot expansion of volume-based procurement, adjustment of the medical insurance drug catalog, the promulgation and implementation of the newly revised Drug Registration Management Measures and Drug Production Supervision and Management Measures, the formal implementation of the new version of the Pharmacopoeia, the revision of the protection period of pharmaceutical patents in the Patent Law, the implementation of the Law on the Promotion of Basic Medical Care, Hygiene and Health, the promulgation and implementation of the Bio-security Law, the pilot advancement of diagnosis-related group, the promulgation of the Opinions on Deepening the Reform of the Medical Security System, the issuance of the medical consortium management measures, and the medical representative registration system created a good environment for the development of the industry, and effectively promoted the development of innovative drugs and the improvement of the quality of generic drugs.

The general generic drug market has entered an era of meager profit. Traditional pharmaceutical companies are accelerating their transformation towards generic drugs and innovative drugs with high technology barriers. Pharmaceutical companies have significantly improved their innovation capabilities. The innovative drug market has risen rapidly. On the whole, under the superposed effect of several pharmaceutical industry reform policies including "Accelerating the Cost-control and Adjusting the Structure, Encouraging the Innovation and Prompting Transformation" , Chinese pharmaceutical industry is still in a period of great changes, and the structural deepening and adjustment, technological innovation and acceleration, and the speeding up of industry reshuffle have proposed higher demand of the operation of pharmaceutical enterprises. China is evolving from a large pharmaceutical country to a strong one. In the coming five years, it is expected that the domestic pharmaceutical market will continue to be one of the most attractive markets in the world, the competition will become more international, the natural selection of the industry will accelerate, centralizing will continue to intensify, and companies face opportunities and challenges alike in the development.

Looking back in 2020, since the outbreak of the COVID-19 epidemic, the Company had actively participated in the fight against the epidemic, and had gone all out to perform anti-epidemic tasks such as ensuring the supply of medical supplies and the production of anti-epidemic drugs. After the epidemic was effectively controlled, the Company quickly resumed operations, and proceeded steadily and orderly with various tasks and achieved good operating results in accordance with the work policy of "adapting to industrial changes, accelerating transformation and development, and striving to lead the industry" . The Company's industry position has been further elevated, entering the world's top 500 enterprises and the world's top 50 pharmaceutical enterprises for the first time. The Company continues to increase investment in R&D and innovation, and accelerate the promotion of innovative development, intensive development, international development, and industry-finance integrated development strategies, achieving major phased results in new drug research and development, product introduction, external R&D cooperation, innovation platform construction, commercial network layout, and in-hospital supply chain extension services.

Against the backdrop of reform and development of the pharmaceutical industry in China, the Company will actively seize the opportunities arising from national strategies, adapt to the industrial changes and accelerate transformation and development by further promote the four major developments with science and innovation as the core, so as to ensure its leading position in China's pharmaceutical industry, sparing no effort to build an internationally competitive and influential Chinese pharmaceutical industry group.

Our overall strength continues to lead in domestic pharmaceutical industry

In 2020, Shanghai Pharmaceuticals recorded an operating income of RMB191.909 billion, representing an increase of 2.86% on a YOY basis. Net profit attributable to the shareholders of the listed company was RMB4.496 billion, representing an increase of 10.17% on a YOY basis. As at December 31, 2020, the owners' equity of the Company was RMB45.397 billion and its total assets were RMB149.263 billion.

No.473

Ranked 473rd in 2020 Fortune Global 500

No.48

Top 50 global pharmaceutical companies

Ranked 48th in American magazine Pharm Exec's Top 50 Pharmaceutical Companies, 3rd in prescription drug sales by listed Chinese pharmaceutical companies

No.57

Ranked 57th in the 2020 Fortune Chinese 500 (Fortune China)



★ Ranked **2nd** in the Development Report of China's Pharmaceutical Distribution Industry issued by the Ministry of Commerce in 2020

★ Ranked **2nd** in Comprehensive Strength in 2020 Forbes Global Top 2000 Chinese Pharmaceutical Companies

★ Ranked **2nd** among Chinese pharmaceutical companies in the 2020 top 25 global pharmaceutical companies by brand value released by Brand Finance

★ Ranked **10th** in the Top 100 Shanghai Enterprises in 2020

★ Ranked **3rd** in the Top 100 Shanghai Manufacturing Enterprises

— Shanghai Enterprise Confederation, Shanghai Entrepreneur Association, Shanghai Federation of Economic Organizations

★ Ranked **118th** in the Top 500 Chinese Enterprises in 2020

★ Ranked **40th** in the Top 100 Chinese Enterprises in Sustainable Development

— China Enterprise Confederation, China Entrepreneurs Association

★ Ranked **3rd** in the top 100 Chemical Drug Companies in China's pharmaceutical industry in 2019

— Medical Economic Report



★ Ranked **5th** among the Top 25 Best Industrial Enterprises in China for Pharmaceutical R&D Product Lines in 2020

★ Ranked **6th** among the Top 100 Chinese Pharmaceutical Manufacturing Enterprises in 2019

— China National Pharmaceutical Industry Information Center

★ 2020 **Favorite Employer for College Students** in China

— 51job.com

★ 2020 The second New Fortune Best Listed Company by **New Fortune Best Listed Company**

— New Fortune

01

Mission

- Persist and strive to improve people's healthy living quality

Vision

- Pursue to become a respectable leading brand pharmaceutical with industry reputation manufacturer and health service provider

Core Value

- Innovation, Integrity, Cooperation, Inclusiveness, responsibility

Value responsible operation

1.1 Responsibility System Management

	Management responsibilities	Management structure
Strategy	Formulation and improvement of corporate social responsibility	Strategic Development Committee of the Group Strategic Development Department of the Group
Management	To be in line with the business Company, our corporate social responsibility practice includes but is not limited to: R&D innovation, lean manufacturing, promotion of access to medicines and services, meeting the medication needs of special groups, providing solutions to resolve social problems, accountable operations, etc. (please refer to relevant sections)	Horizontal: functional responsibility system Vertical: line management system
Communication	Capital market / responsibility brand communication in doctor-patient market, communication with other stakeholders (please refer to relevant sections below)	Board of Directors' Office / Office of the Group Stakeholder Communication Department

1.2 Stakeholders and Communication Channels

Stakeholder	Stakeholders' concerns	Our communication channels
Shareholders	Performance Governance Compliance	Open information disclosure Shareholders' general meeting, investor performance conference, roadshow / reverse roadshow, etc. Investor relations hotline, E interaction, etc.
Customer	Safety / quality Service Price	After-sales service, research on level of satisfaction Academic seminar, rational drug use and popularization, brand communication
Employees	Power enhancement Personal development Protection of rights and interests	Performance management communication, periodic training, workers' congress WeChat, Weibo, BBS, intranet, internal publication
Partners	Supply chain management Cooperation to achieve win-win situation	Industry communication, business exchange, platform Business exchange platform, cooperative assessment
Community and environment	Solutions to resolve social problems Environmental protection	Friendly activities Responsible operation

1.3 Substantive analysis of key responsibility issues



02

Commitments

Our goal

- Take medicine of high quality and make the medicine affordable

Our management ideology

- R&D innovation - Reliable efficacy of new drugs
- Excellent Manufacturing-Quality and safety assurance, reasonably affordable

Our measures

- Continuously increase investment in R&D and enhance the innovation of product lines
- Strengthen R&D cooperation and construct innovative platforms
- Improve product quality and continuously propel consistency evaluation

Our achievements

- Several innovative products have been launched or undergoing clinical trials.
- Several innovative projects have been introduced, so as to further explore to deepen integration of industry, schools, research institution, and hospitals
- Fruitful results in the consistency evaluation of generic drugs
- Invest in new areas with construction of major projects commenced
- Start smart manufacturing and establish industry benchmarks

Committed to safe medication for the public

2.1 Continuously increase investment in R&D and enhance the innovation of product lines

I | R&D comprehensive strength ranks first

Progress of Bio-antibody Drugs under Research/Innovative Drug Lines				
Treatment field	**Apply for clinical**	**Clinical phase I**	**Clinical phase II**	**Clinical phase III**
Anti-tumor	I025 (SPH3261) I022-K I025-A	006（CD30-DM1） I020（SPH3348） I022（SPH4336） I010 (SPH1188-11) B002（Her2 compound antibody） B007（CD20 anti-body subcutaneous injection） B015 (T3011) B003 (T-DM1)	(Cirmtuzumab antibody, USA)	
Digestive metabolism	I024（SPH4480）			
Autoimmune	B001-A (CD20 anti-body injection)		I008（Lei Teng Shu - rheumatoid arthritis） I008-A (Lei Teng Shu - AIDS) I001-B (SPH3127,USA)	
Cardiovascular and cerebrovascular		Salvianolic A for injection I037 (LT3001,the PRC)	I037 (LT3001)	I00(SPH3127)

- The clinical phase II trial on the efficacy and safety of Chemical Drug Class 1 Innovation Project I001 ("SPH3127 Tablets") for the treatment of essential hypertension was completed, and the clinical phase III solution was approved by the CDE to initiate the clinical phase III trial.
- A major breakthrough in the international registration of innovative projects was achieved. I001-B ("SPH3127 Tablets") was qualified for clinical trial by FDA and the clinical phase II trial for ulcerative colitis was initiated, expanding the new indications of the project.
- For the fully human anti-PD-1 monoclonal antibody "Prolgolimab Injection" in cooperation with Russia's BIOCAD, the "Clinical Trial Notice" has been obtained, and the Phase III clinical trial has started
- B003 (recombinant anti-HER2 humanized monoclonal antibody for injection – MCC-DM1 coupling agent) completed clinical phase I trial, with clinical phase II/III trial solution designed and is ready for clinical phase II/III trials
- The initial layout of cell therapy pipeline was completed and three projects were in pre-clinical stage, including B010-A ("Innovative targeted GPC3 CAR-T for advanced hepatocellular carcinoma") and B019 ("CART for relapsed refractory childhood B-lineage acute lymphoblastic leukemia"), which have started non-registered clinical trials
- A new generation of recombinant herpes lysing virus B015 ("T3011 (intratumoral injection)") in collaboration with ImmVira obtained the Notice of Clinical Trial and the first subject was recruited in the clinical phase I trial in May 2020
- The clinical phase II trial for the anti-rheumatoid arthritis indication of Chemical Drug Class 1 Innovation Project I008 ("Lei Teng Shu") completed its first subject recruitment in July 2020
- Chemical Drug Class 1 Innovation Project I020 ("SPH3348 Tablets") clinical phase I trial completed the first subject recruitment in July 2020
- Chemical Drug Class 1 Innovation Project I022 ("SPH4336 Tablets") received the Notice of Clinical Trial and the first subject was recruited in the Phase I clinical trial in November 2020

- I037 ("LT3001 for injection"), a innovative drug for acute stroke in collaboration with Taiwan's Lumosa (6535.TW), received the Notice of Clinical Trial and the first subject was recruited in the Phase I clinical trial in January 2021
- B007 ("recombinant anti-CD20 humanized monoclonal antibody subcutaneous injection") received the Notice of Clinical Trial in January 2021
- Class 2 chemical innovative drug "Bobberry Hydrochloride Dry Suspension" applied for clinical trial
- Tirofiban Hydrochloride and Sodium Chloride Injection, 3 specifications of Rosuvastatin Calcium Tablets and Carbomer Obstetric Gel were approved for production
- Aripiprazole oral liquid applied for production
- International registration: Eslicarbazepine acetate received provisional approval from the U.S. generic drug ANDA, Colesevelam dry suspension and tablet applied for ANDA, and six other products (15 product specifications) completed ANDA filings
- At the 37th session of annual meeting of National Pharmaceutical Industry Information in 2019 sponsored by the China National Pharmaceutical Industry Information Center, the Company was shortlisted by the Ministry of Industry and Information Technology in the list of the top 100 enterprises in the Chinese pharmaceutical industry in 2019, [ranking sixth]; and retained the titled of "Top 2020 Industrial Enterprise with Drug R&D Product Line in China in 2019". Techpool Bio-pharma Co., Ltd. a subsidiary of Shanghai Pharmaceuticals, was awarded the "2020 Best Growing Competence Company in China's Pharmaceutical Industry"; the joint venture Shanghai Hutchison Pharmaceutical Co., Ltd. was awarded the 2020 Pharmaceutical Enterprise with Most Investment Value in China (non-listed)"

2.2 Strengthen R&D cooperation and construct innovative platforms

1. Launched the incubation platform strategic cooperation with Shanghai Jiao Tong University School of Medicine and other institutes

On April 16, the signing ceremony of the strategic cooperation framework agreement on the incubation platform of "Shanghai Pharmaceuticals-Medicine Innovation Achievements of Shanghai Jiao Tong University School" was held at the Yide Building of the Shanghai Jiao Tong University School of Medicine. The platform was jointly established by Shanghai Jiao Tong University School of Medicine, Shanghai Pharmaceuticals, hanghai Bio-pharmaceutical Industry Equity Investment Fund, and Shanghai Eryi Investment. Through innovative cooperation models, it will fully cultivate excellent project teams and connect abundant incubation resources to achieve full coverage from pharmaceutical R&D, clinical research, market operations, business investment, and legal protection, and strive to provide a one-stop solution for the incubation and transformation of scientific and technological achievements. At the same time, it uses screened incubation and targeted R&D to trigger the interest and initiative of scientific and technological workers in colleges and universities to engage in innovation and entrepreneurship, thereby mapping out a characteristic path of exploration and development where medical institutes and schools promote the transformation of scientific innovations, and jointly boosting Shanghai's scientific and technological innovation and promoting the development of pharmaceutical industry clusters in the Yangtze River Delta.



2. The 2nd Science and Technology Innovation Council was established

On the afternoon of July 27, the inauguration conference and scientific forum of Shanghai Pharmaceuticals' 2nd Science and Technology Innovation Council were held in the Shanghai Science Hall. Academician Chen Kaixian was appointed as the chairman of Shanghai Pharmaceuticals' 2nd Science and Technology Innovation Council, and Academician Pei Gang was appointed as the chief scientific consultant of Shanghai Pharmaceuticals' 2nd Science and Technology Innovation Council. The establishment of the Shanghai Pharmaceuticals' 2nd Science and Technology Innovation Council is an important initiative to achieve strategic goals, implement innovative development plans, and enhance corporate innovation and competitiveness. The main members of the Council and the Company's senior management team facilitated the launch of the new Science and Technology Innovation Council, starting a new journey of innovation and development for Shanghai Pharmaceuticals.

3. Introduce new-generation of anti-tumor drugs

On August 6, Shanghai Pharmaceuticals announced that it had signed a License Agreement with ImmVira Group Company，pursuant to which, Shanghai Pharmaceuticals intended to invest no more than RMB1.15 billion to obtain exclusive rights for the development, production and sales of the new-generation anti-tumor drug T3011 (intratumoral injection) project in Greater China (Mainland China, Hong Kong, Macau and Taiwan). T3011 (intratumoral injection) is a new generation of recombinant herpes oncolytic virus, which is currently undergoing clinical trials for a variety of solid tumors in China, Australia and the United States.

4. Cooperate with 10th Hospital on R&D in the micro-ecological field

On August 22, SPH Sine's "Micro-ecological Development Strategy" conference and forum was held in Shanghai Tenth People's Hospital. SPH Sine has been developed in-depth in the field of micro-ecological drugs for nearly 30 years. It has a self-developed Class-1 microecological new drug, Bifico, and has accumulated a wealth of experience in the fields of microecological research and development, production and clinical research. Regarding the implementation of the strategy, Gu Haoliang, vice president of Shanghai Pharmaceuticals and chairman of SPH Sine, proposed that innovative and flexible platform construction should be carried out first, including technology and R&D platforms, investment incubation platforms and e-commerce trading platforms, with the variety launching as the most important indicative output. He specifically emphasized that the ultimate targets of product launching shall be micro-ecological innovative drugs, and the micro-ecological foods shall be the vanguard of micro-ecological development, aiming to achieve the combination of treatment + nutrition, so as to perfectly cover the fields of prevention, treatment and rehabilitation. SPH Sine expected to link the future under the guidance of the "micro-ecological development strategy" and promote multi-party cooperation in the field of micro-ecological development, including industry, schools, institutes and hospitals. At the launch event, SPH Sine signed cooperation agreements with Shanghai 10th People's Hospital, Gut research institute, and Bright Dairy, respectively.

5. Build an innovation achievement incubation platform with the Molecular Cell Center of Excellence of the Chinese Academy of Sciences

On the morning of September 21, the signing ceremony of strategic cooperation between Shanghai Pharmaceuticals, Molecular Cell Center of Excellence of the Chinese Academy of Sciences, and Shanghai Biopharmaceutical Industry Equity Investment Fund was held in Shanghai. The three parties jointly focused on the field of biomedical innovation and jointly created the "Molecular Cell Center of Excellence of the Chinese Academy of Sciences – Shanghai Pharmaceuticals" incubation platform for innovation achievements. The innovation achievement incubation platform jointly built will rely on the Molecular Cell Center of Excellence as the project provider to recommend R&D technologies and results that the scientific research team believe to have market development prospects for the "incubation platform". Shanghai Pharmaceuticals, as the industrial partner of the "incubation platform" , will leverage its R&D and transformation capabilities and advantages, and mobilize its subordinates including SPH Research Institute, SPH Jiaolian , technology centers of various pharmaceutical industry enterprises, and invested scientific research institutions that have basic research conditions to undertake research-related industrialization work in the incubation platform project. Shanghai Biopharmaceutical Industry Equity Investment Fund, as the capital partner of the "incubation platform", will join hands with Shanghai Pharmaceuticals, other social capital and partners to conduct staged demonstrations on funded projects, and provide corresponding business guidance and financial support in the follow-up to promote the transformation of incubation projects and the realization of market value. Based on the principles of complementary advantages, resource sharing, mutual benefit and common development, all parties have established long-term strategic partnerships to provide one-stop solutions for the incubation and transformation of scientific research results, and promote early laboratory research results to quickly enter the market and be applied.

6. Join hands with Shanghai Children's Medical Center to promote the transformation of new CAR-T cell treatment technologies

On October 12, the National Children's Medical Center (Shanghai), Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine, and Shanghai Pharmaceuticals entered into the agreements on "Conversion of CAR-T Clinical Research Technologies Achievements" and "Research Cooperation on CAR-T Combined Targeted Treatment of Acute Lymphoblastic Leukemia and Lymphoma" respectively, with an aim to build a new mechanism for hospital-enterprise cooperation from clinical research to product development and promote the new development of biomedical technology in Shanghai.

The technical cooperation is aimed to combine the biomedical business of Shanghai Pharmaceuticals with Shanghai Children's Medical Center's advantages in talents and clinical resources to explore new models of hospital-enterprise cooperation, and create new mechanisms for cooperation.

7. Co-build a Tumor Cell Treatment Center with the 10th Hospital

On November 24, the Tumor Cell Treatment Center jointly established by Shanghai Pharmaceuticals and the 10th People's Hospital Affiliated to Tongji University was officially completed and an inauguration ceremony was held. Jointly established by Shanghai Pharmaceuticals and Shanghai 10th People's Hospital, the Tumor Cell Therapy Center is an open platform that focuses on providing tumor immune cell treatment, while also engaging in gene editing and stem cell treatment. The Tumor Cell Treatment Center occupies 4 floors, including a GMP cell production workshop, a GMP plasmid and virus production workshop and a quality control center. The laboratory is equipped with an environmental control and monitoring system to control and monitor the air volume, temperature and humidity, pressure difference and important parameters of a variety of equipment in the biological laboratory to ensure the proper and efficient operation of the laboratory and equipment. At the same time, a full life cycle information management system is introduced for cell production to ensure product reliability and traceability.

8. Cooperate with Ruijin Hospital on translational medicine project

On December 19, the first major national technological infrastructure (Shanghai) for translational medicine was officially opened in Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. Trough the strategic cooperation, Shanghai Pharmaceuticals and Ruijin Hospital will combine the R&D capabilities of both parties, leverage Ruijin Hospital and the laboratory and clinical research innovation platform of the "Major National Technological Infrastructure (Shanghai) for Translational Medicine" to conduct project demonstration and evaluation as well as cooperation negotiations in the advantageous areas of grand scientific facilities, take full advantage of the innovation capabilities and resource advantages of grand scientific facilities, carry out commercial operations in the fields of innovation projects, in-hospital preparations, and rare disease drugs that currently have a certain degree of maturity in grand scientific facilities, and invest research and incubation funds for early innovation projects.

As leaders in the respective medical and pharmaceutical fields, the two parties have used the "Shanghai Institute of Endocrinology and Metabolism Diseases - National Metabolic Disease Clinical Research Center - Shanghai Pharmaceuticals Holding Co., Ltd. Clinical Research Cooperation Alliance" and other models in the fields such as micro-ecology and rare diseases. This cooperation will further utilize the advantages and resources of both parties to achieve in-depth complementarity and mutual benefit. In addition, this is another in-depth cooperation and integration of "industry, school, institute and capital" created by Shanghai Pharmaceuticals and scientific research institutions of local medical colleges after the strategic cooperation with Shanghai Jiao Tong University School of Medicine to build innovative drug incubation-transformation platforms. It will bring new opportunities for the early innovation of Shanghai Pharmaceuticals, and is expected to contribute more independent innovative drugs that originate from clinics, are transformed by enterprises, and serve patients.

Key indicators

Clinical Declaration

Unit: number



Clinical Approval

Unit: number



Percentage of R&D expenditure in industrial sales

Unit: %



2.3 Increase investment in the field of biomedicine

1. Strategic layout of the vaccine field

In 2020, relying on our leading position in domestic vaccine distribution, we further extended our layout to the front-end of production and research. In August, we entered into a strategic partnership with CanSino. In November, we participated in the Series A financing of Chengdu Wesker as the lead investor.

2. SPH Biomedicine Industry Base

On the morning of January 4, 2021, the Company held a project commencement ceremony for the SPH Biomedicine Industrial Base at the construction site located at No. 92 Zhangjiang Road, Pudong New Area, Shanghai. The Base covers an area of approximately 150,000 square meters and has an investment of up to RMB8 billion. It focuses on the three major directions of antibodies and vaccines, cell treatment, and gene treatment, and uses the most advanced science and technology to build a leading biomedical innovation industry cluster in the country. As the core pharmaceutical sector of Shanghai Industrial Investment (Holdings) Co., Ltd., Shanghai Pharmaceuticals actively seizes national strategic opportunities to build an internationally leading pharmaceutical company driven by technological innovations. SPH Biomedicine Industry Base will focus on therapeutic antibodies, cell treatment, gene treatment and other biomedical innovation fields, and build a domestic biomedical sector with the most complete layout and technologically advanced incubation and transformation base and industrialization platform to boost the further development of the Chinese pharmaceutical industry. Driven by the national strategy of "Healthy China" , biomedicine has huge room for future development and has become an important pillar of Shanghai's strategic emerging industries. The commencement of the Shanghai Biomedicine Industry Base is not only in line with the development goal of Shanghai for building a science and technology innovation center, with great significance for promoting the optimization and upgrade of Shanghai's industrial structure and cultivating new drivers of development, but also a great boost for the development of China's "healthcare" cause. With the implementation of the national innovation-driven strategy and the promulgation of related policies, the transformation of medical innovations has attracted much attention. The Shanghai Biomedicine Industry Base entirely funded by Shanghai Pharmaceuticals will not only contribute to the development of domestic biomedical research and development, but will also help China usher in a long-lasting, diversified and open "golden age" for health care in the future, serving the health of the whole people!



2.4 Comprehensive management to continuously improve the quality and safety of drugs

With the promulgation and implementation of the Drug Administration Law (revised in 2019) and other laws and regulations, the Company has further strengthened the management of the entire life cycle of drugs.

Upholding the quality policy of "prioritizing people, creating health; winning with quality, pursuing excellence", the Company continues to improve its quality management system and conform to international standards to ensure product safety and effectiveness and stable market supply, striving to demonstrate to customers and other related parties the ability to continuously and stably provide products and services that meet the requirements of applicable laws and regulations.

I Quality system construction

The Company attaches great importance to product quality and abides by relevant national laws and regulations, quality management standards and other requirements. During the Reporting Period, in order to further enforce the responsibilities of the Company's member units, the Company evaluated the completion of the key tasks of the enterprises' quality management in accordance with the Detailed Rules for the Evaluation of Quality Responsibility for Pharmaceutical Production and Operation Enterprises and included the evaluation results in the performance appraisal of operators. In addition, the Company has established the Quality System Management Review Standards to evaluate the suitability and effectiveness of the quality system of subordinate drug manufacturing enterprises, and to urge the Company's senior management to effectively improve the quality management system through measures such as resource allocation.

II Quality risk control

To further strengthen the prevention and control of quality risks and ensure that all member units carry out production and operation activities in compliance with laws and regulations, the Company conducted various special audits of production and operation enterprises in accordance with the quality internal audit system and taking the current focus of supervision into consideration, supervised and urged enterprises to investigate quality risks and improve quality management level. During the Reporting Period, quality audits were completed for 34 enterprises, and all audited enterprises were able to complete rectification on time.

The Company collects product safety or quality information in a variety of ways. The Quality Management Committee holds regular working meetings to analyze the regulation situation, report the Company's quality management condition, raise risk warnings, strengthen the Company's awareness of regulations, integrity and quality, and effectively control and prevent quality risks.

III Optimize production layout and manufacturing

In 2020, the Company continued to optimize production layout and promote intensive management of production bases; optimized resource allocation and created a batch of production bases with obvious characteristics and focused dosage; promoted the planning of chemical raw materials and preparations, and strengthened the integrated development of raw materials + preparations; optimized and integrated the entire industrial chain of traditional Chinese medicine, pursuing controllable source quality and full traceability from the cultivation of Chinese herbal medicines in genuine producing area to the processing layout of Chinese medicine decoction， to ensure the safety, stability and reliability of the traditional Chinese medicine manufacturing process; continued to promote "lean, automated, digital, intelligent, and green" operations to improve the capabilities of production bases; established Shanghai Pharmaceuticals' excellent manufacturing system and built "lighthouse factories" to help enterprises develop with high quality.

IV Promote the consistency evaluation of generic drugs in an orderly manner

In 2020, Shanghai Pharmaceuticals consistency evaluation work yielded fruitful results, with a total of 16 varieties and 18 product-specific solid preparations approved as passing the quality and efficacy consistency evaluation. The approved number in 2020 was twice the sum of the two years of 2018 and 2019, and the total approved number reached 21 varieties and 27 product specifications.

Among the approved products, Benazepril Hydrochloride Tablets, Duloxetine Hydrochloride Enteric-coated Capsules, and Amiodarone Hydrochloride Tablets are the Company's key products; Alprazolam Tablets, Levonorgestrel Tablets, Telmisartan Tablets, and Ambroxol Hydrochloride Capsules are exclusively approved in China; Nitroglycerin Tablets, Duloxetine Hydrochloride Enteric-coated Capsules, Benazepril Hydrochloride Tablets, Amiodarone Hydrochloride Tablets, Dexzopiclone Tablets, Clozapine Tablets and other products are among the top three approved products in China.

In 2020, the Company added 17 varieties and 21 specifications in consistency evaluation application, of which the order of application for such products as Hydroxychloroquine Sulfate Tablets, Lorazepam Tablets, Methotrexate Tablets, Neostigmine Metsulfate Injection, Warfarin Sodium Tablets, Alfacalcidol Soft Capsules was top three in China.

V | Lean Six Sigma management

With the continuous and in-depth advancement of Lean Six Sigma management, the pharmaceutical manufacturing and pharmaceutical services sectors constantly explore and practice systematic innovative management models to support business development. With respect to the system capability, the Company continuously promoted the construction of Shanghai Pharmaceuticals excellent manufacturing system. With the quality first, optimal cost, green development and intelligent manufacturing as the basic principles, with the goal of achieving excellent operation and intelligent manufacturing, the Company conducted full upgrade through benchmarking and transformation and achieved development through innovation for the entire value chain of industrial manufacturing. With respect to the project of Lean Six Sigma, we widely covered our sectors of manufacturing, sales and business and sought pragmatic to select topics, and among the sectors, the manufacturing sector focused on improving quality, reducing costs and increasing efficiency, such as reducing production energy consumption, shortening the inventory turnover days, improving the production per capita and reducing the unit cost, etc.; the sales sector took SFE systematic construction as the core, such as improving the target accuracy of the market, optimizing marketing resources allocation, and perfecting the effectiveness of team incentives, etc.; the commercial sector aimed at the overall operation efficiency of the supply chain, such as inventory turnover, account period of accounts receivable, logistics efficiency, and cooperation with supplier to develop the terminal market, etc. In 2020, the number of initiative and approved projects of Lean Six Sigma reached 177 in total. In terms of the Lean talents training, the Company has passed the certification of 32 employees with black belts, 748 employees with green belts, which reserves sufficient talents for our enterprise. 3,567 employees passed the test of Green Belt Theory, which reserves sufficient talents for our enterprise.

VI | Supply chain management

By further expanding the scope of centralized procurement, the Company implemented centralized procurement of materials, facilities and equipment used by enterprises for which standards could be unified. The Company selected well-known brands that were highly recognized in the industry through investigations, business negotiations and other methods, and conducted strategic cooperation with them. It improved the energy level and material quality of the equipment used by the enterprise. Moreover, centralized procurement can effectively reduce corporate costs and enable the Company to further enhance its competitive advantage.

The subordinated drug manufacturer was responsible for the quality audit of the suppliers, and controlling the purchasing process, so as to ensure the purchased products can conform to the quality standards, and the purchasing process can conform to the provisions of relevant law and regulations, and ensure the stable and constant production of safe and effective drugs.

Case 1 | Starting a new era of intelligent manufacturing of Chinese medicine

Located in Huzhou Moganshan National High-tech Zone, a Deqing "Smart Pharmaceutical Factory" was newly established by Chiatai Qingchunbao Pharmaceutical Co., Ltd. It covers a total land area of about 172 mu, a construction area of over 90,000 square meters with automated production line accounting for 95% and digital equipment accounting for 90%. To build the first smart Chinese medicine production factory in China, Chiatai Qingchunbao applied the complete set of Chinese medicine intelligent manufacturing technology jointly developed by Tianjin University of Traditional Chinese Medicine and Zhejiang University and established the Chinese medicine intelligent manufacturing platform, which mainly includes the whole-process quality intelligent control, equipment intelligent management, lean pharmaceutical intelligent signage, pharmaceutical knowledge mapping and other functions. After the project results were applied to the production of Guanxinning tablets and other varieties, the operating cost decreased by 64%, the material delivery efficiency increased by one time, the production efficiency increased by 148%, the product yield increased to over 95% and the annual water saving was about 50,000 tons. Since the production base went into operation, the related products have achieved sales of RMB358 million and new profits and taxes of RMB108 million. On November 9, 2020, led by Zhang Boli, academician of the Chinese Academy of Engineering and "People's Hero" , the Zhejiang Pharmaceutical Society held a project results appraisal seminar on "Scientific Pharmaceutical-based Traditional Chinese Medicine Technology System and its Industrial Transformation" in Deqing, Zhejiang Province. The director of the appraisal committee was academician Hou Huiming, the deputy director was academician Yang Shengli, and the expert group also included eight people including academician Wang Guangji, academician Chen Wei. Under the 14th Five-Year Plan of the Party, the in-depth development of technological innovation in Chinese medicine industry is an important initiative to "adhere to the core position of innovation and achieve quality and efficiency development of Chinese medicine" . The official opening of Chiatai Qingchunbao Smart Pharmaceutical Factory has realized the new integration of traditional preparation methods of traditional Chinese medicine with Internet technology, cloud computing and artificial intelligence, which is a model of technological leap from "empirical pharmaceuticals" to "scientific pharmaceuticals" in the manufacture of traditional Chinese medicine and marks the significant milestone for the opening of the era of intelligent manufacturing of traditional Chinese medicine.

03

Our goal

- Make taking medicine easier

Our management ideology

- Build a stronger import platform
-Enhance the integrated service capabilities of the entire industry chain
- Innovate business model
- Improve drug access
- Meet the needs of special group

Our measures

- Continue to expand the national commercial network layout
- Speed up the introduction of imported products from multinational pharmaceutical companies
- Help build a multi-level medical security system
- Establish a rare disease development platform

Our achievements

- Become the preferred channel for multinational pharmaceutical companies to import new drugs
- Provide integrated solutions for upstream and downstream players
- Create a new model of prescription drug sales of "delivering medicine to home"
- Ensure the production and supply of drugs for rare diseases

Enhancing the public's medication experience

3.1 Participated in the collective signing of the state-owned assets sub-group of the Shanghai Trade Group for three consecutive years to accelerate the introduction of global innovative products

The 3rd CIIE wes held at the National Exhibition and Convention Center (Shanghai) from November 5 to 10, 2020. Health care has always been a sector that attracted much attention since the opening of the CIIE. China's continuous opening up and development potential are the fundamental reason why multinational pharmaceutical companies are optimistic about the Chinese market in the long run. At present, Shanghai Pharmaceuticals has become the largest distributor and service provider of imported medicines and imported vaccines in China. It has used the CIIE platform for three consecutive years to vigorously match the multinational pharmaceutical companies with the needs Chinese patients, accelerate the introduction of global innovative products, and enable domestic patients to use more high-quality drugs as soon as possible.

During the CIIE, since November 5, Shanghai Pharma and SPH Keyuan, as the two major commercial service platforms of Shanghai Pharmaceuticals, had successively carried out contract signing, cooperation and exchanges with many well-known pharmaceutical companies to move forward together for win-win results.

On November 5, Shanghai Pharma and Servier China signed a strategic cooperation agreement to help Chinese patients with chronic diseases achieve standard treatment, improve their quality of life, extend their life span, and promote the achievement of a healthy community. On the same day, SPH Keyuan and Abbott China reached a strategic cooperation to develop cross-border e-commerce business. On November 6, Shanghai Pharma and Bayer held a strategic cooperation signing ceremony for a new five-year and a new chapter. This is a "extended cooperation" based on the good relationship between the two parties in the past five years. On November 7, Shanghai Pharmaceuticals and Pfizer signed a letter of intent for strategic cooperation to expand all-round cooperation including the import, distribution, and warehousing of drugs (including vaccines). At the same time, Shanghai Pharma and Pfizer reached a purchasing intention on the distribution of imported products such as Clementine Ointment ® (Sultanmine ®) in China. On November 8, the Shanghai Municipal Medical Insurance Bureau held the signing ceremony for the purchase of selected drugs and high-value medical consumables for the first time at the CIIE. Shanghai Pharma signed a cooperation agreement with three multinational companies, Pfizer, Eisai, and Utimes, which were the first to actively participate in the national volume-based procurement. On November 9, Shanghai Pharma and Philips China signed a strategic cooperation memorandum.

During the CIIE, Shanghai Leiyunshang Pharmaceuticals, a subsidiary of Shanghai Pharmaceuticals, demonstrated to domestic and overseas audiences on-site the Leishi Liushenwan Pills, a boutique traditional Chinese medicine, and the craftsmanship of Liushenwan Pills, a national intangible cultural heritage project, in the intangible cultural heritage exhibition area for time-honored brands at the Central Plaza. Leishi Liushenwan Pills and their craftsmanship had met with guests from various countries during the second CIIE. This re-exhibition was not only to showcase the "Made in Shanghai" products that were representative of Shanghai's traditional Chinese medicine industry, but also to combine traditional Chinese medicine culture, intangible cultural heritage and Shanghai-style characteristics to show the unique charm of "Shanghai culture" .

Shanghai Pharmaceuticals' distribution network directly covers 24 provinces, municipalities, and autonomous regions

3.2 Initiated the project of Shanghai Medical Guarantee Base (Phase II at Suide Road)

On October 15, the launching ceremony of the Shanghai Pharmaceuticals Security Base (Suide Road Phase II) Project was held in the Suide Warehousing Area of Shanghai Pharmaceutical Logistics Center Co., Ltd. , which marked a new milestone of the Shanghai Pharma Co., Ltd. in the construction of a leading pharmaceutical logistics security.

Upon completion, Shanghai Pharmaceuticals Security Base (Suide Road Phase II) Project will occupy an area of approximately 51,000 square meters and a planned total construction area of 72,000 square meters. It will be equipped with a series of automated and intelligent logistics equipment to improve its operational efficiency at a faster pace. The Suide Road Phase II Project will take emergency material security as the core function to meet the needs of Shanghai as a super-large city for emergency health material reserve, and truly satisfy Shanghai's requirement for "taking the international first-class level as the benchmark and relying on the city's large-scale pharmaceutical production and distribution enterprises to build a comprehensive security base for public health materials that integrates storage, logistics and supply."

3.3 Build a domestically leading international supply chain service platform

As a leading pharmaceutical import platform in China, Shanghai Pharma has seized development opportunities and established Shanghai Pharmaceuticals International Supply Chain Co., Ltd. On July 10, witnessed by many leaders and industry moguls, Shanghai Pharmaceutical International Supply Chain Co., Ltd. was officially inaugurated, opening a new chapter for the development of the Company. On December 2, Shanghai Pharma and four partners formally settled in the Yangshan Special Comprehensive Bonded Area as the first batch of pharmaceutical companies.

Biomedicine is one of the four major industries to be developed and supported in the Lin-gang New Area. Shanghai Pharma will use Shanghai Pharmaceuticals Supply Chain Co., Ltd. as a platform to continuously build a leading domestic professional import and export and distribution platform with capabilities to introduce global innovative drug, and provide one-stop services for global partners.

3.4 Establish a new cooperation model straddling multiple fields and multiple platforms

Case 1 | Signing a strategic cooperation framework agreement with Halyard and making every effort to implement global procurement of materials

In the face of the sudden outbreak of the pandemic, China saw a united front that went all out. On February 4, Li Qiang, Secretary of Shanghai Municipal Party Committee, visited Shanghai Pharma to inspect the work of material security, highly affirmed its important role to the national health cause, and requested Shanghai Pharma to make further efforts to expand procurement channels and strengthen global procurement, so as to do a better job of material supply security for the prevention and control of the pandemic and further show the role undertaken by the state-owned enterprises.

To meet the expectations of the municipal government leaders and the people, Shanghai Pharma spared no effort to implement global procurement of materials and communicated with O&M Halyard, Inc. to establish a long-term and stable cooperative relationship. Under the strong support and coordination of the municipal government, the Municipal Commission of Commerce, the Municipal Drug Administration, the Municipal Reserve Bureau and other committees and offices, the two sides made good communication and contact. As a global leader in surgical protective consumables, O&M Halyard provides professional and comprehensive sensory control and protection solutions to hospitals and health facilities worldwide. On February 13, Shanghai Pharma and Halyard held an on-site cooperation signing ceremony at Shanghai Municipal People's Government to start a new chapter of win-win cooperation.

Case 2 | Exploring import cooperation model with Takeda in the field of lymphoma drug therapy

On June 10, Keyuan Xinhai (Beijing) Medical Products Trade Co., Ltd. under SPH Keyuan and Takeda (China) International Trade Co., Ltd. held a signing ceremony in Shanghai for the import and exclusive distribution of Adcetris. The cooperation of import and exclusive distribution of Adcetris opened up the import cooperation mode between SPH Keyuan and Takeda in the field of lymphoma drug therapy. Based on the import policy of Beijing Tianzhu Free Trade Zone and taking advantage of the nationwide logistics network, SPH Keyuan Trade will strive to open a new era of precision treatment of lymphoma for Chinese patients with efficient and accurate services, together with Takeda.

Adcetris®(Brentuximab vedotin for injection) was officially approved by the State Drug Administration on May 14, 2020 and entered China through priority review and approval for the treatment of CD30-positive relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) and classic Hodgkin lymphoma (cHL) in adults. Lymphoma is one of the major malignant tumors with the highest mortality rate in China. The marketing of Adcetris®will fill the gap in the field of CD30-positive lymphoma drug therapy in China and bring new treatment options for patients.

Case 3 | Entering into a strategic cooperation agreement with Ipsen China for Forlax® in omnichannel

On August 18, Shanghai Pharma and Ipsen China signed a strategic cooperation agreement on Forlax®(polyethylene glycol 4000 powder) in omni-channel. The cooperation of the Forlax project is the first omni-channel marketing cooperation project for foreign-funded mature product. Shanghai Pharma will provide exclusive omni-channel marketing efforts including hospital and retail for Forlax®in accordance with the cooperation arrangement between the two parties to continue to promote the application of the product in the field and better meet the needs of patients. As a leading company in the national pharmaceutical distribution field, Shanghai Pharma will focus its advantageous resources to further enhance the accessibility of patients' medication through its network system in 24 provinces across the country in order to strengthen further cooperation between the two parties.

Case 4 | Partnering with Shanghai Ninth People's Hospital to create a blue sky for patients with retinoblastoma

On September 4, SPH Health Commerce Co., Ltd. signed a cooperation agreement with the Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine for the follow-up platform for patients with eye tumor. SPH Health Commerce and the Shanghai Ninth People's Hospital had several exchanges and reached a number of consensus on the whole medical cycle of diagnosis, treatment, postoperative response and follow-up services for patients with retinoblastoma. This cooperation will provide patients with retinoblastoma with unlimited access to digital health record management services, establish a disease management follow-up information system, and create a blue sky for patients with retinoblastoma together with the medical and nursing staff of the hospital.

Case 5 | Signing "intention to purchase 13-valent pneumococcal polysaccharide conjugate vaccine" with Pfizer to provide more quality vaccines for children in China

On September 6, Keyuan Xinhai (Beijing) Medical Products Trade Co., Ltd. under SPH Keyuan held a signing ceremony on "intention to purchase 13-valent pneumococcal polysaccharide conjugate vaccine" with Pfizer International Trade (Shanghai) Co., Ltd. in the Public Health and Pandemic Prevention Zone of China International Fair for Trade in Services. Pfizer and SPH Keyuan not only had extensive strategic cooperation in business, but also had outstanding contributions in the field of pneumococcal disease prevention. The signing is dedicated to provide more quality vaccines for the protection of children in China.

Case 6 | Signing a strategic cooperation agreement with Baxter (China) for in-depth cooperation to benefit patients

On October 20, Shanghai Pharma and Baxter (China) Investment Co., Ltd. held a high-level communication meeting and signed a strategic cooperation agreement. The two parties will carry out in-depth cooperation in the areas of import exclusive distribution of acute hemofiltration replacement solution and contract sales of Baitoujia, jointly build and improve the specialized abdominal dialysis service ecology and create various innovative cooperation models. As a leading pharmaceutical business enterprise in China, Shanghai Pharma will make full use of its own advantages to enable Baxter's high-quality products to cover a wider end market and bring benefits to more patients through continuous and in-depth cooperation with Baxter.

3.5 MediTrust Health innovation helps build a multi-level medical security system

In recent years, the urban medical security system has been continuously improved. However, when citizens suffer from a serious disease, there are still relatively large and high medical expenses that are not covered by the basic medical insurance. The price of new specialty drugs is particularly expensive, and the drug access channels cannot be guaranteed. Individuals have a heavy cash burden, and cases of poverty or returning to poverty caused by illness still occur from time to time.

"Dare to be the world's first" is a quality that needs to be promoted especially to overcome risks and challenges and achieve high-quality development. The "Citizen Insurance" successively issued in Ningbo, Hangzhou, Suzhou and other cities has become an active attempt to explore a new and special drug security system for malignant tumors, helping to build a multi-level medical security system. As the technical supporter of "Citizen Insurance" , MediTrust Health responds to the national medical reform policy, and is determined to use the world's advanced payment innovation concepts and practices to effectively improve the affordability and access to advanced treatments of Chinese consumers. It is committed to helping patients solve medical payment problems through innovative payment methods, helping patients manage medical expenditures more efficiently, and bringing health protection to more people.

Case 1 | "Citizen Insurance" in Ningbo

On August 9, Ningbo "Citizen Insurance" , a supplemental medical insurance for Ningbo citizens with technical support from Meditrust Health, was officially launched. Ningbo "Citizen Insurance" breaks through the traditional model of commercial insurance and provides RMB2 million of coverage at a price starting from RMB59, freeing citizens from concerns over major illnesses for a whole year. It is an effective supplement to Ningbo's existing medical insurance policy, which provides universal coverage, reimbursement of out-of-pocket expenses and guarantee for special drugs.

Case 2 | "Citizen Insurance" in Hangzhou

The Hangzhou "Citizen Insurance" , a customized, universal supplemental medical insurance for Hangzhou, was also launched. It costs only RMB59 a year, less than RMB0.2 a day, and provides coverage for inpatient medical expenses and specific high-cost drugs for a total of RMB2 million. On top of the high coverage, Hangzhou "Citizen Insurance" also provides participants with special drug benefits for friends and relatives, consultation services, domestic reservation and delivery services, guidance services for drug application assistance, Hainan Boao Lecheng medical services, clinical trial application services, cancer genetic testing services and early screening services for major diseases.



Case 3 | "Suhui Insurance" in Suzhou

Closely connected to Suzhou basic medical insurance and major medical insurance, "Suhui Insurance" can be purchased by all participants of Suzhou basic medical insurance, regardless of age and occupation, for a yearly fee of only RMB49. The coverage of "Suhui Insurance" includes outpatient and inpatient services and covers the out-of-pocket expenses and the out-of-pocket expenses after compensation from basic medical insurance and major medical insurance, as well as 15 types of purely self-financed oncology special drugs. In addition, "Suhui Insurance" also provides 7 one-stop medical services, such as multidisciplinary consultation, special drugs discount for family and friends, cancer gene reduction, Hainan Boao Lecheng medical service, direct payment for special drugs, drugs delivery to home, and telephone consultation service.

3.6 Recreate a new model for seek medical attention and medication

Shanghai Pharma Health Commerce Co., Ltd., a subsidiary of Shanghai Pharma, actively participates in the construction of Internet hospitals in major hospitals in Shanghai, and has connected to the hospitals' HIS system and Internet hospital platform through the "Yiyao•Electronic Prescription Platform" . After the patient completes the consultation and pays for the prescription drug, the prescription is automatically transferred to the "Yi Yao•Cloud Pharmacy". After professional drug sorting and prescription review, a box of sealed drugs will be delivered to the patient by professional logistics personnel.

To ensure the safety of the electronic prescription data transmission process, the "YiYao•Electronic Prescription Platform", in conjunction with the "Electronic Prescription Circulation and Traceability Platform," adopts QR code-based electronic prescription traceability technology to allow patients, hospitals, and government regulatory agencies to monitor the circulation of electronic prescriptions outside the hospital in real-time. Through the traceability platform, the possibility of electronic prescription data being tampered with in the distribution process is effectively prevented, and at the same time, it effectively prevents the drug distribution companies from missing or sending drugs by mistake, and prevents cloud pharmacies from sending the wrong drugs and patients using the wrong drugs from the source. At the same time, all electronic prescription data will be open to government regulatory agencies for inspection at any time to achieve smart supervision and ensure patient medication safety.

Case | Renji Hospital

"Seeing a doctor without leaving home" and "next-day delivery of re-visit prescription" have become the daily routine of more and more patients. Taking Renji Hospital of Shanghai Jiaotong University as an important project case, SPH Cloud Health joined hands with Renji Hospital to combine the hospital's high-quality medical resources, online payment technology of medical insurance and the home delivery service of "Yiyao•Cloud Pharmacy" , so that patients can wait for the medicine delivery service provided by SPH Cloud Health. In this way, the entire process of consultation, payment and drug obtaining has been integrated, truly realizing one-stop consultation for patients to have return visit without leaving home.

Internet hospital prescribing after the online consultation

The professional delivery staff of Shanghai Pharma picks up and verifies the medicine from the pharmacy

Two-hour delivery and receipt upon patient's signing

3.7 Meet the medication needs of special group

I | Establish a Company for rare disease

As a leading large pharmaceutical company in China's pharmaceutical industry, Shanghai Pharmaceuticals has been committed to the development and production of rare disease drugs for many years. Among its existing products, there are 17 varieties for the treatment of rare diseases, involving 28 rare disease indications, making it one of the companies with the most rare disease drug approvals in China.

On the afternoon of April 8, 2019, the key investigation and research team of the Chinese Peasants and Workers Democratic Party for "optimizing the business environment and promoting the high-quality development of the health industry" came to SIIC and Shanghai Pharmaceuticals for research. Chen Zhu, vice chairman of the Standing Committee of the National People's Congress and chairman of the Chinese Peasants and Workers Democratic Party, sent a message to Shanghai Pharmaceuticals: "Put the people at the center and ensure the supply of rare disease drugs". As such, Shanghai Pharmaceuticals officially initiated special promotion work for the rare disease drug business in the second half of 2019. Our goal is to create a Shanghai model for rare disease drugs, and develop Shanghai Pharmaceuticals into an important national innovation and research base for rare disease drugs, a global influential rare disease drug transformation base, a high-end international production base for rare disease drugs, and a guarantee supply base for urgently needed drugs for rare diseases. In February 2020, Shanghai Pharmaceuticals and Beijing CoSci Med-Tech Co. Ltd. reached an agreement on entrusted technology development of drugs for the treatment of rare diseases, and introduced 3 drugs under development for rare diseases. After careful preparations, Shanghai SPH Ruier Pharmaceutical Co., Ltd., a rare disease business platform company 100% controlled by Shanghai Pharmaceuticals, was formally established on December 29, 2020.

The company's main business is divided into four parts: ensuring the supply of stock rare disease varieties, accelerating the implementation of rare disease projects under development, introducing domestic and foreign rare disease innovation cooperation projects, and building a rare disease business platform integrating R&D, production and sales. Currently, there are more than 10 rare disease products under research and introduced through cooperation, including global innovative drugs, first generic drugs, and many clinically urgently needed shortage drugs, and covering multiple rare disease categories such as tumor, motor neuron, endocrine, cardiovascular, metabolism, etc.

II | Rare Disease Care Project - Aid for Diabetes

For diabetes insipidus, in addition to the treatment of the primary disease, vasopressin supplementation is also the first-line treatment of choice. As the only long-acting insufflation posterior pituitary, vasopressin tannin was discontinued in 2018 due to the accumulation of multiple historical reasons such as the acquisition of raw materials, cost increases, and equipment upgrades. However, compared with short-acting preparations, the drug has advantages in terms of safety, effectiveness, and drug economy. Therefore, the demand for it for clinical treatment is strong, and the market has a high demand for resumption of its production.

In June 2020, the China Primary Health Care Foundation proposed to launch the "Rare Disease Care Project - Aid for Diabetes Insipidus Patients Public Welfare Project", planning to provide services to 30 patients and distribute 200 bottles of tannin vasopressin injection as the aid drug. The aid drug of this project is donated by Shanghai Shangke Pharmaceutical Co., Ltd., aiming to provide drug aid for diabetes insipidus patients falling in poverty or difficulty due to illness, reduce the burden on the family and society, and improve the quality of life of the patients.

In July 2020, the donation agreement was stamped and signed, the medical financing system and PAP system were officially launched, and applications from patients started to be accepted. On August 3, 2020, the first patient was recruited; on August 6, the patient received the drug for the first time. This charity project far exceeded expected effect, and warmed the heart of many patients.



3.8 Guarantee national and local drug reserves

I | Carry out guarantee of national and local drug reserves

Pursuant to the Shanghai Municipal Reserved Commodity Management Measures, a total of 76 varieties are included in important commodity reserves at the municipal level, with a total amount of more than RMB22.02 million. Specifically, there are 68 types of emergency western drugs and 8 types of emergency traditional Chinese medicines, mainly antibiotics, large infusions, antiviral drugs, detoxification and detoxification, and emergency rescue drugs for radiation injuries, reserved by three companies - Shanghai Pharma, Shanghai TCM, and SPH Sine. In accordance with the requirements of the Shanghai Reserve Commodity Management Office, the enterprise medical reserve management network operates normally, its three storage enterprises implement 24-hour duty system to ensure the quality and transportation of the municipal reserve medicine commodity.

In addition, since 2007, the Company has begun to organize and implement drug storage on behalf of the military combat. The amount was more than RMB15 million, and Shanghai Pharma was the storage enterprise while other subsidiaries acted as emergency units. It is now the East China region (shanghai) drug security mobilization center.

04

Our goal

- Effective solutions to resolve social problems

Our management ideology

- Closely align with its own core resources

Our measures

- Targeted poverty alleviation
- Undertaking of public service activities
- Community investment

Our achievements

- Getting more social acknowledge and improving public image
- Better clearing the ideas of public services, and highlighting the resources allocation


Spread positive social
energy

4.1 Targeted poverty alleviation

I | Targeted poverty alleviation plan

In response to the central government's call for poverty alleviation in recent years, Shanghai Pharmaceuticals has assisted in the construction of 14 health centers in Midu County, Dali, trained more than 200 rural physicians, and rescued 82 children with congenital heart disease. At the same time, it built kindergartens, schools, roads, and helped plant traditional Chinese herbal medicines in the local area.

SPH Sine, Shanghai Pharma, and Shanghai TCM under Shanghai Pharmaceuticals paired with Shijia Village, Micheng Town, Xianfeng Village, Qieli Town, and Kanglang Village, Niujie Township, in Midu County, Dali Prefecture, respectively, to carry out a series of corresponding poverty alleviation work from 2018 to 2020, helping local economic development, improving medical and health conditions, and improving the quality of life of the people in Yunnan. Under the correct leadership of the Party Central Committee, the solicitude and care of the Yunnan Provincial Party Committee and the Provincial Government, and the long-term assistance of Shanghai Pharmaceuticals, all the people of Midu made unremitting efforts and officially removed Midu County from the list of poverty-stricken counties on May 17, 2020. Shanghai Pharmaceuticals helped Midu eliminate poverty with "sincere care+ concrete action".

II | Overview of annual targeted poverty alleviation

Case 1 | A Hundred Enterprises Help A Hundred Villages

SPHAPHAR

Since the SPHAPHAR was paired with Xianfeng Village in the action of "A Hundred Enterprises Help A Hundred Villages" in 2018, it, with a high political standing and sense of social responsibility, has made a great contribution to Xianfeng Village by providing genuine help and precise measures, sponsoring poor college students, running a charitable supermarket, building a standardized health room, upgrading and renovating an affiliated kindergarten, purchasing agricultural products and improving the hardening of roads in the village , which has greatly improved the medical care, education and infrastructure of Xianfeng Village and stimulated the endogenous motivation of the masses, and made great contributions to helping Xianfeng Village win the battle to get rid of poverty.

On June 4, 2020, the Party and Workers Group of SPHAPHAR went to help the Xianfeng Village in Midu, Yunnan Province in the A Hundred Enterprises Help A Hundred Villages action, and held a discussion and exchange meeting on "realize true assistance and promote poverty alleviation" construction assistance project seminar to consolidate the results of poverty alleviation and help achieve the dream of being well-off in a century. At the meeting, the village committee reviewed and introduced the construction assistance project and expressed their gratitude for the help from SPHAPHAR. In the future, SPHAPHAR will continue to inject a constant stream of positive energy into the revitalization of Xianfeng Village, and a series of new poverty alleviation projects such as the construction of drought-resistant water cellar and the construction of public toilets in Aqiuhe Village are also being accelerated.





SPH Sine

From June 2 to June 3, 2020, the special poverty alleviation team of SPH Sine went to Shijia Village in Midu County, Dali Prefecture, Yunnan Province, to accept the results of its three-year paired poverty alleviation work. SPH Sine carried out the poverty alleviation with the party building and cultural building as the main lines, established platform mechanism, assistance mechanism, essential mechanism, civilization mechanism, cultural mechanism and driving mechanism, helping Shijia Village to complete poverty alleviation and prevent return to poverty.

On the morning of June 3, accompanied by the sound of a festive salute, the business car with a big red flower on the front and the logo of SPH Sine on the label slowly drove through the pine branch arch woven by the villagers of Shijia and SPH Sine Road was officially opened to traffic. This 4.35-kilometer-long road was not only built through the efforts and sweat of the people of Sine and Shijia, but also concluded the deep friendship between the people of Shanghai and Yunnan. This is a road for the convenience of people, a road of friendship and a road of happiness, to promote Midu trade, agriculture and animal husbandry, processing industry and other industrial development, so that the dream of Shijia people came into reality step by step.



SPH TCM

From May 19 to 20, 2020, during the critical period of achieving significant victories in poverty eradication, the paired assistance work team of SPH TCM came to Kanglang Village again and held a paired assistance promotion meeting as well as on-site training on Chinese herbal medicine cultivation with the village's poverty alleviation team. The meeting discussed the work of paired assistance in 2019, and the participants discussed and determined the next stage of work, including "herb planting, livestock breeding, ecological living construction and scholarship distribution" , focusing on the strategy of rural revitalization, preventing households from returning to poverty and accelerating the construction of a long-term mechanism for poverty alleviation.

In 2019, SPH TCM donated seeds, seedlings and fertilizers of salvia to 39 households in poverty in Kanglang Village to help them plant salvia. It not only organized relevant training in the early stage, but also participated in helping management in the middle stage, and purchased all the salvia planted by the households in difficulty at a price higher than the market price in January 2020. In 2020, in order to expand the industrial poverty alleviation efforts, help more households with difficulties to get rid of poverty and revitalize the countryside, four new herbs such as salvia, teasel root, safflower and scutellaria were selected for promotion and cultivation. Among them, 50 mu each of salvia and teasel root, 80 mu each of safflower and scutellaria were planted.

Case 2 | Ten Thousand Enterprises Help Ten Thousand Villages

In August 2018, in response to the Central Party Committee's call for winning the battle against poverty, SPH Keyuan took part in the "Ten Thousand Enterprises Help Ten Thousand Villages" targeted poverty alleviation project in Beijing and paired with East Liujia Village of Laiyuan County, Hebei Province. Taking advantage of the Company's advantages and in light of the actual situation of East Liujia Village, SPH Keyuan signed a three-year "Paired Poverty Alleviation Agreement" with it, with education as the bearer of poverty alleviation. In mid-September 2020, the Company launched the third phase of assistance activities and continued to provide financial assistance to local poor students and issued a total of RMB0.0429 million charity fund for 109 students.

Since the beginning of winter, the Company has been concerned about the situation of the people in poverty. When receiving the notice of "Ten Thousand Enterprises Help Ten Thousand Villages" from the leading group of poverty alleviation and support cooperation work in Shunyi District, Keyuan Trade immediately arranged relevant personnel to get to know the actual situation of the Beijing-Inner Mongolia paired poverty alleviation areas. After researching and understanding that there were 82 poor households in Qianlonggou Village, Huajialaga Township, Bairin Left Banner, Chifeng City and 71 poor households in Yujiawan Village, it immediately decided to implement the assistance actions in accordance with the standard of one quilt and one cotton coat per household and uniformly distributed to each poor household on December 30. In addition, it also donated cash to Yujiawan Village for the purchase of agricultural watering equipment. In total, it donated winter supplies and cash to Qianlonggou Village and Yujiawan Village, totaling more than RMB0.06 million, to make the poor people feel the warmth and care from Keyuan Trade in the cold winter, hoping they can get through the winter time peacefully and happily.

III | Effectiveness of targeted poverty alleviation

Unit: RMB0'000

Index	Quantity and development status
I. Overall statues	
Including: 1. Funds	1909.9
2. Amount of money converted from materials	187.9
3. Number of the people lifted out of poverty, who were on the records (person)	3425
II. Investment by category	
1. Poverty alleviation by industrial development	
Including: 1.1 Types of industrial poverty alleviation projects	☑ Agriculture and forestry industry poverty alleviation ☐ Tourism poverty alleviation ☐ E-commerce poverty alleviation ☐ Asset income poverty alleviation ☐ Technology poverty alleviation ☑ Others
1.2 Number of industrial poverty alleviation project (no.)	4
1.3 Investment amount of industrial poverty alleviation project	1455.1
1.4 Number of the people lifted out of poverty, who were on the records (person)	3226
2. Poverty alleviation by transfer of employment	
Among which: 2.1 Investment amount of vocational skills training	Nil
2.2 Number of people with vocational skills training (person/times)	Nil
2.3 Number of the poor on the records who are helped to get employed (person)	Nil
3. Lifting the poor out of poverty through relocation	
Including: 3.1 Number of the poor out of poverty through relocation who are helped to get employed (person)	Nil
4. Lifting the poor out of poverty through education	
Including: 4.1 Amount invested for helping the poor students	53.7
4.2 Number of poor people with disabilities assisted (person)	130
4.3 A mount invested for improving educational resources in poor areas	44.67

Unit: RMB0'000

Index	Quantity and development status
5. Lifting the poor out of poverty through better health care	
Including: 5.1 Investment amount of medical and health resources in poverty –stricken areas	115.63
6. Poverty alleviation through ecological protection	
Including: 6.1 Project title	☐ Ecological protection and construction ☐ Establishing Compensation Mode of Ecological Protection ☐ Establish ecological public welfare post ☑ Others
6.2 Amount invested	Nil
7. Guaranteed basic living standard for people unable to work	
Including: 7.1 Investment in left-behind children, women and senior people	Nil
7.2. Number of left-behind children, women and senior people assisted (person)	Nil
7.3. Investment in assisting poor people with physical disabilities	0.3
7.4 Number of poor people with disabilities assisted (person)	1
8. Social poverty alleviation	
Including: 8.1 Investment in coordinated poverty alleviation in East and West China	Nil
8.2 Investment amount of targeted poverty alleviation	Nil
9. Other projects	
Including: 9.1 Number of projects	17
9.2 Investment amount	428.4
9.3 Number of the people lifted out of poverty, who were on the records (person)	199
9.4 Explanation for other projects	
III. Awards (content, level)	Nil

IV | Subsequent targeted poverty alleviation plans

According to the particular environment of each poverty area and the conditions of different poor people, implement accurate identification of poverty target, accurate assistance and accurate management through the application of scientific and effective procedures. Mainly focusing on the promotion plan relating to the "A Hundred Enterprises Help a Hundred Villages" , and "Ten Thousand Enterprises Help Ten Thousand Villages" of the Company, followed by taking into consideration the advantages of the Company's resources, continue to vigorously promote health and industry poverty alleviation in remote and impoverished areas.

4.2 Charity and public welfare

Case 1

In 2020, a raging pandemic swept through China. In this war without smoke, countless medical workers fought on the front line of the pandemic area, writing a touching song of life and protecting people's health with their extraordinary perseverance. In order to pay tribute to the medical workers fighting against the pandemic and to thank people from all walks of life for their support to Shanghai Pharmaceuticals, the "Shanghai Pharmaceuticals' Tribute to Medical Workers Fighting against the Pandemic and Shanghai Pharmaceuticals' Promotion into the Global 500 Appreciation Concert" was held on December 17 at the Shanghai Symphony Orchestra under the guidance of Shanghai Medical Association, Shanghai Medical and Health Development Foundation and Shanghai Shangyi Medical Workers Award Foundation. Academicians and experts from relevant government departments, universities and pharmaceutical industry, pharmaceutical associations and foundations, representatives of anti-pandemic doctors and nurses from Shanghai hospitals and advanced representatives of Shanghai Pharmaceuticals against the pandemic attended the concert.

In this concert, Shanghai Pharmaceuticals sincerely invited Tan Dun, the famous Chinese conductor and composer, and brought the magnificent masterpiece Buddha Passion, which is a work inspired by Dunhuang over six years, divided into six movements: Under the Bodhi Tree, Nine Colored Deer, Thousand Hands and Thousand Eyes, Zen Garden, Sutra and Nirvana. Buddha Passion plays an inner melody about the journey of the heart. The music shows compassion, benevolence and nature and conveys the power of great love and life, which is the supreme tribute to countless heroes in harm's way and heroes against pandemic.





Case 2

By building a perfect TCM and TCM study course system, the Babaodan Traditional Chinese Medicine Cultural Centre hosted social practice and TCM-themed study activities for a number of primary and secondary schools, in which primary and secondary school students were exposed to TCM intuitively and experienced TCM culture up close. In 2020, SPH Xiamen Traditional Chinese Medicine held the first Lujiang Forum event and regularly invited experts to hold TCM-themed public service salons and popular science lectures in the Centre. It served the community residents, TCM enthusiasts and professionals around the Centre; donated nearly 1,000 herbal anti-pandemic scented capsules and 400 boxes of Jinsihuang chrysanthemum to community workers and other front-line volunteers in the fight against pandemic, with a total value of nearly RMB0.04 million of donated items; and helped the disabled people in the street charity house to carry out related operation activities in order to support the public welfare charity of Siming District. Through a series of activities, it promoted the inheritance and development of Chinese medicine culture.

Case 3

To thoroughly implement the major deployment of the 19th CPC National Congress on poverty eradication, in accordance with the important instructions of the State Administration of Traditional Chinese Medicine on "win the battle against poverty through services" and the Chinese Association for Science and Technology on "targeted poverty alleviation by technology", since 2017, the International Department of the Chinese Medicine Society has undertaken the specific tasks of the Society's Secretariat TCM for targeted poverty alleviation and relevant units and individuals have taken the initiative to participate by means of donations, charity clinics and training, making positive contributions to the successful completion of the task of targeted poverty alleviation. The Society gave a commendation to the relevant units and individuals who actively participated in the poverty alleviation work in Wuzhai County, Shanxi Province, which is the designated poverty alleviation county of the State Administration of Traditional Chinese Medicine, Lin County and Lan County, Luliang District, Shanxi Province, and Fuping County, Hebei Province. On November 19, Huqingyutang Pharmaceutical was listed as an outstanding unit of the Chinese Society of Traditional Chinese Medicine for its poverty alleviation work and received commendation.



Case 4

On September 24, 2020, "National Popular Science Day" Shanghai Association of Chinese Integrative Medicine launched the "Western Health Tour of TCM and western medicine" in Kaili, Qiandongnan Prefecture, Guizhou. This activity aims to give full play to the leading role of high-level experts in TCM and western medicine in Shanghai, enhance the service capacity of local TCM and the integration of TCM and western medicine and strengthen the exchange and cooperation with medical institutions in Qiandongnan Prefecture. Shanghai Leiyunshang Pharmaceuticals and Shanghai SPH Xingling Sci. & Tech. Pharmaceutical donated a total of more than RMB0.19 million for the Red Cross Society of Qiandongnan Miao and Dong Autonomous Prefecture.

4.3 Community Investment

Shanghai Pharmaceuticals attaches great importance to community relations. The entire Group actively participate in community affairs in various aspects, and constantly strengthen the positive interaction with the community. While contributing to the community, the Company creates conditions for sustainable development.

Case 1

2020 marks the fourth year of cooperation between Shanghai Pharmaceuticals and Shanghai Symphony Orchestra. Both parties leveraged their respective strengths to integrate health concepts with music quality, shape exclusive cultural brands, spread healthy lifestyles and create Shanghai cultural name cards.

In this special year, Shanghai MISA was coming as promised to deliver love and positive energy with the power of music. From July 20 to July 29, MISA presented a variety of performances in classical, pop, jazz and rock genres at the Shanghai Symphony Orchestra Concert Hall and Shanghai City Music Lawn, bringing together musicians from all walks of life such as Yu Long, Tan Dun, Shen Yang and Song Siheng, as well as many music groups such as the Guangzhou Symphony Orchestra, Kunming Nie Er Symphony Orchestra and Lanzhou Concert Hall Choir, to showcase the unity of Chinese musicians and music business on the MISA stage. Among them, the Hubei Provincial Opera and Dance Theatre from Wuhan also came to Shanghai for the first time after the end of lockdown to play the concert version of the opera "The Red Guards on Honghu Lake" on the stage of MISA.

In addition, Shanghai Pharmaceuticals still sent supplies for the coolness to the audience at the lawn performance. During seven performances in a row, volunteers from Shanghai Pharmaceuticals distributed free SPH Dragon & Tiger brand cooling products and SPH TCM Yutian's saffron mask to the audience to repel mosquitoes and eliminate heat and bring a better performance experience.

Case 2

On April 25, the "Yi Dang Bao Gan" & the online academic conference on the diagnosis and treatment of liver cirrhosis and liver cancer through TCM and Western medicine treatment was hosted by Xiamen Pharmaceutical Society Professional Committee of Chinese Medicine and Health and organized by Xiamen TCM Factory Co., Ltd., which fully discussed diagnosis and prevention of liver cirrhosis and liver cancer. The number of participants in the online conference reached more than 1,700, allowing many "participants" to enjoy a high-level academic conference without leaving home.



Case 3

On the morning of October 13, Expert Charity Clinics & District People's Congress Representatives' Themed Activities in Electorate was held as scheduled in Pudong Jin Yang Cultural Square. Every year, SPH Jingui, a subsidiary of Shanghai Pharma organizes a volunteer service team to participate in the charity clinic and some of the District People's Congress Representatives also came to the clinic site to interact with the residents. Most of the community residents present were volunteers who participated in pandemic prevention and control and garbage sorting and they waited for consultation in an orderly manner under the warm and considerate guidance of the youth volunteers of Shanghai Pharma. The clinic lasted for more than 2 hours, with more than 120 community residents participating. The doctors provided community residents with various charity services such as disease diagnosis and treatment, health consultation, health care herbal tea, free blood sugar and blood pressure measurement.

Case 4

On December 4, Huqingyutang Pharmaceutical participated in the "Direct Access to Famous Doctors 'Xianfeng Yunxi' Station" which was held in the Daijia Village, She Eshan Township, Tonglu, Hangzhou. In the Xianfeng Yunxi Library, the "most beautiful bookstore" located in an ancient village deep in the mountains at an altitude of 600 meters, a health-themed event was held, with volunteers from medical experts in Zhejiang Province comforting and caring for local elders with traditional medicine. The activities included pulses taking, acupuncture, massage, consultation, guidance and communication. The love is like the winter sunshine warming the hearts of the elderly. At the same time, the library donated self-edited books on "health care for the elderly" and "health care for children" and Chinese medicine to spread the culture of health.

05

Responsibility

Our goal

- Focus on fighting the epidemic, and go all out to ensure supply

Our measures

- Ensure the supply of anti-epidemic materials
- Increase production of anti-epidemic drugs
- Accelerate the development of anti-epidemic drugs
- Donate anti-epidemic materials

Focus on fighting the epidemic

5.1 SPH anti-epidemic big data

2020 was an extraordinary year. The sudden outbreak of COVID-19 epidemic was a major public health emergency with the fastest spread, the widest range of infections, and greatest difficulty to prevent and control since the founding of the People's Republic of China, greatly threatening people's lives and health. Epidemic prevention and control are our unshirkable responsibility. As a leading pharmaceutical manufacturing and commercial enterprise in China, Shanghai Pharmaceuticals thoroughly implemented the deployment of the Party Central Committee, the State Council and the Shanghai Municipal Party Committee and Municipal Government on epidemic prevention and control, focusing on fighting the epidemic. Nearly 50,000 employees of the Group from enterprises at all levels from R&D, production, distribution, logistics and distribution to pharmaceutical retail raced against time, bravely pressed forward and took up heavy responsibilities to implement various anti-epidemic work with dedication, professional knowledge and efficient execution. Shanghai Pharmaceuticals was the "vanguard" and "main force" for the supply of medicines and medical supplies in Shanghai and many regions across the country, guaranteeing national and even global supplies, demonstrating the speed, wisdom and responsibility of Shanghai Pharmaceuticals.

Shanghai Anti-COVID-19 Medical Supplies Guarantee Base

Shanghai Anti-epidemic Medical Material Procurement Platform

Hubei Province and Wuhan City Two-Level Epidemic Prevention and Control Emergency Medical Supplies Procurement and Storage Enterprises

Charge Ahead

- The party committee of the Group launched the "Red Vanguard" operation and immediately sounded the assembly call to all party members. **52** "epidemic" task forces and **1,206** party members as commandos fought on the front line
- **400** logistics employees stayed in Shanghai during the Spring Festival and worked for about **540** hours in a month to assist the Shanghai Medical Team Aiding Hubei, relaying more than **800,000** pieces of medical supplies weighing nearly **10** tonnes
- Urgently sourced **1,300** ventilators, **1,500** monitors and more than **3,000** boxes of accessories within **3** days, and delivered them to Wuhan with guaranteed quality and quantity
- Resumed work and production ahead of schedule, produced products **24** hours non-stop, complete the production of **2.8** million chloroquine phosphate tablets in **3** weeks Fought
- against the epidemic globally: completed the first delivery of **250** ventilators for orders from Hungary in **one month**; exported hydroxychloroquine sulfate tablets to more than **30** countries and regions

Anti-epidemic Materials

- As of the end of 2020, the Company has supplied nearly **190** million masks, **2.9** million sets of protective clothing, **320,000** goggles, and **43** million pairs of gloves to **38** tertiary hospitals, municipal and district medical institutions and first-line units of epidemic prevention work that ensure urban operation
- As of end of 2020, we have produced more than **100** million boxes/bottles of various anti-epidemic drugs in Shanghai

Donate materials

- Accumulatively donated medical equipment, anti-epidemic drugs, protective equipment and other epidemic prevention materials worth more than RMB**26** million

Included in the programs and guidelines for treatment of COVID-19



SPH Chloroquine Phosphate

On March 2, 2020, when inspecting scientific research on the prevention and control of COVID-19 in Beijing, Xi Jinping came to the physical drug counter of chloroquine phosphate tablets developed and produced by Shanghai Pharmaceuticals' SPH Zhongxi, and listened to the introduction and suggestions of experts on chloroquine phosphate.

★ Included in the plan and guidelines for treatment of COVID-19

No.	Subsidiaries of Shanghai Pharmaceuticals	Drug name	Included in the national, provincial, and municipal programs/consensus (partial)
1	SPH Zhongxi	Chloroquine Phosphate	Diagnosis and Treatment Program for Novel Coronavirus Pneumonia (Trial Version 7) , Shanghai Expert Consensus on Comprehensive Treatment of COVID-19, Expert Consensus on the Clinical Rational Medication for Novel Coronavirus Pneumonia
2		Hydroxychloroquine Sulfate	Shanghai Expert Consensus on Comprehensive Treatment of COVID-19 , Expert Consensus on the Clinical Rational Medication for Novel Coronavirus Pneumonia
3	SPH Techpool	Ulinastatin	Shanghai Expert Consensus on Comprehensive Treatment of COVID-19, Hunan Province Treatment Program for Severe and Critical Pneumonia Caused by Novel Coronavirus Infection (Trial Version 1), Fujian Province Pneumonia Drug Treatment Guideline Program for Novel Coronavirus Infection (Trial Version 2) , Guangdong Province Expert Consensus on the Clinical Rational Medication for Novel Coronavirus Pneumonia (Third Version)
4	SPH Traditional Chinese Medicine	Jingyin Mixture	Shanghai Expert Consensus on Comprehensive Treatment of COVID-19
5		Jingyin Granules	Shanghai New Coronavirus Pneumonia TCM Diagnosis and Treatment Program (Trial Version 2) 2020"
6		Liushenwan Pills	Shanghai New Coronavirus Pneumonia TCM Diagnosis and Treatment Program (Trial Version 2) 2020" , Recommendations for Integration of Traditional Chinese Medicine and Western Medicine on Several Hot Issues of Novel Coronavirus Pneumonia in 2020, Expert Consensus on the Prevention and Treatment of Novel Coronavirus Pneumonia with Chinese Patent Medicines

Shanghai' s Programs for Treatment of COVID-19

Chloroquine phosphate tablets

Techpool Roan (Ulinastatin for Injection)

Jingyin mixture

No.	Subsidiaries of Shanghai Pharmaceuticals	Drug name	Included in the national, provincial, and municipal programs/consensus (partial)
7	SPH Sine	Ribavirin	Diagnosis and Treatment Program for COVID-19 (Trial Version 7)) Expert Consensus on the Clinical Rational Medication for Novel Coronavirus Pneumonia
8		Intestinal microecological regulator	
9	SPH No. 1 Biochemical and Pharmaceutical	Thymosin α1	Diagnosis and Treatment Program for Severe and Critical Cases of Novel Coronavirus Pneumonia (Trial Version 2) Shanghai Expert Consensus on Comprehensive Treatment of COVID-19
10		Polymyxin B Sulphate	Expert Consensus on the Clinical Rational Medication for Novel Coronavirus Pneumonia
11	SPH Qingchunbao	Shenmai Injection	Diagnosis and Treatment Program for Novel Coronavirus Pneumonia (Trial Version 7)Programs/Guidelines Adopted for Beijing, Liaoning, Shaanxi, Sichuan, Yunnan, etc.
12	SPH Growful	Kugan Granules	Shandong Province TCM Diagnosis and Treatment Program for Pneumonia Caused by Novel Coronavirus Infection
13		Pediatric Lung Heat Cough Granules	Sichuan Province Technical Guidelines for TCM Prevention and Control of Pneumonia Caused by Novel Coronavirus Infection
14	SPH Herbapex	Anti-cold Detoxification Granules	Liaoning Province Novel Coronavirus Pneumonia Prevention Program
15	Huqingyutang & SPH Xiamen Traditional Chinese Medicine	Angong Niuhuang Pills	Diagnosis and Treatment Program for Novel Coronavirus Pneumonia (Trial Version 7) Shandong Province TCM Diagnosis and Treatment Program for Pneumonia Caused by Novel Coronavirus Infection Fujian Province Expert Consensus on Diagnosis and Treatment of Novel Coronavirus Pneumonia Diagnosis and Treatment Program for Pneumonia Caused by Novel Coronavirus Infection (Zhejiang First Version with Clinical Experience) Zhejiang Province Recommended Program for Prevention and Treatment of Novel Coronavirus Pneumonia with Traditional Chinese Medicine
16	SPH Xiamen Traditional Chinese Medicine	Babaodan	Fujian Province Expert Consensus on Diagnosis and Treatment of Novel Coronavirus Pneumonia
17		Xiangsha Liujun Pills	

5.2 Shanghai Pharmaceuticals

Leader Inspection

Li Qiang， Secretary of the Shanghai Municipal Party Committee， came to Shanghai Pharmaceuticals to check the supply of materials for the prevention and control of pneumonia caused by the novel coronavirus infection

Jiang Zhuoqing, Director of the Standing Committee of the Shanghai Municipal People's Congress and Secretary of the Party Leadership Group, inspected Shanghai Pharmaceuticals and put forward expectations for the Company's sustainable development

Chen Yin, member of the Standing Committee of the Shanghai Municipal Party Committee and Executive Deputy Mayor, inspected the city's anti-epidemic medical supplies guarantee base

Xu Kunlin, the then Deputy Mayor of Shanghai, went to SPH Logistics to inspect the supply of medical supplies in this city

Zong Ming, the Deputy Mayor of Shanghai, led a team to inspect, and recognized and thanked Shanghai Pharmaceuticals for fighting the epidemic and ensuring the supply of materials

Bai Tinghui, Secretary of the Party Committee and Director of the Shanghai State-owned Assets Supervision and Administration Commission, visited SPH Logistics to inspect the supply of medical supplies in the city

Xia Kejia, Director of the Shanghai Medical Insurance Bureau, went to Shanghai Pharma to inspect the resumption of work and production



Fight the epidemic and ensure supply Focus on fighting the epidemic Mission will be reached

Shanghai Pharma was identified as Shanghai Anti-COVID-19 Medical Supplies Guarantee Base and Shanghai Shanghai Anti-epidemic Medical Material Procurement Platform

The retail pharmacies of Shanghai Pharmaceuticals prepared and delivered goods 24 hours a day to fully guarantee the supply of anti-epidemic materials

SPH Keyuan

Shanghai Pharma and SPH Keyuan assisted the Shanghai Medical Team Aiding Hubei by ensuring the supply of emergency supplies to Huoshenshan, Leishenshan, mobile cabin hospitals, etc. to fully support Wuhan's fight against the epidemic

Shanghai Pharmaceuticals donated anti-epidemic materials

Shanghai Wai Gao Qiao Pharmaceutical Business and Distribution Center

Shanghai Pharma Zunyi

Sichuan Guojia Pharmaceutical

Shanghai Pharmaceuticals' R&D team participated in national multi-center clinical study

The Company quickly resumed work and production to urgently produce anti-epidemic drugs to ensure continuous supply in the market

Shanghai Pharma

Jiangxi Nanhua Hospital



Shanghai Pharmaceutical Nantong



SPH Sine


Shanghai Pharma Anhui


Shanghai Pharma Hunan


SPH Leiyunshang


SPH Zhongxi


SPH Traditional Chinese Medicine


SPH Techpool


Shanghai Pharma Hangzhou Kailun


SPH No. 1 Biochemical and Pharmaceutical


SPH Changzhou Pharmaceutical


Shanghai Pharma Jiading


SPH Techpool


SPH Cardinal Health (Shanghai)


Shanghai Pharma Zhejiang


SPH Dong Ying


SPH Xiamen Traditional Chinese Medicine


Shanghai Pharma Jinshan


Shanghai New Century Pharmaceutical


SPH Cardinal Health (Hubei)


SPH Herbapex


SPH Zhonghua


SPH Cardinal Health (Beijing)


SPH Cardinal Health (Tianjin)


SPH Cardinal Health


SPH Cardinal Health (Shenzhen)


SPH Cardinal Health (Zhejiang)


SPH Cardinal Health (Chongqing)


SPH Material Supply and Marketing


SPH Qingchunbao Pharmaceutical


SPH Sunway Biotech

Anti-epidemic Award

On the morning of September 29, the grand Commendation Conference for Shanghai's fight against the COVID-19 epidemic was held. The conference commended advanced individuals in fighting the COVID-19 epidemic in Shanghai, advanced collectives in fighting the COVID-19 epidemic in Shanghai, outstanding Communist Party members in Shanghai, and advanced grassroots party organizations in Shanghai. Three collectives and two individuals of Shanghai Pharmaceuticals Holding were on the list.

- The CPC Committee of Shanghai Pharmaceutical Holding Co., Ltd. was awarded the Shanghai Advanced Collective in Fighting the COVID-19 Epidemic
- The CPC Committee of Shanghai Pharmaceutical Holding Co., Ltd. was awarded the Shanghai Advanced Grass-root Party Organization
- Shanghai Pharma Co., Ltd. was awarded the Shanghai Advanced Collective in Fighting the COVID-19 Epidemic
- Li Yongzhong, executive director and vice president of Shanghai Pharmaceutical Holding Co., Ltd., general manager and deputy secretary of the Party Committee of Shanghai Pharma Co., Ltd., was awarded the Shanghai Advanced Individual in Fighting the COVID-19 Epidemic
- The CPC Committee of Shanghai Pharmaceutical Holding Co., Ltd. was awarded the Shanghai Advanced Collective in Fighting the COVID-19 Epidemic

Dragon Television

Li Qiang came to Shanghai Pharmaceuticals to check the supply of materials for epidemic prevention and control

Shanghai Television News Comprehensive Channel

Going all out for stocking and delivery: Shanghai Pharmaceuticals guaranteed the supply of anti-epidemic drugs

Dragon Television

SPH Zhongxi: Completed the production of 2.8 million tablets of chloroquine phosphate and the first batch has been sent to Wuhan



CGTN

Shanghai Pharmaceuticals met overseas demand for anti-epidemic drugs



people.com.cn

Press Releases

Letter of Thanks

06

Our goal

- Create overall value

Our management ideology

Take different stakeholders' appeals seriously
- Responsible to shareholders
- Responsible to employees
- Responsible to the environment

Our measures

- Strengthen transparent management, promote business development and realize synergy of management and control
- Focus on employees' career development and occupational health and raise their remuneration, benefit level and comprehensive capacities
- Integrity, self-discipline and compliant operations
- Insist on green production and low-carbon operation

Our achievements

- Achieved growth in operating performance and successfully entered the list of Global 500
- We provided our employees with professional, high-efficiency and individualized training courses and growth paths in light of their work posts and career development needs
- We worked on legal construction projects, performed standardized operation of pollution treatment facilities, and legally in was the of hazardous waste
- Energy-saving and water-saving effects were significant

Employees develop with the Company

6.1 Governance and control

I Governance mechanism

The Company strictly complies with the Company Law, the Securities Law, and other regulatory requirements. A relatively modern governance mechanism has been established by the Company, and corporate governance was further enhanced.

In 2020, the Company promptly revised the notice time of the shareholders' general meeting in the Articles of Association in accordance with the requirements of Reply of the State Council on the Adjustment to the 《Notice Period for General Meetings and Other Matters Applicable to Overseas Listed Companies》. At the same time, the Company organized directors, supervisors, senior executives and internal employees to conduct in-depth studies on the New Securities Law, conducted self-examinations on securities transactions, information disclosure, changes in controlling shareholders' rights and interests, inside information and investor protection, in strict accordance with the New Securities Law and prepared self-examination reports.

II Risk and internal control system

To cope with the ever-changing risks and satisfy the compliance requirements for listed companies' governance, the Company put in place a work process of identifying, assessing, responding to and reporting risks. The process can identify the internal and external risks, assess the possibility and impact of risks, confirm the risk response strategy and implement the risk response measures. Moreover, risks and risk management outcomes were reported to the Board of Directors, the Audit Committee and management periodically and systematically.

As to internal control, the Company established a corporate legal person governance structure, and organizational structure that fits the Company's business scale and operational needs after fully considering the modern corporate system requirements, business risks as well as the Company's development status. The Company's internal control management system has been further enhanced and optimized in terms of control environment, risk assessment, control activities, information and communication, as well as supervision mechanism.

III Information disclosure

As for information disclosure, the Company kept meeting investors' demand and satisfying applicable compliance requirements. In accordance with China Securities Regulatory Commission's Standards for the Contents and Formats of Information Disclosure by Companies Offering Securities to the Public No. 2-Contents and Formats of Annual Reports (2017 Revision), Shanghai Stock Exchange's Industrial Information Disclosure Guidelines for Listed Companies No.7 – Pharmaceutical Production and Notice on Further Improving Listed Companies' Disclosure on Poverty Alleviation Work, and the Hong Kong Stock Exchange's Environmental, Social and Governance Reporting Guide, the Company actively performed its information disclosure duties in innovative ways and strengthened the timeliness and transparency in information disclosure.

Between January 1, 2020 and December 31, 2020, the Company issued 4 periodic reports (2019 annual report, as well as 2020 first quarter report, interim report and third quarter report), 73 provisional announcements for A-share market, and 93 announcements and circulars for H-share market.

IV | Compliant operation

Shanghai Pharmaceuticals attaches great importance to compliance management, because today's achievements not only derive from stable business performance, but also benefit from sound product quality and the management philosophy of integrity codes.

In 2020, Shanghai Pharmaceutical continued to deepen the construction of compliance management. It examined the development direction of compliance work in accordance with the new developments of the industry environment and the new requirements of the Company's development, and summarized the key issues in compliance work, focusing on key management components such as risk identification, implementation of compliance review, deployment of risk response, and organization of compliance training. It has established an all-round, multi-level compliance management system that integrates organization, process and system and can achieve continuous self-improvement.

In 2020, Shanghai Pharmaceuticals promoted the integration and unification of regulatory resources in an effort to break through the barriers between different management modules. Based on risk identification and assessment, it continuously adjusted the management focus and improved the corresponding internal control measures. At the same time, it dynamically embedded compliance management requirements in the internal control process, and gradually established an effective structure oriented by risk control, focusing on compliance management, and using internal control processes as the carrier.

V | Investor Communication and Rights Protection

The Company regularly held conference calls involving global investors and conducted roadshows for global institutional investors. Meanwhile, the Company positively responded to and answered the investors' questions through the "E-interactive Platform" of the Shanghai Stock Exchange, investor hotline and e-mails. In 2020, the Company maintained good interaction with domestic and overseas investors, positively participated in and received investor survey, and participated in the medical investment strategy meeting held by many influential investment banks and securities companies at home and abroad, ensuring investors could be promptly informed of the Company's operating results and strategy plans. In 2020, the Company has made invitations to its investors for more than 400 times in total.

The Company attaches great importance to and promptly responds to investor questions received by SSE's "E Interview". As of December 31, 2020, it has answered a total of 190 questions.

Case 1 | Information disclosure

The Company attaches great importance to investors' right to know and discloses corporate information in a true, accurate, complete and timely manner. Since 2016, the Company has been given Grade Highest the highest grade, in employees (2014 information disclosure evaluation by the Shanghai Stock Exchange for two consecutive years, ensuring investors could be adequately and promptly informed of important corporate information and protecting investors' rights and interests.

Case 2 | Market value management

For major events, the Company has established a rapid communication mechanism of "IR+PR" linkage. After the announcement is made, it will simultaneously publish press releases and hold investor exchange meetings to explain the purpose of the project at the first time and convey the Company's strategy, which is well received by the market. In 2020, the Company also opened a new corporate account on the Tonghuashun platform to provide small and medium investors with more proactive and timely updates on the Company's business dynamics.

VI | Anti-corruption

In respect of the discipline inspection commission, we comply with relevant anti-corruption and anti-bribery laws and regulations applicable to the Company, effectively carry out the study, publicity, and implementation of the Standards on Integrity and Self-discipline of the Communist Party of China , Regulation of the Communist Party of China on Disciplinary Actions and the spirit of the eight-point frugality code issued by the Party Central Committee, carry out education on party spirit, party style, party discipline and honest employment, and deepen the construction of the "four responsibilities coordination" mechanism. We focus on strengthening prevention and system construction, carry out supervision on "key minorities" and key areas, and build a long-term mechanism for enterprise internal risk prevention and control.

Key indicators

Operating revenue
Unit: 100 million



Net profit attributable to equity holders of listed company
Unit: 100 million



Earnings per share
Unit: 100 million

Total assets
Unit: 100 million

6.2 Employee development

I | Career development

The Company gradually established employee career development channels. We pay attention to the development of different groups of people, design a rank system suitable for their development based on their sequence characteristics, and constantly improve job standards.

Meanwhile, the Company adhered to the market-based employment mechanism, organized talent review, and promoted the merit- based selection of talents on a competitive basis; strengthened the introduction of market-oriented talents, established a unified recruitment management platform, set up an internal employee recommendation system, integrated internal & external recruitment channels and resources, optimized recruitment process and established internal & external talent pools; attached great importance to the introduction and training of international talents, so as to promote the development of its international business; The Company annually organized theme recruitment in the campus. Due to the impact of the epidemic, offline job fairs could not be held this year. To allow more recent graduates to keep abreast of the recruitment information at home and ensure timely employment, the Company adjusted the originally planned offline spring job fair to an online presentation. The novel presentation was well received by the students, enhancing the Company's image as an employer. In 2020, the Company once again won the title of China's Favorite Employer for College Students and was selected as one of China's 100 Model Employers. The Company continuously established strategic alliances with relevant universities and jointly established national education practice bases and master graduate internship bases to improve students' practical ability through internships, graduation guidance, exchange of experts, directed and entrusted trainings, so as to shorten their run-in period after entering the company. Through overall planning and expansion of management trainee programs, the Company attracted and developed top outstanding graduate talents.

II | Remuneration and Benefits

The Company adhered to the remuneration payment concept centered on position, ability, performance and market and kept improving the normal growth mechanism and the underpinning mechanism for employee salaries, with reference to the Company's development, so as to improve the income level of employees of the enterprise.

The Company developed differentiated remuneration systems for managers, marketing personnel, R & D personnel, technical-quality management personnel and production personnel based on the characteristics of their posts, and effectively mobilized the staff's initiatives and creativity to continuously improve its performance, contributing to the realization of its strategic objectives.

With reference to the enterprise's development, the Company actively promoted implementation of the benefit items such as commercial medical insurance, supplementary provident fund and enterprise annuity to improve employee welfare system.

The Company continuously promotes the share option incentive scheme to enhance the core competitiveness of enterprises and fully unlock the Company's potential and consolidate its position. This move also seeks to keep Employee team stable and motivate core and key employees, allowing the Company to grow rapidly and healthily.

III | Training and development

The Company paid high attention to employees' growth and development and provided employees with systematic learning and development paths and training courses.

The Company paid high attention to employees' growth and development. Shanghai Medical University continuously exerted its "Five Platforms" functions and unremittingly empowered employees at all levels and of all lines of the Group in the form of a combination of online and offline under the adverse impact of the COVID-19 epidemic.

In 2020, as Shanghai Pharmaceuticals entered the Fortune Global 500, Shanghai Medical University completed a total of 89 learning programs revolving around the main goose array program, professional program, thematic programs, rotating training program, and university forums, with 732 training hours in total and 3,614 participants accumulatively. The main program deepened the training of the Goose Array System. The professional program covered security, finance, legal affairs, quality, marketing, manufacturing and lean management lines. The thematic program carried out targeted expansion of international capabilities, popularization of pharmacy knowledge, new media competency, internal trainer training projects, and the organization of the National Biomedical Leadership Class for the Ministry of Industry and Information Technology, expanding the influence of Shanghai Pharmaceuticals Holding in the industry. This year, the rotation training program added a two-week business English training course to Mini-MBA. At the same time, we diversified the establishment of university forums and held a total of 22 "health care and medicine, comprehensive management, and general education and culture" sub-topic forums to enhance the knowledge structure of employees. The interweaving of various training programs effectively empowered the management ability of leaders and the ability of employees to perform their duties, and also enhanced the soft power of those at Shanghai Pharmaceuticals.

The Company solidly promoted the "young geese growth partnership program" and provided new graduates with guides acted by excellent league cadre, so as to accompany the "young employee" in growth during the one-year growth partnership period and help them change from a good student to a good employee.

Upon approval of Shanghai Municipal Human Resources and Social Security Bureau, the Company set up "Continuing Education Base of Medical Professional and Technical Personnel in Shanghai", for knowledge updating and continuing education of medical professional and technical personnel. Affected by the epidemic this year, the Company changed the "professional subjects" continuing education from offline training to online training and opened more than ten professional training courses to provide professional knowledge and policies from different fields; cooperated with the National Food and Drug Administration and other government departments to use the Internet to held advanced seminars on "Knowledge Update Course-New Drug Law Implementation and Policy Interpretation"; assisted various industry associations and enterprises to carry out "professional subjects" (optional courses) guidance and training.

The Company has been one of the key companies that integrate production and teaching and are nurtured by the national government. It has actively advanced the building of high-skill talents and formed a relatively sophisticated skill and talent development system. In 2020, the Company continued to hold continued training for technicians. Through continuous systematic training and master instructing apprentice, a number of leading skilled personnel with exquisite craftsmanship and working in the frontline emerged in the Company. In particular, eight persons were selected as "Shanghai Craftsmen".

The Company continuously pays attention to the training of high-skilled talents. It organized the "2020 Group Vocational Skills Competition" and participated in the second "Shanghai 'Four Brands' Vocational Skills Competition" and "Shanghai Service, Shanghai Manufacturing" special competition, including a total of 5 categories: pharmaceutical preparation workers (intermediate level), pharmaceutical preparation workers (advanced level), drug inspectors (intermediate level), drug inspectors (advanced level) and chemical synthesis pharmaceutical workers (advanced level). 231 contestants from 28 companies under the Group (including 9 companies outside Shanghai) signed up for the competition. Before the competition, the Company carried out targeted theoretical training and operational training for the contestants. For the first time, the scope of the competition has expanded from companies in Shanghai to companies outside Shanghai. The number of participating companies and contestants hit a record high, and the contestants showed a trend of higher education and younger age. Through the skill competition, we have enhanced training and practice through competition, continuously improved the skill level of front-line employees, and trained a team of highly skilled talents who are good at learning and innovation, providing talent support for the development of Shanghai's biomedical industry.

Facts and Data

89
learning programs in total

732 hours
of training in total

3614
participants



Case | Shanghai Pharmaceuticals and East China University of Science and Technology launched the "Education Poverty Alleviation, Motivation & Morality" program.

To respond to the spirit of President General Secretary Xi's speeches - "it is better to teach one the skill of fishing than to offer him fish. As poverty alleviation requires the support of education, it is necessary to help the children in poverty areas receive good education", and to further implement the special plan of the State Council on expanding the implementation of targeted enrollment in rural poverty areas, Shanghai Pharmaceuticals has actively participated in the "Education Poverty Alleviation, Motivation & Morality" program of East China University of Science and Technology since October 2015. The two parties signed the agreement concerning "Shanghai Pharmaceuticals Motivation & Morality Class", and set up the plan for "Scholarships of Shanghai Pharmaceuticals Young Geese Motivation & Morality Class". Since 2019, the number of students receiving scholarships and the amount of scholarship and allowance have increased. The Company hopes that through donations, it can help more students to build confidence in self-improvement and success.

In the past five years, under the united care of Shanghai Pharmaceuticals and school leaders, the number of students of Motivation & Morality Class has grown from 42 in 2014 to 230 in 2020, and the total number of students has reached 794, covering all majors in the university. Through their own efforts, some the students completed their undergraduate studies. Among them, 61 students obtained a master's degree, and 3 were recruited into Shanghai Pharmaceuticals. Over the past five years, 60 students obtained the "Scholarships of Shanghai Pharmaceuticals Young Geese Motivation & Morality Class"; 140 students obtain allowance.

In the past five years, the "Shanghai Pharmaceuticals Inspirational Mingde Club" was established under the name of Shanghai Pharmaceuticals. At the beginning of its establishment in 2016, it had only 42 members. After three re-elections, it has developed into a club with 794 members. The club is self-managed by the students, and has organized various cultural and sports and career consulting activities that are beneficial to physical and mental health. Shanghai Pharmaceuticals organized some alumni of East China University of Science and Technology to participate in the "Dragon Boat Invitational Tournament of Shanghai Pharmaceuticals Motivation & Morality Class" for three consecutive years, to play against the students of Motivation & Morality Class. To help these students fit into enterprises as soon as possible and learn more about the society, Shanghai Pharmaceuticals has organized nearly 100 students of Motivation & Morality Class to participate in its summer social practice activities for three consecutive years.

Over the past five years, the poverty alleviation programme of Shanghai Pharmaceuticals and East China University of Science and Technology organized various student-aid and social practice activities, which ignited the students' dreams of "Unwilling to Mediocrity" in their studies and helped them build self- confidence in study and ceaseless self-improvement, opening up a new chapter in the cooperation the between schools and enterprises in promoting "education poverty alleviation, cooperation in education".

IV | Health and Safety

Occupational health

The Company strove to achieve the work objective of 5 100% in occupational health management (100% report rate and detection rate of occupational hazardous factor, 100% notification rate of post occupational hazard, 100% physical examination rate and 100% training rate), and realized full coverage of occupational hazard management， ensuring that the Company had no occurrence of occupational diseases throughout the year.

The Company further promoted the occupational health infrastructure construction, inspected and urged the production enterprises involving occupational disease hazard factors to control and eliminate the hazard factors at the source, and improve and replace obsolete production equipment.

To improve the safety of production facilities, and improve the working condition, all enterprises increased their safety input, and improved and replaced obsolete production equipment. The investment holding company continued to worked out rectification and transformation plan in advance for the elimination of obsolete equipment that was expressly stipulated by the state, so as to make timely preparations and track the progress.

Case 1

Zhongxi Pharmaceutical installed two online monitors for dust in the production posts of hydroxychloroquine sulfate tablets in the granule room 1 of solid preparation M4 workshop to monitor the dust concentration in real time. This is the first unit in the group to monitor the dust in the workplace online. When the equipment exceeds the set limit, an alarm is triggered and corresponding measures can be taken in time to ensure that the dust concentration in the production environment is effectively controlled, and the data can be queried and summarized through a remote access channel, allowing a more intuitive observation of the data trend. The total investment is RMB0.085 million.

Case 2

Jinjin Pharmaceutical, a subsidiary of SPH Sine, has added VOCs treatment facilities to the thio workshop, laboratory and fine baking package respectively, with a total investment of RMB4 million.

Case 3

The assembly line packaging posts of cephalosporin preparation workshop of the New Pioneer Pharmaceutical Factory reduced noise by using inkjet printing with a total investment of RMB0.57 million. New Asiatic Pharmaceutical Factory achieved automation in wastewater treatment, achieved automatic monitoring in refrigeration equipment, reduced labor intensity with a total investment of RMB0.5 million.

Production safety

In accordance with Production Safety Law and relevant laws and regulations, the Group continued to enhance the work safety responsibility system to control the risk of work safety accidents. The Company has implemented the principle of "party organization and administration should bear the same responsibility, and a person on the single position should bear double responsibilities. Concerted efforts should be made to control jointly. Those who have performed their duties will not be held liable, while those who have not will be held accountable" . The Company aims to fully implement the principle both vertically and horizontally. The Company ensures that safety work and operational work are planned, deployed, implemented, examined and assessed concurrently.

The Company has established a set of Work Safety Management Norms and Systems, continued to develop a safety production management system to improve the level of safety standardization. To achieve the work objective of "no serious production safety accidents, no significant fire and explosion accidents, no largely responsible major traffic accidents, no major occupational hazard accidents and less serious injury accident and general accidents", the Company organized education programs regarding production safety to increase employees' safety knowledge and conducted safety risk evaluation and inspection to responsively spot and eliminate safety risks.

On January 6, 2020, the President of Shanghai Pharmaceuticals signed a Letter of Responsibilities for Work Safety in 2020 with the general managers of 26 subordinate enterprises, specifying the work safety work objective for each year.

Throughout 2020, the Company and its subordinate units compiled and effectively implemented the "Three-year Action Plan for Special Remediation of Production Safety" in accordance with the requirements of the Municipal Safety Commission Office, the State-owned Assets Supervision and Administration Commission and higher-level companies. The Company further proceeded with the arrangement of "double prevention by safety risk classification and hazard treatment" , and key tasks including the special treatment projects "limited space" , "idle workshops" , "laboratory hazardous chemicals", "anti-habitual violation" , and "non-flame retardant colored steel plate" .

Throughout the year, we maintained tight control on key works and improved the safety across the board.

The Company continued to push forward the review of work safety standardization. The production companies subordinate to Shanghai Pharmaceuticals completed the review (preparation) of 12 second-tier companies and maintained standardized and full-scale work safety management.

The Company encouraged enterprises to participate in the contests for demonstration enterprises of safety culture construction in Shanghai and throughout the country. One enterprise (SPH No. 1 Biochemical & Pharmaceutical Co., Ltd.) in Shanghai were awarded national "Demonstration Enterprise of Safety Culture Construction in Shanghai", and two enterprises (Shanghai Hutchison Pharmaceutical Co., Ltd. and Shanghai Sine Tianping Pharmaceutical Co., Ltd.) in Shanghai were awarded Shanghai "Demonstration Enterprise of Safety Culture Construction in Shanghai".

In 2020, a total of 71 enterprises organized various exercises (including 23 complex exercises and 48 special exercises), involving about 16,000. Such exercises improved employees' emergency response capability and safety awareness.

V | Employment and Labour Standards

According to the requirements of the Labor Contract Law of the People's Republic of China and local labor laws, regulations and policies, Shanghai Pharmaceuticals recruited employees according to job requirements on the basis of impartiality and fairness and did not discriminate employees because of their gender, age, disease and race; the Company paid social insurance and other statutory benefits for all regular employees in a timely and fixed manner; the Company granted statutory holidays and paid leave to employees according to regulations to protect their leave entitlements; Shanghai Pharmaceuticals had always insisted on legitimate employment and was not involved in use of child labor or forced labor.

Key indicators



Work safety accidents or work-related accidents in the year

Unit: accident

There was a safety production accident involving two deaths in a holding company outside Shanghai, and the rest were minor and minor injuries.



Safety education and training

times | Total headcount



Health Supervision and Safety and replaced

Unit: RMB0'000



Incidence rate of occupational diseases

Unit: %

2020 is the selection year for model workers. Through the selection of enterprises and the democratic process and after the examination by the All-China Federation of Trade Unions and the Municipal Federation of Trade Unions, Bi Linli of Shanghai Huayu Pharmaceutical was awarded the honorary title of National Model Worker in 2020; 11 people including Xia Guangxin of SPH Research Institute, Ding Jingguo of SPH No. 1 Biochemical and Pharmaceutical and Maimaiti Aili of Shanghai Pharma were awarded the honorary title of Shanghai Model Worker; SPH Zhongxi hydroxychloroquine sulfate workshop, SPH Sine information center and SPH Zhonghua pill manufacturing group were awarded the honorary title of Shanghai Model Collective.

National Model Worker

Bi Linli, a person who can identify all kinds of herbs

Beverage tablet quality officer of Shanghai Huayu Pharmaceutical Co., Ltd.

She is determined to inherit the culture of Chinese medicine for the benefit of the people.

For twenty-six years, she has been working in the field of Chinese herbal medicine identification, and has developed the skills of "touch, see, taste, smell" for accurate identification of herbs.

For twenty-six years, she has treated every herbal identification with professionalism, dedication and selfless devotion.

She is the pride of the master, the mentor of the apprentice, the leader of the team, the master in the eyes of her peers, and the model of the times in the hearts of the public. She is Bi Linli, a person who can identify all kinds of herbs.

Shanghai Model Worker

Xia Guangxin, persistent explorer of new drug research and development

Vice President of Central Research Institute and Technical Director of Drug Design of Shanghai Pharmaceuticals Holding Co., Ltd.

He indulges in thousands of experiments, detects the subtle changes of each molecular formula with rigorous concentration, builds the ladder of drug candidates to clinical trials with innovative thinking, and defines the meaning of summer and winter with hard work and perseverance.

By thinking and researching, denying and trying, Xia Guangxin is always exploring the shimmering light for public health and finding the fulcrum for the rhythm of life in the ocean of scientific research based on his professional field.

Shao Qi, innovator in inhalation formulation research

Assistant Director of Pharmaceutical Research Institute and Director of Inhalation Formulation Research and Development of SPH Sine Pharmaceutical Factory Co., Ltd.

Breathing is our innate instinct and we will not stop for a moment.

There is such a young researcher in SPH Sine. With his dedication and love for the R&D of inhalation drugs, he has interpreted the continuous "breathing" with his conscientious work attitude.

He has been working hard for ten years in order to learn new knowledge and develop safe, effective and high-quality inhalation drugs. His dream is to give every patient with respiratory disease a breath of fresh air.

Li Yuexiong, the artisanal guardian of wild ginseng germplasm resources

Deputy General Manager of Shanghai SPH Shenxiang Health Pharmaceutical Co., Ltd.

He has been studying ginseng for 30 years and has developed extraordinary sensory skills to distinguish the true from the false.

He is the guardian of the sacred herbs, setting standards and building bases to guarantee the quality traceability.

He is a craftsman and an innovator, helping Chinese medicine culture to go abroad and show a new presence.

He sticks to his original intention and passes on his skills to promote the national quintessence and spare no efforts to teach.

He is Li Yuexiong, the exemplary person who is committed to developing traditional Chinese medicine and has a heart for the enterprise and the artisanal guardian of wild ginseng germplasm resources.

Chen Long, the inheritor of antibiotic preparation

Deputy General Manager of New Pioneer Pharmaceutical Factory of Shanghai SPH New Asiatic Pharmaceutical Co., Ltd.

He is committed to pharmaceuticals, taking the protection of people's health as his mission; he is dedicated to his work and is making progress on the road of pharmaceuticals.

For 15 years in the industry, he has adhered to the original intention of passing on the antibiotics to others and practiced the rigorous spirit of pharmaceutical people. Being good at discovering, he pays attention to every detail, does not let go omissions, does not miss the node; being good at creation and action, he implements every technical reform, overcomes every technical difficulty, makes bold innovation and seeks evidence rigorously. He is the "antibiotic inheritor" - Chen Long

Leader in lean management - Sun Hua

Deputy General Manager of Shanghai Pharmaceuticals Holding Co., Ltd.

She has been dedicated to SPH for dozens of years, "only making progress" - taking up heavy burdens, making achievements for others and for the team.

Being dedicated and responsible, she is the leader of risk prevention and control; being dedicated and perfection-seeking, she is the founder of the industry benchmark refined operation system; being visionary and wise, she is the model of nationalization and operation integration of the company.

She is Sun Hua, "leader in lean management".

Maimaiti Aili, the traveler who pursues dreams around the world

General Manager of International Headquarters of Shanghai Pharmaceuticals Holding Co., Ltd.

Crossing half of the world and stepping over the yellow sand, he came from Tianshan Mountain and headed for Sudan, just like a young boy. Under his innovation, he has promoted the localization process of Chinese pharmaceutical enterprises in Africa; in the midst of joint growth, he has brought together the staff and culture of China and Sudan. Faced with the pandemic, he led the international headquarters to complete the global procurement of anti-pandemic materials with quick determination and family sentiment, giving a new light to the "Sudanese spirit" in the fight against the "pandemic".

Pu Yuting, Senior Pharmacist of drug retail terminal

Regional Manager and General Store Manager of Shanghai Huashi Pharmacy

She serves the people at the front line of drug retailing.

Eighteen years of perseverance have ignited the fire in her heart.

She always faces customers with a smile

She always treats her exertion as honey water

She always treats pharmacy as a small home

Focusing on the field of pharmaceutical sales, she adheres to the value of "proud of service"

She is Pu Yuting, "Senior Pharmacist of Drug Retail Terminal"

Li Xueqin, pioneer of precise academic marketing of drugs

Psychoneurological products group, Shanghai Pharma Sales Co., Ltd. Deputy Director and Eastern Region Manager of Psychoneurological Products Group

She is deeply involved in the front-line market, holding on to her beliefs strictly.

Over the years, she has been working around the clock to open up the territory and build up the network. With tough courage and clear goals, she has perfectly completed the tasks given by the company.

Over the years, with professionalism, dedication and keen insight, she has impressed customers with sincerity and persistence, dug deep into the potential market, and built a firm foundation for the development of the company.

She is Li Xueqin, "pioneer of precise academic marketing of drugs".

Chen Yuanyuan, pioneer in marketing

Manager of Respiratory Business Department of Sine United Business Division, Shanghai Sine United Medicinal Herbs Co., Ltd.

It is his goal to realize the dream of ten billion of Sine in a century.

With twelve years of perseverance, he has fought on the front line of marketing and is able to handle different fields and different businesses with ease and comfort.

With twelve years of precipitation, rooted in the creation of marketing culture, he is diligent in thinking, brave to explore and grows into the backbone of the business front.

He is the screw of the enterprise. He is the "source of power" of the marketing organization. He is a red flag of the business front and our "marketing pioneer"

Wang Ping, Inheritor of Shanghai-style Chinese medicine processing

Secretary of Branch, Deputy General Manager, Director of Technical Center of Shanghai Dehua State Medicine Products

He is determined to devote himself to the cause of traditional Chinese medicine and has been devoted to the work of Chinese medicine processing for thirty-five years. He is dedicated to the research of traditional processing process and quality standard of Chinese medicine tablets. He inherits without fear of difficulty, inherits without sticking to the old-fashioned methods, and inherits and innovates the technique of Chinese medicine processing.

He always takes inheritance and promotion as his responsibility and insists on inheriting and innovating the process, which is always his thought and pursuit. He is the caring person and leader of the staffs, the good teacher and friend of the students and apprentices and the expert and scholar recognized by his peers. He is Wang Ping, known as the inheritor of our Shanghai-style Chinese medicine processing.

Shanghai Model Collective

The united and practical production team of special API

- SPH Zhongxi Hydroxychloroquine Sulfate Workshop

Established in October 2008, it is responsible for the production of hydroxychloroquine sulfate, the main API of the company. It currently has 32 employees, including 14 with college degree or above and 1 intermediate engineer.

The production workshop of hydroxychloroquine sulfate, located on the shore of Hangzhou Bay on the East China Sea, is committed to forge ahead, persistently strive to make products more refined and bigger; "patient first, integrity first, seek excellence, create value" is their noble enterprise spirit; they make courageous research, innovation and stick to high standards, strict requirements; they are dedicated to growing the company and they are determined to get through thick and thin with the company.

The inheritance and innovation team of the 100-year "Dragon & Tiger" Panacea

- The pill manufacturing team of the first workshop of SPH Zhonghua

The team, consisting of 16 employees, is a team of post-80s and post-90s who are full of energy and dare to fight hard. It is the key front-line team for the production of the company's fist product, "Dragon Tiger" Panacea

With the "Dragon & Tiger Spirit" of never giving up, pursuing excellence and daring to break through, they have added countless bright performance to the Chinese old-fashioned products.

They are the backup force of the talent pool of SPH Zhonghua. With the "craftsmanship" of determination, practicality and excellence, they have cultivated many craftsman talents to help the development of the enterprise.

They crack the development problem with honest labor and polish the national brand with scientific labor. They are the pill manufacturing team of the first workshop of SPH Zhonghua, the main bearer of the hundred-year inheritance.

The innovation team of intelligent transformation

- SPH Sine Information Center

It currently has 7 technical staffs. It is mainly responsible for the information planning, project construction and implementation of industrial production of SPH Sine. Meanwhile, it guides the informatization work of the subordinate enterprises of SPH Sine.

They contribute their core strengths to achieve a high degree of integration of businesses and informatization.

They understand the importance of their self-development and realize the intersection of informationization theory and manufacturing practice through a deep understanding of pharmaceutical manufacturing intelligence.

As the spearhead of intelligent transformation and innovation, each member holds the determination make SPH manufacturing information-based and continuously challenges themselves during the project implementation and accomplishes disruptive innovations in new models, new applications, new technologies and new services.

"Master of Craftsmanship" of Shanghai Pharmaceuticals Holding

In 2020, the Group's labor union started the "Master Craftsman" training and selection work. The first batch of the Group's "Master Craftsman" will be selected among employees in "R&D, manufacturing" and other positions, favoring front-line employees. Recommended by the trade unions of various enterprises, through expert review, review defense and other procedure, 22 comrades including Shang Ding from SPH New Asia Pharmaceutical Co., Ltd. were named "Master Craftsman" of Shanghai Pharmaceuticals Holding in 2020, and 7 comrades including Zhang Xiongyi from Shanghai Leiyunshang Pharmaceutical Co., Ltd. who have been awarded the Shanghai Craftsman were name "Master Craftsman" of Shanghai Pharmaceuticals Holding in 2020.

In accordance with the requirements of the Shanghai Federation of Trade Unions, the Company continued to implement the insuring and claim settlement of Shanghai Trade Union Membership Service Cards. In 2020, more than 19,600 members participated in the insurance, accounting for 97.03% of the total number of corporate members in Shanghai. The trade union of Shanghai Pharmaceuticals Holding paid nearly RMB1.9 million in security money. By the end of 2020, 34 members have received RMB0.02 million per person for serious illness insurance claims, 7 have received illness and death claims, receiving a total of RMB0.75 million in claims. The claims of others are under review.

In 2020, in order to further implement the spirit of the Central and Municipal Federation of Trade Unions to help alleviate poverty, highlight the service concept of "inclusive assistance to the poor + preferential assistance to patients" , and continue to implement the "Love and Assistance" plan, Shanghai Pharmaceuticals provided compensation for claims to members who had received the exclusive protection plan of the Shanghai Federation of Trade Unions Membership Service Cards at a 1:1 ratio, and assisted members' self-payment portion of personal medical expenses and self-payment portion of categories with a proportion of 70-80%. In 2020, the Company reviewed and compensated 32 members who had applied, with the compensation exceeding RMB0.5875 million. Such compensation significantly reduced financial burdens of patients with critical illness and improved their lift quality.

In 2020, Shanghai Municipal General Trade Union continued to implement the municipal government's key relief project – "Love Stations for Outdoor Employees" . Shanghai Huashi Pharmacy Co., Ltd. has made improvements to the hardware "6+X" configuration and facilities of its 40 "Love Stations for Outdoor Employees". The trade union of Shanghai Pharmaceuticals Holding allocated RMB0.1 million to the Fahrenheit Pharmacy for the designated use. In response to the outbreak of the COVID-19 epidemic in 2020, the Group has overcome the shortage of supply of anti-epidemic supplies such as masks and disinfectants, and tried every means to purchase them and distribute them to some outdoor employees for free.

And bought summer and winter supplies for the total of 40 stations, thereby ensuring that outdoor employees can deliver services in good environment and under sound protection. Statistics show that each station has provided services for more than 37,000 outdoor workers in 2020. The 40 stations have been highly rated in the unannounced inspections and topical inspections that were conducted by the Shanghai Municipal General Labour Union-commissioned third parties and district general trade unions.

In 2020, 2 new "love cabins" were built, sending the total number of the Group's "love cabins" to 38. This enhanced the soft power of those at Shanghai Pharmaceuticals.

Facts and Data

2

new "love cabins" built in 2020

38

"love cabins" of the Group in total

Key indicators:

1. Total



On-post employees
Unit: person



Other employees
Unit: person



Total
Unit: person

2. Sex composition



Male
Unit: person



Female
Unit: person

2. Age composition



2. Education composition



Doctor degree
Unit: person



Master degree
Unit: person



Bachelor's degree
Unit: person



Higher vocational college
Unit: person



Technical secondary
Unit: person



Others
Unit: person

2. Employee structure



Unit: %





3. Efficiency indicator



Per capita sales income
Unit: 0'000



Total per capita profit
Unit: 0'000

6.3 Environmental protection and energy conservation

I Health and Safety

On January 6, 2020, 20 directly-controlled units of Shanghai Pharmaceuticals signed the Statement of Responsibility on Environmental Protection Work for 2020 on the meeting of the Safe Production and Environmental Protection Committee of Shanghai Pharmaceuticals. Managers of the 20 units signed the statement, promising that they will fulfill the annual environmental protection targets set by the Group as well as other unit-specific environmental requirements. During the year, Shanghai Pharmaceuticals finished the audit and assessment on all signatory units. Those with outstanding performance were recognized and rewarded.

In 2020, Shanghai Pharmaceuticals continued to strengthen the awareness of corporate self-responsibility to encourage enterprises to actively carry out independent management and self-examination and self-correction. At the beginning of the year, the subordinate enterprises were required to compile an annual key work plan for environmental protection in accordance with the Group management requirements and the actual needs of enterprise, and gradually implemented various key environmental protection tasks in accordance with the plan requirements.

In accordance with the work requirements for 2020, the Group revised the its "Basic Environmental Protection Work Requirements for Enterprises" (Article 111), adding new requirements for standardization of pollution prevention and control facilities and "Sing-Table" environmental management work, which were revised as Article 112 after the merger. At the beginning, middle and end of the year, the Group required all companies to find gaps in accordance with the "Basic Environmental Protection Work Requirements for Enterprise" in stages. Through the continuous self-inspection and self-correction of enterprises, not only the existing problems can be found in time, and the problems found can be solved in time, but also the self-inspection and self-correction ability of the enterprises can be continuously enhanced, and the environmental management level of the enterprises can be improved.

The COVID-19 epidemic broke out in early 2020. Due to the needs of epidemic prevention and control, the Spring Festival holiday was longer this year. After February 10, companies began to resume work and production. On February 8, before the resumption of work and production, the Group issued the "Environmental Protection Precautions for the Resumption of Work and Production of Enterprises", requiring companies to ensure the normal operation of corporate pollution prevention facilities. At the same time, the environmental management departments of the enterprises must inspect the pollution prevention and control facilities of the enterprises once a day in the early stage of the resumption of work, and solve the problems in time and make records. All units strengthened environmental management before and after the resumption of work and production, to ensure the normal operation of pollution prevention facilities, with pollution discharge always meeting the standards.

In accordance with the document requirements of the Ministry of Ecology and Environment's "Notice on Carrying out the Cleanup and Rectification of Pollutant Discharge Permits for Stationary Pollution Sources and the Registration of Pollutant Discharge Permits in 2020", the nationwide pollutant discharge permit issuance was completed before September 30.



On February 4, 2020, the Group issued the "Notice on Applying for Pollutant Discharge Permits in 2020"， which required that the pollutant discharge units that have not obtained the national pollutant discharge permit and have been included in the "Classification Management List for Pollutant Discharge Permits from Fixed Pollution Sources (2019 Edition)" shall apply for and obtain the national pollutant discharge permit or complete the pollutant discharge registration and filing before September 30, 2020. All units have completed the application for pollutant discharge permits before September 30 in accordance with the requirements of the Group. In order to do a good job in management after obtaining the pollution permit, the Group issued the "Notice on Post-Pollution Discharge Permit Management Work" on October 12, requiring pollutant discharge units to do a good job of permit management in 10 aspects, implement main responsibilities, standardize pollutant discharge behavior, and comply with legal requirements, so as to promptly change the pollution permit when there is a change, complete implementation report and self-monitoring and environmental management files, discharge according to the permit, and prove compliance with the law.

In 2019, the Group released the "Management Requirements for Standardization of Pollution Prevention and Treatment Facilities". To strengthen the management of corporate pollution prevention facilities, the Group issued the "Notice on Further Strengthening the Operation and Management of Pollution Prevention Facilities" on April 2, 2020, requiring all units to strictly implement the eight work requirements and comprehensively revise the enterprise's "Operational Regulations for Pollution Prevention and Control Facilities". For existing pollution prevention facilities that do not meet the "Management Requirements for Standardization of Pollution Prevention and Treatment Facilities", a rectification plan should be formulated and the rectification should be completed within 2020. All units have fully completed the revision of the "Operational Regulations for Pollution Prevention and Control Facilities", managing to have special operating procedures and operating records for each set of pollution control facilities to ensure that pollution facilities can operate normally in accordance with operating requirements.

In accordance with the requirements of the Ministry of Ecology and Environment, the Group issued a group document of "Notice on the Promotion of Environment Day of 2020 by Enterprises" on May 7, requiring companies to carry out various publicity activities during the Environment Day to reflect the theme for the publicity of the Environment Day of "For Beautiful China, I Am a Practicer". The member companies carried out Environment Day publicity activities, and summarized and reported the activities in accordance with the requirements of the Group. The headquarters of the Group carried out the "My Green Dream" Environment Day publicity campaign in which employees of the headquarters express their green aspiration and green hopes.

On August 27, at the Security Line work meeting, the Group released a corporate environmental protection responsibility template, a three-level education PPT template for new employees, a standardization requirement for hazardous waste storage sites, and a PPT template for introduction to corporate environmental management. Enterprises were required to complete the revision of corporate post environmental protection responsibilities, the revision of the three-level education PPT for new employees, and the revision of PPT for the introduction to corporate environmental management in accordance with the requirements of the Group, and implement the standardization and improvement of corporate hazardous waste storage sites. All enterprises have completed and submitted relevant PPT files and other documents in accordance with the requirements of the Group.

The Group makes plans every year to conduct mid-year audits and year-end assessments. Audits and assessments were carried out in accordance with the Group's 112 basic work requirements for environmental management, the Group's environmental management documents issued during the year, and the daily environmental protection tasks. Enterprises were required to report monthly environmental work summary, carry out monthly risk source tracking and inspections, record daily work in 30 singe-table management tables in a timely manner, and complete drills and training in accordance with the requirements of environmental emergency plans. Mid-year audits were conducted on a total of 33 units from June to August, and year-end appraisals were conducted on a total of 20 units from October to December. The problems found in the audits and appraisals were recorded and fed back, and improvement suggestions were put forward to help enterprises continue to improve. Upon considering the work performance of each unit, winning units were selected and granted commendations and rewards.

Shanghai Pharmaceuticals adheres to the path of "green products and green factories". Up to now, 5 subsidiaries of Shanghai Pharmaceuticals have been awarded the title of National Green Factory by the Ministry of Industry and Information Technology, including Shanghai SPH Sine Pharmaceutical Laboratories Co., Ltd., Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd., Shanghai SPH Zhongxi Pharmaceutical Co., Ltd., SPH No. 1 Biochemical & Pharmaceutical Co., Ltd. and Shanghai New Asiatic Pharmaceutical Minhang Co., Ltd.

In order to speed up the process of establishing green factories by Shanghai Pharmaceuticals' subsidiaries, further improve the Group's policy support, form a mechanism for promoting green development of industrial enterprises, help more companies to win the honorary title of National Green Factory, Shanghai Pharmaceuticals organized an event on December 8, 2020 with the theme of "Energy-saving and Emission Reduction to Create Benefit, Green Development for Brighter Future". Shanghai Pharmaceuticals promoted the establishment of a green factory forum in 2020. The purpose of this forum was to introduce advanced energy-saving and emission-reducing green technologies, answer questions in the process of creating green factories, and communicate relevant government green development policies. At the same time, it aimed to commend green factory enterprises and encourage other enterprises to actively create them.

The forum was organized by Shanghai Pharmaceuticals Holding Co., Ltd., and was strongly supported by the Energy Conservation and Comprehensive Utilization Department of the Shanghai Economic Information Technology Commission, the Shanghai Energy Conservation and Environmental Protection Service Industry Association, and the Shanghai Green Industry and Industrial Development Promotion Association.

Ruan Li, deputy director of Shanghai Municipal Commission of Economy and Information Technology; Lu Yin, director, and Wang Qianqian, deputy director, of Shanghai Energy Conservation and Comprehensive Utilization Division; Zhao Yong, deputy secretary of the Party Committee of Shanghai Pharmaceuticals Holding and vice president of Shanghai Pharmaceuticals; Zhang Yaohua, vice president of Shanghai Pharmaceuticals; Xu Hong, deputy mayor of Waigang, Jiading District; and other leaders attended the meeting. Leaders from Shanghai Energy Efficiency Center, Shanghai Energy Conservation and Environmental Protection Service Industry Association, Shanghai Green Industry and Industrial Development Promotion Association, Shanghai Waigang Industrial Development Co., Ltd., Shanghai Carbon Energy Service Co., Ltd., Shanghai Chemical Industry Research Institute Co., Ltd., Shanghai Guorui Environmental Protection Technology Co., Ltd., Shanghai Wuai Technology Development Co., Ltd., Shanghai Aerospace Smart Energy Technology Co., Ltd., and other unites participated in the forum. Ruan Li, deputy director of the Shanghai Municipal Commission of Economy and Information Technology, represented the Shanghai Municipal Commission of Economy and Information Technology to award licenses to five enterprises that had been awarded the title of National Green Factory by the Ministry of Industry and Information Technology.

Shanghai Pharmaceuticals actively promoted subsidiaries' work of obtaining certification of ISO14001 Environmental Management System. In 2020, 22 drug makers obtained certification of ISO14001 Environmental Management System, which is 5 more than that in 2019.

No.	Name of company
1.	Shanghai SPH Sine Pharmaceutical Laboratories Co., Ltd.
2.	Shanghai Sine Tianping Pharmaceutical Co., Ltd.
3.	Shanghai Harvest Pharmaceutical Co., Ltd.
4.	Shanghai Sine Jinzhu Pharmaceutical Co., Ltd.
5.	Shanghai Sine Wanxiang Pharmaceutical Co., Ltd.
6.	Shandong Sine Pharmaceutical Co., Ltd.
7.	Shanghai SPH New Asiatic Pharmaceutical Co. Ltd. New Asiatic Pharmaceutical Factory
8.	Shanghai SPH New Asiatic Pharmaceutical Co., Ltd., Asia Pioneer Pharmaceutical Factory
9.	Shanghai New Asiatic Pharmaceutical Minhang Co., Ltd.
10.	Liaoning Medya Pharmaceutical Co., Ltd.
11.	SPH No. 1 Biochemical & Pharmaceutical Co., Ltd.
12.	Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd.
13.	Shanghai SPH Zhongxi Pharmaceutical Co., Ltd.
14.	Chiatai Qingchunbao Pharmaceutical Co., Ltd.
15.	Hangzhou Huqingyutang Pharmaceutical Co., Ltd.
16.	SPH Dong Ying (Jiangsu) Pharmaceutical Co., Ltd.
17.	SPH Changzhou Kony Pharmaceutical Co., Ltd.
18.	Changzhou Pharmaceutical Factory Co., Ltd.
19.	Changzhou Wuxin Pharmaceutical Co., Ltd.
20.	Nantong Changyou Pharmaceutical Technology Co., Ltd.
21.	Liaoning SPH Herbapex Pharmaceutical (Group) Co., Ltd.
22.	Techpool Bio-pharma Co., Ltd.





II | Energy management

Shanghai Pharmaceuticals completed annual energy saving goals and tasks, monthly energy statistics and planned water use in accordance with the requirements of Shanghai Municipal Commission of Economy and Informatization, Shanghai Municipal Statistics Bureau and Shanghai Water Authority, passing their annual assessment on its energy saving, statistics, planned water use and so on.

The Shanghai Municipal Commission of Economy and Information Technology conducts annual energy-saving target responsibility assessments for industrial groups to assess the completion of the industrial group's targets of total annual energy consumption and output value energy consumption, and the completion of the industrial group's energy-saving work in respect of energy-saving operation mechanism, energy-saving management of key enterprises, key energy-saving projects, and other aspects. Under the leadership and guidance of the Department of Energy Conservation and Comprehensive Utilization of Shanghai Municipal Commission of Economy and Information Technology, Shanghai Pharmaceuticals was able to complete various energy-saving tasks. Its energy consumption per RMB0.01 million of output value has dropped significantly every year, with a decrease of 10.78% in 2017, 11.82% in 2018 and 5.48% in 2019. In the annual industrial group energy-saving target responsibility assessment of the Shanghai Municipal Commission of Economy and Information Technology, it was rated as over-fulfilling the energy-saving management tasks.

In 2020, the Shanghai Municipal Commission of Economy and Information Technology issued an energy-saving indicator to Shanghai Pharmaceuticals that the annual comprehensive energy consumption shall not exceed 127,000 tonnes of standard coal, and the energy consumption per RMB0.01 million of output value shall decrease year-on-year. In 2020, Shanghai Pharmaceutical Group recorded an annual comprehensive energy consumption of 118,000 tonnes of standard coal, achieving a result beyond the annual energy saving goal set by the Shanghai Municipal Commission of Economy and Informatization.

III | Energy Conservation and Emission Reduction Projects

In 2020, manufacturers subordinate to Shanghai Pharmaceuticals Group continued to increase investment in energy saving and environmental protection. They reduced energy consumption to save energy; and strengthened governance to reduce pollution.

1.Shanghai SPH No. 1 Biochemical and Pharmaceutical Co., Ltd.

In November 2020, the enterprise invested a total of RMB0.5026 million to implement the residue heat recovery project of Building 11, which would be used for air conditioning dehumidification and heating in Building 11. After the project is completed, it is expected to save RMB0.40 million of natural gas annually. The enterprise implemented RO reverse osmosis water recovery for the cooling tower water supply of Building 5 and Building 11, saving 30,000 m^3 of water annually.

2. Shanghai Sunway Biotech Co., LTD.

In November 2020, the enterprise invested a total of RMB0.068 million to improve the exhaust gas tube of the Oncorine workshop to meet environmental protection requirements. It installed a set of activated carbon treatment facilities in the laboratory to collect and treat waste gas in experiments in a centralized manner.

3.Shanghai SPH New Asiatic Pharmaceutical Co., Ltd., New Asiatic Pharmaceutical Factory

In March 2020, the enterprise invested RMB0.192 million in energy-saving renovation of air compressors. It set up a 6 cubic meter air compressor to replace the 12 cubic meter air compressor for production during the night shift to avoid excessive capacity.

In June 2020, the enterprise invested RMB0.29 million to implement the automation transformation project of wastewater treatment equipment. After completion, the project not only improved the efficiency of wastewater treatment, but also saved labor costs and power consumption.



In June 2020, the enterprise invested RMB0.383 million to implement a centralized monitoring system for refrigeration and air-conditioning power. It improved the automation and information level of equipment through transformation, and eliminated potential safety hazards due to insufficient personnel.

4.Shanghai New Asiatic Pharmaceutical Minhang Co., Ltd.

In 2020, the enterprise invested RMB3.82 million to rebuild a sewage treatment station and carry out soil surveys. It improved the level of automation control through the reconstruction of sewage treatment stations, reducing labor intensity and operational risks. Soil surveys confirmed that currently the enterprise's soil was not polluted.

In October 2020, the enterprise invested RMB0.02 million to transform the temporary storage of hazardous waste in accordance with the Group's standardization requirements. It increased the use area of the warehouse, added emergency supplies boxes, electrostatic balls, eye washes, etc.; updated warning signs and hazardous waste signs.





5 Shanghai Zhonghua Pharmaceutical Co., Ltd.

In August 2020, the enterprise invested RMB0.29 million to replace the waste gas treatment equipment in the coating and drying section of the second workshop, and improved the treatment effect and safety through the improvement of the treatment process.

In October 2020, the enterprise invested RMB0.30 million to transform the sewage station, cover the sewage tank and add odor treatment equipment to reduce the odor emission of the sewage tank.

6. Shanghai Sine Wanxiang Pharmaceutical Co., Ltd.

In November 2020, the enterprise invested RMB0.30 million to cover the sewage tank of the company's sewage treatment station and install the waste gas terminal treatment project to reduce the odor emission of the sewage tank.

7. Shanghai Sine Yanan Pharmaceutical Co., Ltd.

In October 2020, the enterprise invested RMB0.46 million in the anti-corrosion treatment of the biochemical sewage tank.

8. Shanghai Leiyunshang Pharmaceutical Co., Ltd.

In April 2020, the enterprise invested RMB0.30 million in the optimization and transformation project of the dust collector. It upgraded the original dust bag filter of the coating machine to a water curtain dust removal device to improve the dust removal effect. It completed joint control operations for water curtain dust removal equipment and coating machine production equipment. The discharge port of the dust collector was equipped with a particulate matter concentration monitoring sensor, and the discharge data was displayed in real time on the production equipment. An early warning would be given when exceeding the standard. The data interface was reserved for the remote monitoring system in the future.




9. SPH Shenxiang Health Pharmaceutical Co., Ltd.

In July 2020, the enterprise invested RMB0.05 million to establish a exhaust gas collection and activated carbon treatment system in the laboratory to ensure that the exhaust gas from experiments always meets the emission standards.

10. Shanghai Huapu Chinese Herbal Medicine Company Limited

In January 2020, the enterprise invested approximately RMB0.80 million to build a sewage treatment station. Through continuous commissioning and optimization, currently the station functions normally, and the discharge of sewage has always met relevant standards.




11. Shanghai Dehua Traditional Chinese Medicines Co., Ltd.

In May 2020, the enterprise invested RMB0.80 million to implement oven automation. The emission of pungent medicinal smell is inevitable during the baking process of traditional Chinese herbal medicines. Through the upgrading of the oven, the baking process is scientifically controlled, reducing the emission of medicine smell.


12.Hangzhou Huqingyutang Pharmaceutical Co., Ltd.

In July 2020, the enterprise invested RMB1.68 million to implement the sewage treatment station renovation project, which improved the sewage treatment capacity.


In July 2020, the enterprise invested RMB40,000 to install 6 sets of activated carbon adsorption devices in the laboratory to realize the compliance treatment of volatile organic compounds.


In November 2020, the enterprise invested RMB0.03 million to install two sets of activated carbon adsorption devices in the medicine frying room to improve the treatment effect.


13.Changzhou Pharmaceutical Factory Co., Ltd.

In April 2020, the enterprise invested nearly RMB0.90 million to add two diaphragm plate and frame filter presses. After treatment, the moisture content of the sludge was reduced to about 60%, and the average annual sludge reduction was 25%, reducing the sludge disposal fee by RMB0.15 million/year.


In April 2020, the enterprise invested RMB0.03 million to install a steam stabilizing system, which re-arranged steam pipelines to reduce pipeline losses, reducing steam consumption from 0.109 tonne per RMB0.01 million to 0.089 tonne per RMB0.01 million, reducing steam consumption by 867 tonnes, and reducing costs by approximately RMB0.3 million.


In April 2020, the enterprise invested RMB0.30 million to add a new set of 30m3/h neutralization and air flotation integrated machine for high-concentration wastewater pretreatment, which can automatically adjust the pH, remove suspended solids and some organic matter in the water, and keep the pH stable at 8-9, with the removal rate of suspended matter greater than 90%, the removal rate of organic matter of about 20%, enabling stabilize the water intake for the subsequent biochemical system, reducing the impact load caused by large fluctuations, and ensuring the stable discharge of the effluent water.

14.Nantong Changyou Pharmaceutical Technology Co., Ltd.

In January 2020, the enterprise invested RMB0.45 million to optimize the exhaust gas treatment system, optimize the collection system of unorganized emissions in the workshop, connect exhaust gas (including anaerobic biogas) from workshop 701, workshop 702 and sewage station to RTO furnace for treatment, and remove the original treatment facilities and exhaust pipes, which reduced the electricity consumption and natural gas consumption of the RTO furnace, saved energy consumption, and improved the production environment of the workshop.

In February 2020, the enterprise invested RMB0.19 million to optimize the energy saving of refrigeration units and circulating water systems. By adopting measures such as using frequency converter for stabilization of water supply, cooling tower fan and water temperature automatic control in the circulating cooling water system, it saved electricity for utilities projects and reduced energy consumption.



IV | Information of key pollutant-discharging units in 2020

After sorting out, the Shanghai Ecological Environment Bureau, Changzhou Ecological Environment Bureau, Nantong Ecological Environment Bureau, Nantong Rudong County Ecological Environment Bureau, Benxi Ecological Environment Bureau, Guangzhou Ecological Environment Bureau and other government administrative departments issued documents confirming the following enterprises of Shanghai Pharmaceuticals as key pollutant discharging units in 2020:

No.	Type of key pollutant-discharging units	Name of key pollutant discharging units
1.	Key water environment pollutant-discharging units	Shanghai SPH No.1 Biochemical and Pharmaceutical Co., Ltd. (Jianchuan Road)
2.		Shanghai SPH No.1 Biochemical and Pharmaceutical Co., Ltd. (Bijiang Road)
3.		Shanghai Ziyuan Pharmaceutical Co., Ltd.
4.		Shanghai Sine Jinzhu Pharmaceutical Co., Ltd.
5.		Changzhou Pharmaceutical Factory Co., Ltd.
6.		Nantong Changyou Pharmaceutical Technology Co., Ltd.
7.		SPH Changzhou Kony Pharmaceutical Co., Ltd.
8.		Liaoning Medya Pharmaceutical Co., Ltd.
9.		SPH Qingdao Growful Pharmaceutical Co., Ltd.
10.		Techpool Bio-pharma Co., Ltd.
1.	Key atmospheric environment pollutant-discharging units	Shanghai SPH No.1 Biochemical and Pharmaceutical Co., Ltd. (Jianchuan Road)
2.		Shanghai SPH No.1 Biochemical and Pharmaceutical Co., Ltd. (Bijiang Road)
3.		Shanghai Ziyuan Pharmaceutical Co., Ltd.
4.		Shanghai SPH Zhongxi Pharmaceutical Co., Ltd.
5.		Changzhou Pharmaceutical Factory Co., Ltd.
6.		Nantong Changyou Pharmaceutical Technology Co., Ltd.
7.		SPH Changzhou Kony Pharmaceutical Co., Ltd.
8.		Shanghai Pharmaceutical Group (Benxi) Northern Pharma Co., Ltd.
9.		Liaoning SPH Herbapex Pharmaceutical (Group) Co., Ltd.
10.		Liaoning Medya Pharmaceutical Co., Ltd.
11.		Techpool Bio-pharma Co., Ltd.

No.	Type of key pollutant-discharging units	Name of key pollutant discharging units
1.	Key soil monitoring units	Shanghai SPH No.1 Biochemical and Pharmaceutical Co., Ltd. (Jianchuan Road)
2.		Shanghai SPH No.1 Biochemical and Pharmaceutical Co., Ltd. (Bijiang Road)
3.		Shanghai Ziyuan Pharmaceutical Co., Ltd.
4.		Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd.
5.		Shanghai Leiyunshang Pharmaceutical Co., Ltd.
6.		Changzhou Pharmaceutical Factory Co., Ltd.
7.		Nantong Changyou Pharmaceutical Technology Co., Ltd.
8.		Techpool Bio-pharma Co., Ltd.
1.	Key Regulatory Units for Hazardous Waste(This type is identified in the "Notice on Printing and Distributing the List of Key Pollutant Discharge Units in Shanghai in 2020" issued by the Shanghai Ecological Environmental Protection Bureau)	Shanghai SPH No.1 Biochemical and Pharmaceutical Co., Ltd. (Bijiang Road)
2.		Shanghai Ziyuan Pharmaceutical Co., Ltd.
3.		Shanghai SPH No.1 Biochemical and Pharmaceutical Co., Ltd. (Jianchuan Road)
4.		SPH New Asia Pharmaceutical Co., Ltd.
5.		Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd.

(I) Pollutant discharge information

All key pollutant-discharging units of Shanghai Pharmaceuticals obtained national pollution discharge permits and did a good job in information disclosure, environmental monitoring, ledger management, and executive report, etc., in accordance with pollution discharge permits so as to ensure normal operation of pollution control facilities and stable and up-to-standard pollutant discharge, and complete in time various tasks assigned by the local ecology and environment departments. According to the general statistical principles, the data were rounded to the second digit after the decimal point or, if the two digits after the decimal point are zero, the third digit after the decimal point.

In order to unify the disclosure criteria, the key pollutant discharging units of the water environment disclosed indicators of COD, ammonia nitrogen; key pollutant discharging units of the air environment disclosed indicators of sulfur dioxide, nitrogen oxides, volatile organic compounds (VOCs), particulate matter, and another pollutant with the largest emissions; and key pollutant discharging units of soil and other pollutants disclosed indicators of COD and ammonia nitrogen. The pollution discharge standard is determined in accordance with the environmental assessment of the construction project of the enterprise or the description of the pollution discharge permit.

No.	Name of key pollutant discharging	Name of key pollutants	Discharge mode	Discharge condition	Discharge concentration Waste water (mg/L), exhaust gas (mg/m3)	Total discharge amount (tonne)	Excessive discharge	Implemented standards for discharge of pollutants	Approved total amount of discharge (tonne)
1	Shanghai SPH No.1 Biochemical and Pharmaceutical Co., Ltd. (Jianchuan Road)	COD	Interval	Main waste water outlet	41.85	2.76 (including discharge of raw materials and preparations)	Nil	Discharge Standards of Pollution of Biopharmacy Industry (DB31/373-2010)	0.75（Contains only the total amount of raw materials discharged, the pollution discharge permit is being changed）
		Ammonia nitrogen			1.21	0.08(including discharge of raw materials and preparations)	Nil		0.06（Contains only the total amount of raw materials discharged, the pollution discharge permit is being changed）
		SO2	Continuous	Exhaust gas outlet	0	0	Nil	Emission Standard of Air Pollutants for Boilers (DB31/387-2014)	0.6
		Particulate matter			2.03	0.12	Nil		0.57
		NOx			33.37	2.67	Nil		11.48
		Volatile organic compound (VOCs)	Interval	Exhaust gas outlet	6.52	0.32	Nil	GB37823-2019Emission Standard of Air Pollutants for the Pharmaceutical Industry Table 2)	1.25
		Ammonia	Interval	Exhaust gas outlet	0.56	0.05	Nil	Emission Standards for Odor Pollutants	/
1	Shanghai SPH No.1 Biochemical and Pharmaceutical Company, Ltd. (Bijiang Road)	COD	Interval	Main waste water outlet	30.84	0.44	Nil	DB31/199-2018 Comprehensive Discharge Standards on Sewage Table 2	20.06
		Ammonia nitrogen			0.35	0.005	Nil		1.82
		SO2	Continuous	Exhaust gas outlet	0	0	Nil	Emission Standard of Air Pollutants for Boilers (DB31/387-2014)	0.05
		Particulate matter			1.1	0.01	Nil		0.09
		NOx			35.58	0.2	Nil		1.59
		Volatile organic compound (VOCs)	Interval	Exhaust gas outlet	12	1.72	Nil	GB37823-2019Emission Standard of Air Pollutants for the Pharmaceutical Industry Table 2)	10.3
		Ammonia	Interval	Exhaust gas outlet	0.53	0.05	Nil	Emission Standards for Odor Pollutants DB31/1025-201	/

No.	Name of key pollutant discharging	Name of key pollutants	Discharge mode	Discharge condition	Discharge concentration Waste water (mg/L), exhaust gas (mg/m3)	Total discharge amount (tonne)	Excessive discharge	Implemented standards for discharge of pollutants	Approved total amount of discharge (tonne)
2	Shanghai Ziyuan Pharmaceutical Co., Ltd.	COD	Interval	Main waste water outlet	116.75	0.91	Nil	Comprehensive Discharge Standards on Sewage (DB31/199 - 2018)	/
		Ammonia nitrogen			16.58	0.13	Nil		/
		SO2	Continuous	Exhaust gas outlet	0	0	Nil	Emission Standard of Air Pollutants for Boilers (DB31/387-2018)	0.036
		NOx			45.55	0.067	Nil		0.068
		(smoke) PM			1.85	0.004	Nil		0.009
		Volatile organic compound (VOCs)	Interval	Exhaust gas outlet	29.22	0.71	Nil	Comprehensive Emission Standard of Air Pollutants (DB31/933-2015)	0.72
		Toluene			0.023	0.0005	Nil		/
3	Shanghai SPH Zhongxi Pharmaceutical Co., Ltd.	COD	Continuous	Main waste water outlet	36.64	3.49	Nil	Comprehensive Discharge Standards on Sewage (DB31/933-2015)	23.76
		Ammonia nitrogen			2.69	0.26	Nil		1.09
		SO2	Continuous	Exhaust gas outlet	ND	0	Nil	Emission Standard f Air Pollutants for Boilers (DB31/387-2018)	0.44
		NOx			25.56	1.07	Nil		3.87
		Volatile organic compound (VOCs)			5.32	0.24	Nil	Emission Standard of Air Pollutants for the Pharmaceutical Industry (GB37823-2019)	0.31
		Particulate matter	Interval		1.78	0.21	Nil		1.07
4	Shanghai Sine Jinzhu Pharmaceutical Co., Ltd.	COD	Continuous	Main waste water outlet	25	4.33	Nil	Comprehensive Discharge Standards on Sewage (DB31/199-2018)	7.21
		Ammonia nitrogen			0.11	0.02	Nil		0.11
5	Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd.	COD	Continuous	Main waste water outlet	37.85	2.23	Nil	Comprehensive Discharge Standards on Sewage (DB31/199-2018)	30.80
		Ammonia nitrogen			7.39	0.43	Nil		0.54
6	Shanghai SPH New Asiatic Pharmaceutical Co., Ltd. (New Asiatic Pharmaceutical Factory)	COD	Interval	Main waste water outlet	35.33	7.78	Nil	Comprehensive Discharge Standards on Sewage (DB31/199 - 2018)	9.55
		Ammonia nitrogen			2.76	0.61	Nil		2.74
7	Shanghai Leiyunshang Pharmaceutical Co., Ltd.	COD	Continuous	Main waste water outlet	49.82	7.59	Nil	Comprehensive Discharge Standards on Sewage (DB31/199 - 2018)	19.48
		Ammonia nitrogen			4.35	0.66	Nil		4.86
8	Changzhou Pharmaceutical Factory Co., Ltd.	COD	Interval	Main waste water outlet	177	27.94	Nil	As per the takeover contract with the Changzhou Southeast Industrial Wastewater Treatment Plant Co. Ltd.	78.91
		Ammonia nitrogen			1.58	0.25	Nil		3.16
		Volatile organic compound (VOCs)		Exhaust gas outlet	0.79	0.14	Nil	Emission Standard of Air Pollutants for the Pharmaceutical Industry GB37823-2019	40.99
		Particulate matter		Exhaust gas outlet	9.05	0.42	Nil		45.98
		Methanol		Exhaust gas outlet	5.25	0.297	Nil		/

No.	Name of key pollutant discharging	Name of key pollutants	Discharge mode	Discharge condition	Discharge concentration Waste water (mg/L), exhaust gas (mg/m3)	Total discharge amount (tonne)	Excessive discharge	Implemented standards for discharge of pollutants	Approved total amount of discharge (tonne)
9	Nantong Changyou Pharmaceutical, Ltd.	COD	Interval	Main waste water outlet	200	22.54	Nil	As per the takeover contract with the Rudong Deepwater Environmental Technology Co., Ltd.	76.19
		Ammonia nitrogen			3	0.34	Nil		5.51
		Volatile organic compound (VOCs)		Exhaust gas outlet	20	2.25	Nil	Emission Standard of Air Pollutants for the Pharmaceutical Industry GB37823—2019	15.93
		Particulate matter			Not detected	/	Nil		0.13
		Ammonia			1	0.06	Nil		/
10	SPH Changzhou Kony Pharmaceutical Co., Ltd.	COD	Interval	Main waste water outlet	41	2.05	Nil	As per the takeover contract with Jiangsu Dayu Water Co., Ltd. (Wunan Sewage Treatment Plant)	22.34
		Ammonia nitrogen			0.43	0.02	Nil		1.56
		SO2	Interval	Boiler main waste water outlet	0	0	Nil	Emission Standard of Air Pollutants for Boilers （GB13271-2014）	Nil
		NOx			17.27	0.17	Nil		
		Particulate matter	Interval	Main waste water outlet	0	0	Nil		
		Volatile organic compound (VOCs)			7.71	0.17	Nil	Emission Standard of Volatile Organic Compounds for Chemical Industry (DB32/3151-2016)	7.68
		Methanol	Interval	Main waste water outlet	1.86	0.07	Nil	Emission Standard of Air Pollutants （GB16297-1996）	1.15
11	SPH Qingdao Growful Pharmaceutical Co., Ltd.	COD	Interval	Main waste water outlet	114	9.98	Nil	Water Quality Standard on Discharge of Sewage into Cities and Towns Sewer GBT 31962-2015	92.59
		Ammonia nitrogen			2.12	0.19	Nil		5.224
12	Techpool Bio-pharma Co., Ltd.	COD	Interval	Main waste water outlet	24.62	0.67	Nil	Discharge Limits of Water Pollutants (DB44/26 - 2001)	33.45
		Ammonia nitrogen			0.48	0.02	Nil		3.01
		SO2	Continuous	Exhaust gas outlet of boilers	0.22	0.0008	Nil	Emission Standard of Air Pollutants for Boilers （GB13271-2014）	0.049
		NOx			102.67	0.54	Nil		2.297
		Particulate matter			1.58	0.000008	Nil		0.302
		Volatile organic compound (VOCs)	Interval	Exhaust gas outlet	2.85	0.016	Nil	Discharge Limits of Air Pollutants (DB44/27 - 2001)	3.181
		PM	Interval	Exhaust gas outlet	6.98	0.00000036	Nil	Discharge Limits of Water Pollutants	0.302

No.	Name of key pollutant discharging	Name of key pollutants	Discharge mode	Discharge condition	Discharge concentration Waste water (mg/L), exhaust gas (mg/m3)	Total discharge amount (tonne)	Excessive discharge	Implemented standards for discharge of pollutants	Approved total amount of discharge (tonne)
13	Liaoning Medya Pharmaceutical Co., Ltd.	COD	Interval	Main waste water outlet	37.18	2.62	Nil	Liaoning Province Comprehensive Discharge Standards on Sewage (DB21/1627-2008)	12.24
		Ammonia nitrogen			1.71	0.10	Nil		2.55
		SO2	Interval	Exhaust gas outlet	23	0	Nil	Emission Standard of Air Pollutants for Boilers (GB13271-2014)	0.72
		NOx			60	0	Nil		2.88
		Particulate matter			27	0	Nil		0.29
		VOCs (Non-methane hydrocarbon)	Interval	Exhaust gas outlet	1.51	0	Nil	Comprehensive Emission Standard of Air Pollutants (GB16297-1996)	5.5
14	Liaoning SPH Herbapex Pharmaceutical (Group) Co., Ltd.	SO2	Interval	Boiler fuel gas	13	0.87	Nil	Emission Standard of Air Pollutants for Boilers GB13271-2014	45.89
		NOx			148.13	5.95	Nil		31.2
		Particulate matter			15.2	0.6	Nil		8.61
15	Shanghai Pharmaceutical Group (Benxi) Northern Pharma Co., Ltd.	SO2	Continuous	Exhaust gas outlet of boilers	13.5	0.48	Nil	Emission Standard of Air Pollutants for Boilers (GB13271-2014)	0.92
		NOx			96.76	2.67			4.3
		Particulate matter			6.6	0.25			Nil
		Non-methane hydrocarbon	Interval	Exhaust gas outlet	18.15	0.55	Nil	Comprehensive Emission Standard of Air Pollutants (GB16297-1996)	20.22
		Sulfuric acid mist	Interval	Exhaust gas outlet	0.33	0.002	Nil	Comprehensive Emission Standard of Air Pollutants (GB16297-1996)	Nil

(II) Construction and operation of pollution prevention & treatment facilities and administrative permission

No.	Name of key pollutant discharging units	Construction and operation of pollution prevention & treatment facilities	Administrative permission for environmental protection	Environmental self-detection solution
1	Shanghai SPH No.1 Biochemical and Pharmaceutical Co., Ltd. (Jianchuan Road)	Has a sewage treatment station with a daily capacity of 300 tonnes of sewage and several sets of exhaust gas treatment equipment, which were all running normally in 2020. The waste water and exhaust gas were discharged under certain standards after treatment.	On September 14, 2016, obtained the Drainage Permit from Shanghai Water Authority. On November 4, 2020, obtained the national Drainage Permit, which is valid until December 31, 2025. Drainage Permit number: 91310112133747458R003P.	Installed a set of automatic monitoring equipment was at the main sewage outlet to detect such data as COD, PH value and quantity of flow every hour. The online monitoring equipment was networked to Ministry of Ecology and Environment. Online monitoring equipment for exhaust gas was installed on the roof of Building 7 to detect non-methane hydrocarbon and other data as required. Commissioned a third-party environmental inspection company to monitor the pollution emission indicators such as PH value, COD, ammonia nitrogen, and total nitrogen in accordance with the monitoring plan. Commissioned a third-party environmental inspection company to monitor exhaust emissions every month and a third-party environmental inspection company to inspect soil and groundwater every year. In 2020, the monitoring data was all up to standards.
	Shanghai SPH No.1 Biochemical and Pharmaceutical Co., Ltd. (Bijiang Road)	Has a sewage treatment station with a daily capacity of 210 tonnes of sewage and several sets of exhaust gas treatment equipment, which were all running normally in 2020. The waste water and exhaust gas were discharged under certain standards after treatment.	The company obtained the Drainage Permit Shanghai District Water Authority on September 4, 2019. On November 4, 2020, obtained the national Drainage Permit, which is valid until December 31, 2025. Drainage Permit number: 9131011213374758R001P.	Commissioned a third-party environmental inspection company of to monitor PH value, COD, ammonia nitrogen, and total nitrogen. Commissioned a third-party environmental inspection company to monitor the pollution emission indicators such as PH value, COD, ammonia nitrogen, total nitrogen, and total phosphorus. Commissioned a third-party environmental inspection company to monitor exhaust emissions every month. In 2020, the monitoring data was all up to standards.
2	Shanghai Ziyuan Pharmaceutical Co., Ltd.	Established two VOCs exhaust treatment facilities, which were running normally in 2020. The exhaust gas was discharged under certain standards after treatment. In January 2021, planned to complete the networking for online monitoring of one of the VOCs exhaust gas treatment facilities. Industrial waste water was treated as hazardous waste by the entrusted qualified unit.	The company obtained the Drainage Permit from Shanghai Water Authority on 10 August 2020. On January 1, 2018, obtained the national Drainage Permit. In December 2020, completed the application for the renewal of expired Drainage Permit， which is valid until December 31, 2025. Drainage Permit number: 91310112133345686900 1P.	Prepared a corporate environmental self- detection solution according to standards and authorized a qualified third party to detect various pollution factors according to the requirements and frequency specified in the solution. In June 2020, completed soil and groundwater detection and hidden danger investigation. In 2020, the monitoring data was all up to standards.
3	Shanghai SPH Zhongxi Pharmaceutical Co., Ltd.	Has a sewage treatment station with a daily capacity of 600 tonnes of sewage and several sets of exhaust gas treatment equipment. In 2020, the sewage treatment station and exhaust gas treatment facilities were running normally and the sewage and exhaust gas were discharged under certain standards after treatment.	On September 17, 2020, completed the renewal of the Drainage Permit, which is valid until until September 16, 2025. On August 21, 2020, the company obtained the national Drainage Permit, which is valid until August 20, 2023. Drainage Permit number: 9131011413362209XY001V.	Two sets of VOCs online monitoring equipment were networked to environmental protection departments. The company prepared a corporate environmental self- detection solution and the third-party environmental detection company monitored the pollutant discharge indicators such as exhaust gas, waste water and noise every quarter. In 2020, the monitoring data was all up to standards.
4	Shanghai Sine Jinzhu Pharmaceutical Co., Ltd.	Has a sewage treatment facility with a daily capacity of capabilities to 750 tonnes of wastewater, which was all running normally in 2020. The wastewater was discharged under certain standards after treatment.	On July 11, 2018, completed the renewal of the Drainage Permit in accordance with the requirements of the Shanghai Water Authority. On August 21, 2020, the company obtained the national Drainage Permit. On October 31, 2020, it completed the change of Drainage Permit, which is valid until August 20, 2023. Drainage Permit number: 91310116134248861600 1V	Installed a set of automatic monitoring equipment at the main industrial wastewater outlet for trial operation, detecting such data as COD, PH value and quantity of flow every four hours. The online monitoring equipment was networked to the district environmental protection bureau. Carried out inspection according to the requirements of the Drainage Permit. In November 2020, commissioned a third party to test, and the data indicated all standards were met.
5	Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd.	Has two sewage treatment stations with a daily capacity of 150 tonnes and 300 tonnes of sewage per day, and several sets of exhaust gas treatment facilities, which were all running normally in 2020. The waste water and exhaust gas were discharged under certain standards after treatment.	In January 2018, completed the renewal of the Drainage Permit in accordance with the requirements of the Shanghai Water Authority. On January 1, 2018, obtained the national Drainage Permit. In April 2019, completed renewal of the Pollutant Discharge Permit . In the end of December 2020, completed the change and extension of the Drainage Permit, which is valid until December 31, 2025. Drainage Permit number: 91310120607349938600g1P.	Prepared an annual environmental monitoring plan, and commissioned environmental monitoring companies to conduct self-monitoring work on pollution emission indicators such as exhaust gas, waste water, noise, and factory boundary exhaust gas in accordance with the self-monitoring requirements, monitoring frequency, and monitoring content of the Drainage Permit. In 2020, the monitoring data was all up to standards.
6	Shanghai SPH New Asiatic Pharmaceutical Co., Ltd. (New Asiatic Pharmaceutical Factory)	Has a sewage treatment station with the daily capacity of 1,500 tonnes and multiple sets of VOC treatment equipment. In 2020, the sewage treatment station and VOC treatment equipment were running normally and the sewage and exhaust gas were discharged under certain standards after treatment.	On July 4, 2017， obtained the Drainage Permit from Shanghai Pudong Water Authority. On December 31, 2019, obtained the national Drainage Permit, which is valid until December 31, 2025. Drainage Permit number: 91310115133738906M001V.	A set of online monitoring equipment was installed at the main sewage outlet to detect such data as COD, PH value and quantity of flow. The online monitoring equipment was networked to the district environmental protection bureau. Formulated a monitoring plan in accordance with the requirements of the Drainage Permit, and entrusted a third-party environmental testing company to monitor pollutant emission indicators such as the PH value, suspended solids, petroleum, chemical oxygen demand, five-day biochemical oxygen demand, ammonia nitrogen, total nitrogen, chromaticity, and volatile phenol. Commissioned a third-party environmental inspection company to monitor exhaust emissions every year. In 2020, the monitoring data was all up to standards.
7	Shanghai Leiyunshang Pharmaceutical Co., Ltd.	Has a sewage treatment station with the daily capacity of 1,200 tonnes of sewage. Commissioned a third party to run the station. In 2020, the sewage treatment station was running normally and the sewage was discharged under certain standards after treatment.	The company obtained the Drainage Permit from Fengxian District Water Authority on February 5, 2018. On September 29, 2020, the company obtained the national Drainage Permit, which is valid until August 28, 2023. Drainage Permit number: 91310000631291406P001U.	Installed a set of online wastewater monitoring equipment at the main sewage outlet to monitor as COD, PH value, ammonia nitrogen and quantity of flow. Installed exhaust gas automatic monitoring equipment at the organic exhaust gas outlet, and the monitoring indicator was non-methane total hydrocarbons. The online monitoring system was connected to the networked to Fengxian District Ecological Environment Bureau. Entrusted a third-party unit to operate the online monitoring system.
8.	Changzhou Pharmaceutical Factory Co., Ltd.	Has a sewage treatment station with a daily capacity of 1500 tonnes of sewage and 10 sets of exhaust gas treatment facilities. In 2020, the sewage treatment station and factory exhaust gas treatment facilities were running normally operation of sewage and exhaust gas were discharged under certain standards after treatment.	In December 2017, obtained the national Drainage Permit. In December 2020, completed the change and renewal of Drainage Permit, which is valid until December 7, 2025. Drainage Permit number: 91320400137158490L001P	An automatic detection device has been installed at the main sewage outlet to detect COD, PH value, ammonia nitrogen, total phosphorus and other data 4 times a day, and has been connected to the EPA platform. The total salt, total zinc, suspended solids and other indicators were entrusted to a qualified third party for testing as required. Each exhaust gas outlet was entrusted to a qualified third party to conduct inspections in accordance with the requirements of the Drainage Permit. In 2020, the monitoring data was all up to standards.

No.	Name of key pollutant discharging units	Construction and operation of pollution prevention & treatment facilities	Administrative permission for environmental protection	Environmental self-detection solution
9	Nantong Changyou Pharmaceutical, Ltd.	Has a sewage station with a daily capacity of 1000 tonnes of sewage and several sets of exhaust gas treatment equipment. In 2020, the sewage treatment station and factory exhaust gas treatment facilities were running normally operation of sewage and exhaust gas were discharged under certain standards after treatment.	Completed renewal of the National Pollutant Discharge Permit in November 2017. On October 30, 2020, completed the change and renewal of the Drainage Permit, which is valid until November 13, 2025. The discharge permit number is 9132062357537648XH001P.	Installed a set of automatic monitoring equipment was at the main sewage outlet to detect such data as COD, PH value, ammonia nitrogen, total phosphorus, and quantity of flow every hour. Online monitoring equipment was connected to local environmental protection bureaus. Other indicators of wastewater were entrusted to a qualified third party to conduct inspections in accordance with the requirements of the Drainage Permit. Each exhaust gas outlet was entrusted to a qualified third party to conduct inspections in accordance with the requirements of the Drainage Permit. In 2020, the monitoring data was all up to standards.
10	SPH Changzhou Kony Pharmaceutical Co., Ltd.	Has a sewage treatment station with a designed capacity of volume of 200 tonnes and 10 sets of exhaust gas treatment facilities. The wastewater and exhaust gas treatment facilities of the whole plant were managed by dedicated personnel. In 2020, the sewage treatment station and factory exhaust gas treatment facilities were running normally operation of sewage and exhaust gas were discharged under certain standards after treatment.	On December 4, 2018, obtained the national Drainage Permit, which is valid until December 3, 2021. Drainage Permit number: 9132041271689963X2001P.	The online COD and ammonia nitrogen automatic detection device was installed at the waste water outlet and connected to the local and municipal environmental protection departments. Prepared an annual environmental monitoring plan. Pursuant to self-monitoring requirements, prepared an annual environmental monitoring plan. Commissioned third-party environmental monitoring companies to conduct self-monitoring work on pollution emission indicators such as exhaust gas, waste water, and noise, in accordance with the monitoring frequency and monitoring content. In 2020, the monitoring data was all up to standards.
11	SPH Qingdao Growful Pharmaceutical Co., Ltd.	Established a sewage treatment station with the daily capacity of 1500 tonnes and multiple sets of dust treatment equipment. In 2020, the sewage treatment station and dust treatment equipment were running normally and the sewage and exhaust gas were discharged under certain standards after treatment.	The company obtained the Drainage Permit from Urban Management Bureau of West Coast New District of Qingdao City on August 18, 2019. On July 29, 2020, obtained the Drainage Permit, which is valid until July 28, 2023. Drainage Permit number: 91370200264584097H001V.	Installed a set of automatic monitoring equipment was at the main sewage outlet to detect such data as COD, ammonia, PH value and quantity of flow every 2 hours. The online monitoring equipment Bureau networked to Qingdao Municipal Ecology and Environment Bureau. Conducted self-monitoring of total nitrogen and total phosphorus in accordance with its self-monitoring plan, and commissioned qualified third-party environmental testing companies to monitor pollutant emission indicators such as suspended solids, BOD5, and chromaticity. In 2020, the monitoring data was all up to standards.
12	Techpool Bio-pharma Co., Ltd.	Has a sewage treatment station with the daily capacity of 252.6 m3 and 2 sets of exhausted gas treatment equipment. In 2020, the sewage treatment station and exhaust gas treatment equipment was running normally and the sewage and exhaust gas were discharged under certain standards after treatment.	December 18, 2017, obtained the national Drainage Permit. On December 16, 2020, completed the renewal of the Drainage Permit, which is valid until December 18, 2025. Drainage Permit number: 91440101190490505C001P.	Installed a set of automatic monitoring equipment was at the main sewage outlet to detect such data as COD, PH value and ammonia nitrogen every four hours. The online monitoring equipment was networked to the local environmental protection bureau. Commissioned a third-party environmental inspection company to monitor the pollution emission indicators such as PH value, COD, ammonia nitrogen, animal and vegetable oil and suspended solids in accordance with the requirements of the sewage regulations. Commissioned a third-party environmental inspection company to monitor exhaust emissions every year in accordance with the requirements of the sewage regulations. In 2020, the monitoring data was all up to standards.
13	Liaoning Medya Pharmaceutical Co., Ltd.	Has a sewage treatment station with the daily capacity of 1,500 tonnes and multiple sets of VOC treatment equipment. In 2020, the company was in a semi-discontinued state. The sewage treatment and VOC treatment equipment were running intermittently and the sewage and exhaust gas were discharged under certain standards after treatment.	On December 22, 2017, the API Plant obtained the Drainage Permit issued by Fushun Environmental Protection Bureau. On December 24, 2018, it changed the Drainage Permit, which is valid until December 21, 2020. Drainage Permit number: 91210400603732518E001P.	A set of online monitoring equipment was installed at the main sewage outlet to detect such data as COD, ammonia nitrogen, total phosphorus, total nitrogen, and quantity of flow. The online monitoring equipment was networked to the on-line monitoring system for pollution sources of Fushun Environmental Protection Bureau. According to the plan, entrusted a third-party environmental testing company quarterly to monitor total phosphorus, total organic carbon, volatile phenol, five-day biochemical oxygen demand, total nitrogen, chromaticity, total cyanide, aniline, suspended solids, total zinc, nitrobenzene, PH value, dichloromethane, total copper and other pollution emission indicators; detected sulfide emission indicators every six months. Commissioned a third-party environmental inspection company to monitor exhaust emissions every year. In 2020, the monitoring data was all up to standards.
14	Liaoning SPH Herbapex Pharmaceutical (Group) Co., Ltd.	Has a sewage treatment station with the daily capacity of 600 tonnes, a 20-tonne boiler, and multiple sets of dust treatment equipment. In 2020, the sewage treatment station, boiler, and production dust treatment equipment were running normally and the sewage and exhaust gas were discharged under certain standards after treatment.	On June 23, 2020, obtained the national Drainage Permit, which is valid until June 23, 2023. Drainage Permit number: 91210000701855714F001V.	Carried out self-monitoring in accordance with the requirements of the Drainage Permit. All pollutant discharges met the standard. In 2020, the monitoring data was all up to standards.
15	Shanghai Pharmaceutical Group (Benxi) Northern Pharma Co., Ltd.	Has a sewage treatment station with a daily capacity of 200 tonnes of sewage, two sets of VOC exhaust gas treatment devices for organic exhaust gas treatment in raw material workshops, and a set of odor treatment devices for sewage treatment station. The unorganized exhaust gas in the raw material workshop was collected and processed with an activated carbon adsorption box. In 2020, the sewage treatment station and exhaust gas treatment equipment were running normally and the sewage and exhaust gas were discharged under certain standards after treatment.	In May 2018, obtained the Drainage Permit issued by the Ministry of Environmental Protection; in 2019, changed the Drainage Permit, and in May 2019, obtained the change approval for the Drainage Permit, which is valid until May 28, 2021. Drainage Permit number: 91210500318644906M001P.	Installed a set of automatic monitoring equipment was at the main sewage outlet to detect such data as COD, ammonia nitrogen, and PH value every four hours. The online monitoring equipment was networked to the local environmental protection bureau. At the beginning of the year, formulated the 2020 Self-Monitoring Plan to carry out self-monitoring of various pollutants according to the plan. In 2020, the monitoring data of pollutants at exhaust gas outlet, factory boundary exhaust gas and noise all met the standards.

(III) Environmental impact assessment on construction project

1. Shanghai SPH No. 1 Biochemical and Pharmaceutical Co., Ltd.

On October 26, 2020, the second phase of the Injection, API Production Line Adjustment and Boiler Clean Energy Substitution Project completed the independent acceptance.

2. Shanghai Ziyuan Pharmaceutical Co., Ltd.

In 2020, the enterprise had no construction project or project under construction.

3. Shanghai SPH Zhongxi Pharmaceutical Co., Ltd.

In August 2020, the Environmental Impact Report of the Reconstruction Project of Traditional Chinese Medicine Extraction Workshop was approved by the Jiading District Ecology and Environment Bureau. Approval number: Hu 114 Huan Bao Xu Guan [2020] No.342. In October 2020, completed the environmental protection acceptance work (independent acceptance) for completion of the solid preparation dedicated workshop (including the comprehensive overhead three-dimensional warehouse) and the supporting quality control laboratory construction project (Phase I).

4. Shanghai Sine Jinzhu Pharmaceutical Co., Ltd.

In May 2019, the construction of the industrialization R&D platform project of enterprise sealing technology started. The commissioning stage was carried out in October 2020, and is currently in the acceptance stage.

5. Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd.

In 2020, the company completed a environmental impact assessment analysis report on non-significant changes, which mainly involved changes in some products, changes in the production process and output of Hydroxychloroquine Sulfate, the transfer of production locations from the second workshop to the third workshop, and changes in supporting environmental protection facilities. The report on non-significant changes was sent to the Fengxian District Ecological Environment Bureau for the record. The Company passed the change and renewal of the Drainage Permit of Fengxian District Ecological Environment Bureau based on the content of this report.

6. Shanghai SPH New Asiatic Pharmaceutical Co., Ltd., New Asiatic Pharmaceutical Factory

In 2020, the enterprise had no construction project or project under construction.

7. Shanghai Leiyunshang Pharmaceutical Co., Ltd.

In September 2020, the environmental impact assessment report of the TCM granule project passed the expert review conducted by the district environmental protection organization. After the report has been revised and reviewed, it is pending the approval of the environmental protection department.

8. Changzhou Pharmaceutical Factory Co., Ltd.

On April 15, 2020, the Environmental Assessment Approval was obtained for the Quality Inspection Building Construction Project, which is currently under construction.

On July 2, 2020, the environmental assessment registration form was completed for the Folic Acid, Thalidomide, Hydrochlorothiazide Workshop Exhaust Gas Treatment Facilities Upgrade and Transformation project, which is currently under construction. On July 3, 2020, the environmental assessment approval was obtained for the Original Site Reconstruction and Expansion Phase I Project. The project is currently under construction by stage. On December 30, 2020, the environmental assessment approval was obtained for the Pollutant Treatment Facilities Technical Renovation Project.

9. Nantong Changyou Pharmaceutical Technology Co., Ltd.

In April 2020, the Environmental Assessment Approval was obtained for the Quality Inspection Building Construction Project. The project is currently under construction. In May 2020, the Construction Project with an Annual Output of 113.80-Tonne of API passed the independent inspection and acceptance and is currently in normal production.

10. SPH Changzhou Kony Pharmaceutical Co., Ltd.

In 2020, the enterprise had no construction project or project under construction.

11. SPH Qingdao Growful Pharmaceutical Co., Ltd.

On December 31, 2019, the company obtained the "Approval of the Environmental Impact Report on the Technical Transformation Project of SPH Qingdao Growful Pharmaceutical Co., Ltd. Polysaccharide Iron Workshop". On October 30, 2020, the company received the environmental assessment approval of "SPH Qingdao Growful Pharmaceutical Co., Ltd. Shuanghuanglian Drops and Kujin Tablets Production Project", of which the Kujin Tablets production project started construction in November.

12. Techpool Bio-pharma Co., Ltd.

In 2020, the enterprise had no construction project or project under construction.

13. Liaoning Medya Pharmaceutical Co., Ltd.

On August 30, 2019, Fushun City Ecological Environment Bureau's "Approval of Liaoning Medya Pharmaceutical Co., Ltd. Relocation Project Environmental Impact Report" Fu Huan Shen [2019] No. 30; the groundbreaking date for the relocation project of Liaoning Medya Pharmaceutical Co., Ltd.: June 28, 2020, the commencement date: July 22, 2020, and the suspension date: December 15, 2020.

14. Liaoning SPH Herbapex Pharmaceutical (Group) Co., Ltd.

In 2020, the enterprise had no construction project or project under construction.

15. Shanghai Pharmaceutical Group (Benxi) Northern Pharma Co., Ltd.

On November 11, 2020, completed the environmental protection acceptance of the second stage of the "Shanghai Pharmaceutical Group (Benxi) Northern Pharma Co., Ltd. R&D pilot and Industrialization Base Project (Phase I)" . Phase I of the project fully completed the environmental protection acceptance.

(IV) Contingency plan for emergency environmental incident

1. Shanghai SPH No. 1 Biochemical and Pharmaceutical Co., Ltd.

On February 27, 2019, the enterprise completed the preparation of the Contingency Plan for Emergent Environmental Incidents and filing with the environmental protection agency; filing no.: 3102212019009. On October 30, 2020, the company organized and carried out training and drills in relation to the emergency plans for environmental emergencies (one comprehensive, five on-site) in

accordance with the requirements of the plan, and standardized the recording of the training and drill process. The enterprise constantly summarized and improved the contingency plan via exercises to enhance the employees' ability to cope with the emergent environmental incidents.

2. Shanghai Ziyuan Pharmaceutical Co., Ltd.

On April 17, 2018, the enterprise completed the preparation of the Contingency Plan for Emergent Environmental Incidents and filing with the environmental protection agency; filing no.: 310221208016. On November 17, 2020, the enterprise conducted exercises according to the plan, constantly summarized and improved the contingency plan via exercises to enhance the employees' ability to cope with the emergent environmental incidents and strengthen the treatment of environmental pollution at the accident site after the accident.

3. Shanghai SPH Zhongxi Pharmaceutical Co., Ltd.

On November 3, 2020, the enterprise completed the amendments to the Contingency Plan for Emergent Environmental Incidents and filing with the environmental protection agency; filing no.: 02-310114-2020-076-L. On June 12 and November 17, 2020, the enterprise conducted two exercises according to the plan, constantly summarized and improved the contingency plan via exercises to enhance the employees' ability to cope with the emergent environmental incidents.

4. Shanghai Sine Jinzhu Pharmaceutical Co., Ltd.

On May 28, 2019, the enterprise completed the preparation of the Contingency Plan for Emergent Environmental Incidents and filing with the environmental protection agency; filing no. 02-310116-2019-022-L. On October 23, 2020, the enterprise conducted exercises according to the plan, constantly summarized and improved the contingency plan via exercises to enhance the employees' ability to cope with the emergent environmental incidents.

5. Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd.

On December 17, 2020, the enterprise completed the preparation of a new edition of Contingency Plan for Emergent Environmental Incidents and filing with the environmental protection agency; filing no.: 02-310120-2020-078-M. On the afternoon of June 30, 2020, carried out emergency plan drills for environmental emergencies of hydrochloric acid storage tank leakage in accordance with the plan requirements; on the afternoon of November 29, 2020, carried out an emergency plan drill for environmental emergencies involving the leakage of waste liquid storage tanks in the workshop; through drills, continuously summarized and improved the emergency plan, and enhanced the ability of employees to respond to environmental emergencies.

6. Shanghai SPH New Asiatic Pharmaceutical Co., Ltd., New Asiatic Pharmaceutical Factory

On November 11, 2020, the enterprise completed the preparation of the Contingency Plan for Emergent Environmental Incidents and filing with the environmental protection agency; filing no.: 02-310115-2020-309-M. On August 25, 2020, the enterprise conducted exercises according to the plan, constantly summarized and improved the contingency plan via exercises to enhance the employees' ability to cope with the emergent environmental incidents.

7. Shanghai Leiyunshang Pharmaceutical Co., Ltd.

In 2017, the enterprise completed the preparation of the Contingency Plan for Emergent Environmental Incidents and filing with the environmental protection agency; filing no.: 02-310120-2017-008-L.

On October 19, 2020, the enterprise conducted exercises according to the plan, constantly summarized and improved the contingency plan via exercises to enhance the employees' ability to cope with the emergent environmental incidents. A review evaluation of the emergency plan was carried out in January 2021.

8. Changzhou Pharmaceutical Factory Co., Ltd.

On February 28, 2018, the enterprise establishing and and filed the Contingency Plan for Emergent Environmental Incidents; filing no.: 3204022018011M. On June 29, 2019, carried out an emergency drill for wastewater exceeding the standard; through the drill, the effectiveness of the emergency plan was tested and the ability of employees to respond to environmental emergencies was improved. On June 19, 2020, carried out an emergency drill wastewater exceeding the standard; on September 23, 2020, launched a special emergency drill for hazardous waste leakage; through the drill, tested the effectiveness of the emergency plan and improved the ability of employees to respond to environmental emergencies.

9. Nantong Changyou Pharmaceutical Technology Co., Ltd.

On November 2, 2020, the enterprise completed the renewal and filing of the Contingency Plan for Emergent Environmental Incidents; filing no.: 320623-2020-162-H. On May 7, 2020, the enterprise conducted exercises according to the plan, constantly summarized and improved the contingency plan via exercises to enhance the employees' ability to cope with the emergent environmental incidents.

10. SPH Changzhou Kony Pharmaceutical Co., Ltd.

On August 24, 2020, the enterprise completed the preparation of the Contingency Plan for Emergent Environmental Incidents and filing with the environmental protection agency; filing no.: 320412-2020-7HW057-H. On August 18, 2020, the enterprise conducted exercises according to the plan, constantly summarized and improved the contingency plan via exercises to enhance the employees' ability to cope with the emergent environmental incidents.

11 SPH Qingdao Growful Pharmaceutical Co., Ltd.

In 2017, the enterprise completed the preparation of the Contingency Plan for Emergent Environmental Incidents and filing with the environmental protection agency; filing no.: 02-310120-2017-008-L.

In March 2020, the company initiated the revision and filing of the "Enterprise Emergency Response Plan for Environmental Incidents". On August 24, 2020, it completed the review of the Contingency Plan for Emergent Environmental Incidents and filing with the environmental protection agency; filing no. 370211-2020-5017-L. On August 28, 2020, it carried out emergency plan training for all staff. On October 27th, it conducted training for members of the headquarters. On October 30, it carried out emergency drills for environmental emergencies in the sewage station, and conducted summary evaluations to enhance the ability of employees to respond to environmental emergencies.

12. Techpool Bio-pharma Co., Ltd.

On March 21, 2018, the enterprise completed the preparation of the Contingency Plan for Emergent Environmental Incidents and filing with the Tianhe District Ecological Environment Bureau; filing no.: 440106-2018-005-L. On June 28, 2020, the enterprise conducted exercises according to the plan, constantly summarized and improved the contingency plan via exercises to enhance the employees' ability to cope with the emergent environmental incidents.

13. Liaoning Medya Pharmaceutical Co., Ltd.

On December 15, 2020, the enterprise completed the preparation of the Amended Contingency Plan for Emergent Environmental Incidents of Liaoning Medya Pharmaceutical Co., Ltd. and filing with the environmental protection agency; filing no. 2104042019022. On May 20, 2020, the enterprise conducted exercises according to the plan, constantly summarized and improved the contingency plan via exercises to enhance the employees' ability to cope with the emergent environmental incidents.

14. Liaoning SPH Herbapex Pharmaceutical (Group) Co., Ltd.

On January 3, 2020, the enterprise completed the preparation of the Contingency Plan for Emergent Environmental Incidents and completed filing with the environmental protection agency on January 9, 2020; filing no.: 201522-2020-001-L. On June 30, 2020, the enterprise conducted exercises according to the plan, constantly summarized and improved the contingency plan via exercises to enhance the employees' ability to cope with the emergent environmental incidents.

15. Shanghai Pharmaceutical Group (Benxi) Northern Pharma Co., Ltd.

On February 26, 2019, the enterprise completed the preparation of the Contingency Plan for Emergent Environmental Incidents and filing with the environmental protection agency; filing no.: 2019-003-Shui L, Qi M. On September 11, 2020, the enterprise conducted exercises according to the plan, constantly summarized and improved the contingency plan via exercises to enhance the employees' ability to cope with the emergent environmental incidents.

(V) Other environmental information which shall be disclosed

1. Shanghai SPH No. 1 Biochemical and Pharmaceutical Co., Ltd.

On October 16, 2020, won the title of the fourth batch of national green factories by the Ministry of Industry and Information Technology. On August 12, 2020, completed the external review of the ISO14001 system and obtained the certificate of renewal system.

It commissioned a third party to inspect the company's soil and groundwater in accordance with the requirements of the Shanghai Minhang District Ecological Environment Bureau and compile and complete the inspection report on hidden soil hazards. Cooperated with a third party commissioned by the Shanghai Municipal Bureau of Ecology and Environment to complete soil and groundwater sampling.

2. Shanghai Ziyuan Pharmaceutical Co., Ltd.

In 2020, commissioned a third party "Ingle" to conduct soil and groundwater testing and hidden hazard investigation. Cooperated with a third party commissioned by the Shanghai Municipal Bureau of Ecology and Environment to complete soil and groundwater sampling.

3. Shanghai SPH Zhongxi Pharmaceutical Co., Ltd.

In May 2020, won the title of Shanghai Water-saving Enterprise;in October 2020, obtained title of the fourth batch of national green factories by the Ministry of Industry and Information Technology.

4. Shanghai Sine Jinzhu Pharmaceutical Co., Ltd.

In April 2020, started the clean production audit work. In December 2020, determined the clean production plan.

In October 2020, completed the review of ISO140001.

5. Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd.

In 2020, completed the preparation of the EIA report on non-significant changes, and completed the change and renewal of the Drainage Permit through the report on non-significant changes. The new version of Drainage Permit is valid from December 31, 2020 to December 31, 2025.

6. Shanghai SPH New Asiatic Pharmaceutical Co., Ltd., New Asiatic Pharmaceutical Factory

In 2020, it carried out self-monitoring work in accordance with the requirements of the Drainage Permit, and upload all data on the national pollution source monitoring information management and sharing platform.

7. Shanghai Leiyunshang Pharmaceutical Co., Ltd.

It commissioned a third party to inspect the company's soil and groundwater in accordance with the requirements of the District Ecological Environment Bureau and compile and complete the inspection report on hidden soil hazards, report it to the District Environmental Protection Bureau for the record and published it online.

8. Changzhou Pharmaceutical Factory Co., Ltd.

In April 2020, passed the clean production audit and acceptance; on September 4, 2020, obtained the ISO50001 energy management system certificate. Carried out ISO14064 greenhouse gas verification, verified the company's greenhouse gases in 2019, and obtained verification reports and certificates; was awarded the title of "Changzhou 2020 Environmental Protection Demonstration Enterprise and Institution".

On September 2, 2020, the company carried out formulation of the plan for soil and groundwater self-inspection and self-test, expert review and other work in accordance with the requirements of Chang Huan Tu [2020] No. 84 on the special rectification work for the prevention and control of soil pollution, and completed the filing in October 2020.

9. Nantong Changyou Pharmaceutical Technology Co., Ltd.

On September 2, 2020, the company carried out formulation of the plan for soil and groundwater self-inspection and self-test, expert review and other work in accordance with the requirements of Tong Ru Dong Huan [2020] No. 24 on strengthening the soil environmental management of key supervisory units for soil pollution, and completed the filing in September 2020.

10. SPH Changzhou Kony Pharmaceutical Co., Ltd.

In May 2020, passed the ISO14001 system review and obtained the system certification. Pursuant to Article 8 "Requirements for VOCs Leakage Control of Equipment and Pipeline Components" in GB37822-2019 "Control Standards for Unorganized Emission of Volatile Organic Compounds", signed a leak detection and repair (LDAR) service contract with a third-party qualified unit. Related work was completed in September.

11 SPH Qingdao Growful Pharmaceutical Co., Ltd.

Disclosed the information before publishing the application for a Drainage Permit on the national pollutant discharge permit platform and after evidence was obtaining, and disclosed self-monitoring information on the online pollution source monitoring information sharing platform in Shandong Province.

12. Techpool Bio-pharma Co., Ltd.

There was no other environmental information which shall be disclosed

13. Liaoning Medya Pharmaceutical Co., Ltd.

There was no other environmental information which shall be disclosed

14. Liaoning SPH Herbapex Pharmaceutical (Group) Co., Ltd.

There was no other environmental information which shall be disclosed

15. Shanghai Pharmaceutical Group (Benxi) Northern Pharma Co., Ltd.

There was no other environmental information which shall be disclosed

V | Information of pollutant-discharging units in 2020

According to the Guidelines for Reporting of Performance Indicators of Environmental Key Data proposed by the Stock Exchange of Hong Kong and requirements of relevant documents, the environment and energy data disclosed this time include the amount of greenhouse gas generated from annual paper use and sewage treatment, amount of greenhouse gas reduced due to tree planting, and quantity of particulate matters, sulfur dioxide and nitrogen oxide generated by vehicles. Greenhouse gas emissions were calculated with reference to the Guidelines for Reporting of Performance Indicators of Environmental Key Data and Guidelines for Calculation Methods and Reporting of Greenhouse Gas Emissions from Industrial and Other Industrial Enterprises.

In 2020, three companies including Shanghai Sine Jiufu Pharmaceutical Co., Ltd., Shanghai Xinde Chinese Herbal Medicine Company, and Changzhou Wuxin Pharmaceutical Co., Ltd. were shut down and no longer disclosed information. Two new companies, Hongqing Huiyuan Pharmaceutical Co., Ltd. and Sichuan SPH Shendu Traditional Chinese Medicine Co., Ltd., entered the scope of information disclosure. The enterprises under Shanghai Pharmaceuticals Holding disclosed here are as follows:

SN.	Name of enterprises directly under the Group	Name of subsidiaries of drug manufacturers directly under the Group
1	Shanghai SPH Sine Pharmaceutical Laboratories Co., Ltd.	1-1 Shanghai SPH Sine Pharmaceutical Laboratories Co., Ltd., General Factory
		1-2 Shanghai SPH Sine Pharmaceutical Laboratories Co., Ltd., No. 2 Subsidiary
		1-3 Shanghai Harvest Pharmaceutical Co., Ltd.
		1-4 Shanghai Fuda Pharmaceutical Co., Ltd.
		1-5 Shanghai Sine Tianping Pharmaceutical Co., Ltd.
		1-6 Shanghai Sine Yanan Pharmaceutical Co., Ltd.
		1-7 Shanghai Sine Wanxiang Pharmaceutical Co., Ltd.
		1-8 Shanghai Sine Jinzhu Pharmaceutical Co., Ltd.
		1-9 Shandong Sine Pharmaceutical Co., Ltd.
		1-10 Tianjin Jinjin Pharmaceutical Co., Ltd.
		1-11 Gansu Sine Tiansen Pharmaceutical Co., Ltd.
2	Shanghai SPH No. 1 Biochemical and Pharmaceutical Co., Ltd.	2-1 Shanghai SPH No. 1 Biochemical and Pharmaceutical Co., Ltd.
		2-2 Shanghai Ziyuan Pharmaceutical Co., Ltd.
3	SPH New Asia Pharmaceutical Co., Ltd.	3-1 Shanghai SPH New Asiatic Pharmaceutical Co., Ltd., Asia Pioneer Pharmaceutical Factory
		3-2 Shanghai SPH New Asiatic Pharmaceutical Co., Ltd. (New Asiatic Pharmaceutical Factory)
		3-3 Shanghai New Asiatic Pharmaceutical Minhang Co., Ltd.
		3-4 Liaoning Medya Pharmaceutical Co., Ltd.

SN.	Name of enterprises directly under the Group	Name of subsidiaries of drug manufacturers directly under the Group
4	Shanghai Traditional Chinese Medicine Co., Ltd.	4-1 Shanghai Leiyunshang Pharmaceutical Co., Ltd.
		4-2 Shanghai Leiyunshang Fengbang Pharmaceutical Co., Ltd.
		4-3 Shanghai SPH Xingling Sci. & Tech. Pharmaceutical Co., Ltd.
		4-4 Shanghai Dehua Traditional Chinese Medicines Co., Ltd.
		4-5 Shanghai Yutiancheng Chinese Herbal Medicine Company Limited
		4-6 Shanghai Huapu Chinese Herbal Medicine Company Limited
		4-7 Shanghai Huaying Pharmaceutical Co., Ltd.
		4-8 Shanghai SPH Shenxiang Health Pharmaceutical Co., Ltd.
		4-9 Hongqing Huiyuan Pharmaceutical Co., Ltd.
		4-10 Sichuan SPH Changzhou Kony Pharmaceutical Co., Ltd
5	Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd.	5-1 Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd.
		5-2 Shanghai SPH Zhongxi Pharmaceutical Co., Ltd.
		5-3 Shanghai Jinhe Bio-Pharmaceutical Co., Ltd.
6	Shanghai Zhonghua Pharmaceutical Co., Ltd.	6-1 Shanghai Zhonghua Pharmaceutical Co., Ltd.
		6-2 Shanghai Zhonghua Nantong Pharmaceutical Co., Ltd.
7	Shanghai Sunway Biotech Co., Ltd.	7-1 Shanghai Sunway Biotech Co., LTD.
8	SPH Changzhou Pharmaceutical Co., Ltd.	8-1 Changzhou Pharmaceutical Factory Co., Ltd.
		8-2 Nantong Changyou Pharmaceutical Technology Co., Ltd.
		8-3 Chifeng Arker Pharmaceutical Technology Co., Ltd.
		8-4 Chifeng Mysun Pharmaceutical Co., Ltd.
9	SPH Qingdao Growful Pharmaceutical Co., Ltd.	9-1 SPH Qingdao Growful Pharmaceutical Co., Ltd.
10	Xiamen Traditional Chinese Medicine Co., Ltd.	10-1 Xiamen Traditional Chinese Medicine Co., Ltd.
11	Chiatai Qingchunbao Pharmaceutical Co., Ltd.	11-1 Chiatai Qingchunbao Pharmaceutical Co., Ltd.
12	Hangzhou Huqingyutang Pharmaceutical Co., Ltd.	12-1 Hangzhou Huqingyutang Pharmaceutical Co., Ltd.
13	Liaoning SPH Herbapex Pharmaceutical (Group) Co., Ltd.	13-1 Liaoning SPH Herbapex Pharmaceutical (Group) Co., Ltd.
14	SPH Dong Ying (Jiangsu) Pharmaceutical Co., Ltd.	14-1 SPH Dong Ying (Jiangsu) Pharmaceutical Co., Ltd.
		14-2 SPH Changzhou Kony Pharmaceutical Co., Ltd
15	Shanghai Pharmaceutical Group (Benxi) Northern Pharma Co., Ltd.	15-1 Shanghai Pharmaceutical Group (Benxi) Northern Pharma Co., Ltd.
16	Techpool Bio-pharma Co., Ltd.	16-1 Techpool Bio-pharma Co., Ltd.

1-1 Company name: Shanghai SPH Sine Pharmaceutical Laboratories Co., Ltd., General Factory

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
21.09	8.86	0.65	96.39	0.59	486.02	231.62	0
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
33475.56	1040.29	32435.27	575.49	525.27	50.22	59.95	89.95

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
23.43	11695.68	2706	1.18	113114.5	0	0	0	31.02

Overall description: In 2020, the company invested RMB2.15 million in environmental protection. Specifically, the main expenses of RMB1 million were used for solid waste (including hazardous waste) disposal costs, RMB0.39 million was for operating costs of wastewater treatment facility, RMB0.125 million was for environmental testing costs, RMB0.25 million was for new laboratory exhaust gas treatment equipment, and RMB0.2 million was for maintenance of environmental protection equipment and facilities. In 2020, it completed the acceptance of green integration project for the national green factory, and operated in accordance with the new version of the ISO14001 environmental management system and passed the external review. It added an online wastewater monitoring device and an environmental information system to monitor wastewater discharge in real time. On July 24, 2020, obtained the national Drainage Permit, which is valid until July 23, 2023. Drainage Permit number: 91310000694249651T001Y.

1-2 Company name: Shanghai SPH Sine Pharmaceutical Laboratories Co., Ltd., No. 2 Subsidiary

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
6.01	2.64	0.13	0	0.13	721.89	108.97	0
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
3794.53	1247.83	2546.70	51	27	24	73.25	73.25

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
6.68	1508.58	259.66	55.65	0	0	5	3.2	3.58

Overall description: In 2020 the Company invested RMB0.15 million operation & maintenance of pollution prevention facilities RMB0.655 million for treatment of solid wastes and RMB0.005 million for association newspapers books publicity etc. and RMB0.06 million for environmental monitoring fee. Total investment in environmental protection amounted to RMB0.87 million. Compared with 2019, the water consumption for 2020 increased by 8,621 tonnes, the discharge of COD in wastewater decreased by 2.12 tonnes, the discharge of N-NH3 decreased by 0.51 tonnes, and the discharge of nitrogen oxides in exhaust gas decreased by 488.47 kg. Comprehensive energy consumption increased by 285.01 tonnes, output decreased by 262.55 million pieces, and output value increased by RMB19.4346 million. On April 22, 2020, it obtained the registration form of emergency response plan for environmental emergencies, which is valid until April 21, 2023. On December 31, 2020, it obtained the ISO14001 Environmental Management System and 45001 Occupational Health and Safety Management System certifications, which are valid until December 30, 2023. On December 20, 2019, obtained the national Drainage Permit, which is valid until December 19, 2022. Drainage Permit number: 91310115691646766000 1V.

1-3 Company name: Shanghai Harvest Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of benzene series in exhaust gas emitted (kg)
6.03	1.75	0.01	60.03	31.48	320.17	12.62	149.63
Greenhouse gas emissions (tonne)	**Direct greenhouse gas emissions (tonne)**	**Indirect greenhouse gas emissions (tonne)**	**Amount of general solid waste produced (tonne)**	**Amount of general solid waste disposed (tonne)**	**Amount of general solid waste utilized (tonne)**	**Amount of hazardous waste produced (tonne)**	**Amount of hazardous waste disposed of (tonne)**
5409.72	12.08	5397.64	93.56	77.7	15.86	18.22	18.22

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
6.70	1971.4	435.67	0.42	20514.3	0.00	0.00	5.34	2.62

Comprehensive description: In 2020 the company invested RMB0.013 million to transform the temporary storage of hazardous waste; and invested RMB0.048 million to repair the underground rain and sewage pipe network in the factory area. It invested RMB0.03 million to entrust a third party to conduct pollution monitoring; invested RMB0.2 million to treat hazardous waste generated from production. On July 24, 2020, obtained the national Drainage Permit, which is valid until July 23, 2023. Drainage Permit number: 91310000607229530G001Y.

1-4 Company name: Shanghai Fuda Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
2.19	1.84	0.01	18.11	0	0	45.89	0
Greenhouse gas emissions (tonne)	**Direct greenhouse gas emissions (tonne)**	**Indirect greenhouse gas emissions (tonne)**	**Amount of general solid waste produced (tonne)**	**Amount of general solid waste disposed (tonne)**	**Amount of general solid waste utilized (tonne)**	**Amount of hazardous waste produced (tonne)**	**Amount of hazardous waste disposed of (tonne)**
1633.78	540.55	1093.23	38	38	12.7	24	23.74

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
2.44	500.39	154.88	23.45	0	0	2.8	0	0.31

Overall description: In 2020 the company invested a total of RMB0.618 million in environmental protection. Specifically a total of RMB0.22 million was used for QC laboratory VOC canteen oil fume discharge outlets workshop exhaust gas discharge outlets collection and renovation and hazardous waste warehouse renovation; RMB0.175 million was used for hazardous waste disposal; RMB0.075 million was used for operating expenses of wastewater treatment station equipment; a total of RMB0.137 million was used for Drainage Permit consulting service fees and technical renovation project completion inspection fees; and RMB0.011 million was used for testing fees. On August 26, 2020, obtained the national Drainage Permit, which is valid until August 25, 2023. Drainage Permit number: 91310120134003418G001V.

1-5 Company name: Shanghai Sine Tianping Pharmaceutical Co., Ltd.August 25, 2023

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
5.06	8	0.19	190.05	0.19	72.89	161.07	0
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
6592.96	102.02	6490.94	68.03	25.37	42.66	86.77	78.23

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
5.63	2434.52	573.70	0.80	22203.25	0	0	0	10.11

Overall description: In 2020, the company invested about RMB1.857 million in environmental protection. This included hazardous waste disposal costs of RMB0.5593 million operating costs of wastewater treatment facilities of RMB0.382 million environmental monitoring costs of RMB0.052 million and new laboratory waste gas treatment facilities and sewage station waste gas treatment facilities of RMB0.335 million. Compared with 2019, waste COD emissions decreased by 5.07 tonnes (38%) and ammonia nitrogen emissions decreased by 0.2 tonnes (50%) in 2020. Compared with 2019, the amount of hazardous waste generated decreased by 17.53 tonnes (16.8%)in 2020. It obtained ISO50001 energy management system certificate on December 25, 2020. On August 19, 2020, obtained the national Drainage Permit, which is valid until August 18, 2023. Drainage Permit number: 91310112832231856K001V. In 2020, the National Drainage Permit required that the pollutant type VOCs (in terms of total non-methane hydrocarbons) be added, and statistics on their pollutant emissions be recorded. Therefore, in 2020, the data for the emission of non-methane total hydrocarbons in exhaust gas was added.

1-6 Company name: Shanghai Sine Yanan Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of benzene series in exhaust gas emitted (kg)
2.12	5.85	0.08	390	0.99	160.21	15.84	0
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
2117.42	516.42	1601	80.08	60	20.08	22.58	22.08

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
2.33	921.67	226.73	20.67	0	0	0	0	0

Overall description: In 2020 the company invested about RMB0.523 million in environmental protection. It completed the upgrade of the sludge filter press and the transformation of the biochemical tank of the sewage treatment station, which improved the sludge output rate and the stable discharge of sewage in accordance with the standards. In 2020, the enterprise used 23,300 tonnes of water, 2,500 tonnes less than in 2019, a year-on-year decrease of 1%; natural gas consumption was 206,700 cubic meters, 31,100 cubic meters less than in 2019, a year-on-year decrease of 13%. On August 27, 2020, obtained the national Drainage Permit, which is valid until August 26, 2023. Drainage Permit number: 91310116753162119M001V.

1-7 Company name: Shanghai Sine Wanxiang Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
5.05	6.06	1.09	108.49	0.09	627.94	10.90	0
Greenhouse gas emissions (tonne)	**Direct greenhouse gas emissions (tonne)**	**Indirect greenhouse gas emissions (tonne)**	**Amount of general solid waste produced (tonne)**	**Amount of general solid waste disposed (tonne)**	**Amount of general solid waste utilized (tonne)**	**Amount of hazardous waste produced (tonne)**	**Amount of hazardous waste disposed of (tonne)**
2060.51	511.61	1548.90	74.08	8.00	66.08	19.89	19.89

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
5.61	818.32	218.71	13.54	0	0	0	0	8.55

Overall description: In 2020 the company invested RMB0.8 million in environmental protection including the sealing and anti-corrosion coating of the gas explosion tank and the collection tank of the sewage station and setting up VOCs treatment device to collect and treat exhaust gas from sewage station in order to achieve exhaust gas collection and compliance emission; transformed the steam pipeline by adding a steam recovery pipeline to convert the recovered residue heat into hot water for bathing and other daily use of the employees in the factory allowing the residue heat in the steam pipe to be fully utilized to achieve the purpose of saving energy. The project was completed in May and saved 3984 cubic meters of natural gas. In 2020, the electric energy consumption decreased by 221,900 kWh compared with 2019. On January 8, 2020, it obtained the ISO14001 Environmental Management System certificate. On August 29, 2020, obtained the national Drainage Permit, which is valid until August 31, 2023. Drainage Permit number: 91310000631358877Y001V.

1-8 Company name: Shanghai Sine Jinzhu Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
17.31	4.33	0.02	6.38	0.19	218.07	41.33	0
Greenhouse gas emissions (tonne)	**Direct greenhouse gas emissions (tonne)**	**Indirect greenhouse gas emissions (tonne)**	**Amount of general solid waste produced (tonne)**	**Amount of general solid waste disposed (tonne)**	**Amount of general solid waste utilized (tonne)**	**Amount of hazardous waste produced (tonne)**	**Amount of hazardous waste disposed of (tonne)**
8442.56	479.74	7962.82	62.75	20.2	42.75	59.84	56.84

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
19.23	2894	560	0	35702	0	8.7	2.5	9.4

Overall description: In 2020 the company invested about RMB1 million in environmental protection. Specifically, RMB0.5 million was used for hazardous waste compliant disposal, RMB0.02 million was used for general industrial solid waste disposal, RMB0.25 million was used for the compliant and standardized hazardous waste storage sites and RMB0.04 million was used for pipeline reconstruction and wastewater discharge outlet transformation and renovation, RMB0.05 million was used for system certification, RMB0.04 million was used for Sewage Permits, RMB0.04 million was used for third-party testing of environmental protection and RMB0.06 million was used for the operation and maintenance of the water quality online monitoring system. Compared with 2019, electricity consumption decreased by 10 percentage points in 2020. Compared with 2019, water consumption decreased by 10 percentage points in 2020. COD emissions decreased by 2.39 tonnes compared with 2019. On June 23, 2020, it obtained the ISO50001 Energy System certificate. in September 2020, it passed the ISO14001 Environmental System review.
Clean production entered the application evaluation stage in 2020. On August 21, 2020, obtained the national Drainage Permit. On October 30, 2020, it changed the Drainage Permit, which is valid until August 20, 2023. Drainage Permit number: 91310116134248861600 1V.

1-9 Company name: Shandong Sine Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
0.62	0.47	0.02	396.5	0.21	98.97	9.48	0
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
2053.02	32.02	2021	48	48	0	55.22	39.62

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
1.13	739	146.2	0	8878	0	0	6.65	3.74

Overall description: the company invested RMB0.6085 million for annual environmental protection, of which RMB0.012 million was used for solid waste disposal costs, RMB0.1863 million was used for hazardous waste disposal costs, RMB0.15 million was used for testing costs RMB0.226 million was used for other certification costs and RMB0.045 million was used for water fee. Compared with 2019, the emissions of waste water (including COD and N-NH3), exhaust gas particulate matters, nitrogen oxides, particulate matter, and hazardous waste generation decreased to a certain extent in 2020. Compared with 2019, the energy consumption of gasoline and diesel significantly decreased in 2020. The emission of non-methane total hydrocarbons in exhaust gas increased compared with 2019, mainly due to the extension of production cycle and the increase in production varieties. In 2020, it completed the preparation of the clean production review report and submit it to the local ecological environment bureau. In February 2020, it won the title of Advanced Unit for Corporate Environmental Protection in 2019 issued by the local government. On December 27, 2017, it obtained the national Drainage Permit. On December 16, 2020, it conducted the change of Drainage Permit. On December 23, 2020, it completed the renewal application for Drainage Permit, which until December 26, 2025. Drainage Permit number: 91371426065926234K001P.

1-10 Company name: Tianjin Jinjin Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of VOCs in exhaust gas emitted (kg)
6.52	20.64	0.01	0	0.14	1284.94	50.83	338.4
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
20091.19	6658.67	13432.52	95.6	95.6	0	36.41	6

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
7.25	6386.35	2265	244.19	0	0	0	8.76	5.84

Overall description: In 2020, the company invested RMB11.7416 million in annual environmental protection, of which RMB4.1436 million was invested in fixed assets and equipment, and RMB7.598 million was invested in daily management. As the old plant's fermentation and hydrogenation workshop started, the new plant increased the production of preparation workshops. The new plant used tap water to commission the newly renovated sewage treatment station, so the water consumption increased and the drainage volume also increased. Since the previous Drainage Permit only required the monitoring of VOCs and did not require monitoring of non-methane total hydrocarbons, it planned to increase the monitoring of non-methane total hydrocarbons in 2021 in accordance with the requirements of the new Drainage Permit. The changes in VOCs emissions in other exhaust gases were due to the shutdown of some processes in the plant, which led to changes in the total emissions. On December 29, 2017, the new plant obtained the national Drainage Permit, which is valid until December 28, 2020. Drainage Permit number: 91120111103851027X001P. On December 23, 2020, it submitted an extension application and was approved. On June 23, 2020, the old plant obtained the national Drainage Permit, which is valid until June 23, 2022. Drainage Permit number: 91120111103851027X002P.

1-11 Company name: Gansu Sine Tiansen Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
0.23	0.00002	0.000004	0	0.093	73.77	0	0
Greenhouse gas emissions (tonne)	**Direct greenhouse gas emissions (tonne)**	**Indirect greenhouse gas emissions (tonne)**	**Amount of general solid waste produced (tonne)**	**Amount of general solid waste disposed (tonne)**	**Amount of general solid waste utilized (tonne)**	**Amount of hazardous waste produced (tonne)**	**Amount of hazardous waste disposed of (tonne)**
200.43	60.99	139.44	15.5	15.5	0	0	0

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
0.26	73.60	19.50	2.13	0	0	0	1.68	3.11

Overall description: In 2020, the company's environmental protection investment was RMB0.002 million, which was used for the addition of activated sludge and normal operating expenses of the sewage treatment station. Due to production and operation reasons, the company is currently in a state of suspension. On November 23, 2017, it obtained the national Drainage Permit. On December 22, 2020， it conducted the change of Drainage Permit. On January 8, 2021, it completed the renewal application for Drainage Permit, which until November 25, 2025. Drainage Permit number: 91620500224902468W001P.

2-1 Company name: Shanghai SPH No. 1 Biochemical and Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted Ammonia (kg)	Amount of ammonia in exhaust gas emitted (kg)
17.49	5.81	0.18	2035.69	0.18	2947.69	136.97	99.18（Ammonia）
Greenhouse gas emissions (tonne)	**Direct greenhouse gas emissions (tonne)**	**Indirect greenhouse gas emissions (tonne)**	**Amount of general solid waste produced (tonne)**	**Amount of general solid waste disposed (tonne)**	**Amount of general solid waste utilized (tonne)**	**Amount of hazardous waste produced (tonne)**	**Amount of hazardous waste disposed of (tonne)**
29475.96	9950.27	19525.69	490	490	0	651.17	651.17

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
50.8397	13108.98	2772.51	393.24	0	0	0	8.38	0.59

Overall description: In 2020, the company invested RMB11 million in environmental protection, including RMB2 million for the operation and maintenance of pollution facilities, RMB0.46 million for the online operation and maintenance of wastewater and exhaust gas, and RMB7.7 million for hazardous waste treatment. On September 24, 2012, it obtained the first certification of the ISO14001 Environmental Management System, and completed the system supervision and review on August 10-12, 2020, with no non-conformities found. On December 9, 2020, it won the title of national green factory. On April 15, 2020, it applied for a voluntary unit for clean production review in 2020. Compared with 2019, it has reduced waste water emissions, waste water COD emissions, waste water N-NH3 emissions, waste gas non-methane total hydrocarbon emissions, exhaust gas nitrogen oxide emissions, and exhaust gas particulate matter emissions in 2020. On November 4, 2020, Jianchuan Road Workshop obtained the national Drainage Permit, which is valid until December 31, 2025. Drainage Permit number: 91310112133747458R003P. On November 4, 2020, Bijiang Road Workshop obtained the national Drainage Permit, which is valid until December 31, 2025. Drainage Permit number: 91310112133747458R001P.

2-2 Company name: Shanghai Ziyuan Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted Toluene (kg)	Amount of others in exhaust gas emitted (kg) Ammonia
0.78	0.91	0.13	710.2	0	67.2	2.43	134
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
894.77	118.64	776.13	0.25	0	0.25	237.22	237.82

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
0.87	363.77	110.11	0	0	0	0	5.81	32

Overall description: In 2020, the company invested RMB3.844 million in environmental protection, including maintenance and operation costs of pollution control facilities of RMB1.698 million, and hazardous waste disposal costs of about RMB1.795 million. Compared with 2019, COD in wastewater discharged decreased by 56% and f particulate matter in exhaust gas decreased by 55% in 2020. In 2020, due to the increase in production, the amount of hazardous waste generated increased. On December 29, 2020, passed the expert review of the cleanliness verification review. On January 1, 2018, obtained the national Drainage Permit. In December 2020, completed the application for the renewal of expired Drainage Permit， which is valid until December 31, 2025. Drainage Permit number: 9131011213334568690O1P.

3-1 Company name: Shanghai SPH New Asiatic Pharmaceutical Co., Ltd., Asia Pioneer Pharmaceutical Factory

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
48.24	18.29	0.12	3155.24	0.25	61.95	77.19	0
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
17593.92	165.67	17428.25	653.3	337.66	315.64	11.68	11.68

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
50.88	6331.59	1310.67	0	74575.22	0	6	9.4	3.28

Overall description: In 2020, the company invested about RMB2.536 million in environmental protection, including annual environmental monitoring, waste disposal (general industrial solid waste and hazardous waste), environmental protection facility operation and maintenance, update of wastewater lift pump in sewage treatment station, ISO three systems review certification and other costs. Compared with 2019, wastewater emissions decreased by 23.4%, N-NH3 in wastewater discharged decreased by 50%, SO2 in exhaust gas discharged decreased by 30%, NOx in exhaust gas discharged decreased by 75.5%, and greenhouse gas emissions decreased by 17.2%. Among them, direct emissions decreased by 46.5%, indirect emissions decreased by 16.7%, general solid waste generation decreased by 20.7%, and hazardous waste generation decreased by 79.2%. Compared with 2019, water consumption decreased by 27.3%, comprehensive energy consumption decreased by 15.9%, electricity consumption decreased by 12.4%, outsourcing heat consumption decreased by 21%, and gasoline consumption decreased by 39.9%. On December 25, 2019, it obtained the ISO14001 Environmental Management System certification, and on December 30, 2020, it obtained the ISO50001 Energy Management System certification and ISO45001 Occupational Health Management System certification. In 2020, it implemented clean production review. On December 18, 2020, obtained the national Drainage Permit, which is valid until December 17, 2023. Drainage Permit number: 91310115133738906M002X.

3-2 Company name: Shanghai SPH New Asiatic Pharmaceutical Co., Ltd. New Asiatic Pharmaceutical Factory

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
22.03	7.78	0.6	869.68	28.08	491.54	167.23	14.73
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
64070.14	57897.58	6172.56	92.27	0	92.27	72.43	72.43

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
24.48	4216.4	876.52	129.44	0	0	3.75	6.36	0.71

Overall description: In 2020, the company invested RMB3.6746 million throughout the year for the automation transformation of wastewater treatment equipment, repair of VOC devices, hazardous waste treatment fees, partial replacement of wastewater treatment station devices, operation of environmental protection facilities, and transformation of purified water distribution systems in preparation workshops, etc. Compared with 2019, wastewater emissions, exhaust gas emissions, greenhouse gas emissions, general solid waste and hazardous waste generation decreased in 2020; compared with 2019, the consumption of water, electricity, natural gas, liquefied petroleum gas and gasoline also decreased in 2020. In 2020, it completed the ISO14001 revision review , obtained the ISO50001 Energy Management System certification, and implemented the high and low cost plan in the clean production review. On December 31, 2019, obtained the national Drainage Permit, which is valid until December 30, 2022. Drainage Permit number: 91310115133738906M001V.

3-3 Company name: Shanghai New Asiatic Pharmaceutical Minhang Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of methanol in exhaust gas emitted (kg)
4.28	6.12	0.15	39.198	40.05	436.82	45.64	146.48
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
4941.25	828.59	4112.66	69.34	0	69.34	37.72	33.76

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
4.76	1112.27	516.43	24.61	4125.15	0	0	11.94	0.65

Overall description: In 2020, the company invested about RMB70,534 million in environmental protection, representing an increase of 183.2% year-on-year, including expenses for maintenance of various environmental protection facilities, new sewage treatment station, centralized steam supply transformation, annual water and gas sound testing costs, and hazardous waste disposal. In 2020, the amount of solid waste generated was 4.79 tonnes less than in 2019, a year-on-year decrease of 6.9%. At the end of September, it completed the transformation of centralized steam supply. The two natural gas boilers that originally supplied steam were out of service, reducing two boiler exhaust gas outlets, with no boiler exhaust gas generated in the subsequent period. On August 7, 2020, obtained the national Drainage Permit, which is Certificate valid until August 6, 2023. Drainage Permit number: 91310112133354160Q001V.

3-4 Company name: Liaoning Medya Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Emission of others （canteen oil fume） in exhaust gas (kg)
14.78	2.725	0.115	3.85	70	379	32	8.38
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
7496.65	311.71	7184.94	300	300	0	230.64	105.84

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
7.55	2739	461.92	11.14	64974.28	0	5.266	14.63	3.15

Comprehensive description: In 2020, it invested RMB1.8 million in the repair project of the sewage station of the intermediate plant, RMB1.5 million in the accident storage tank of the raw material plant, and RMB0.032 million in the landfill of the flood discharge ditch of the intermediate plant. Reasons why wastewater discharge is larger than water consumption: As the sewage station of the raw material plant was adjacent to No. 1 pump station in the development zone, the pump station in the undeveloped zone does not pump water as the pump was under repair, which caused sewage to invert, resulting in abnormal drainage data; the intermediate plant received and treated the production sewage of Fushun Yifengshun Chemical Co., Ltd. and treated the sewage of the spillway of the Organic Chemical Park, resulting in a significant increase in drainage. On December 22, 2017, the API Plant obtained the Drainage Permit issued by Fushun Environmental Protection Bureau. On December 24, 2018, it changed the Drainage Permit, which is valid until December 21, 2020. Drainage Permit number: 91210400603732518E001P. The Drainage Permit for the intermediate plant has been submitted for review and is pending the issuance of the permit by the ecological environment department of the government.

4-1 Company name: Shanghai Leiyunshang Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
15.23	7.59	0.66	24.12	29.43	1380.47	158.99	0
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
12871.78	4052.79	8818.99	1276	1276	0	34.56	34.56

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
20.95	6077.69	1253.11	182.70	0	0	0	9.71	16.83

Overall description: In 2020, the company invested about RMB3.02 million in environmental protection, of which RMB1.03 million was invested in the operation investment of sewage treatment facilities, RMB0.9 million was invested in the renovation of waste gas treatment facilities, RMB0.56 million was invested in general solid waste treatment, RMB0.33 million was invested in hazardous waste treatment, RMB0.11 million was invested in environmental monitoring, and RMB0.09 million was invested in online monitoring. In 2020, energy consumption such as electricity and gas was basically the same as last year. Industrial output value increased by 5.12% year-on-year, and energy consumption per RMB0.01 million of output value decreased by 3.38% year-on-year. On August 28, 2020, obtained the national Drainage Permit, which is Certificate valid until August 28, 2023. Drainage Permit number: 91310000631291406P001U.

4-2 Company name: Shanghai Leiyunshang Fengbang Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
0.77	0.29	0.0014	0	0	1400	904	0
Greenhouse gas emissions (tonne)	**Direct greenhouse gas emissions (tonne)**	**Indirect greenhouse gas emissions (tonne)**	**Amount of general solid waste produced (tonne)**	**Amount of general solid waste disposed (tonne)**	**Amount of general solid waste utilized (tonne)**	**Amount of hazardous waste produced (tonne)**	**Amount of hazardous waste disposed of (tonne)**
2085.02	961.71	1123.31	30	30	0	10.82	6.7

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
1.1	608.43	159.06	0	0	0	0	0	90

Overall description: In 2020 the company invested about RMB0.1 million in environmental protection. In 2020, energy consumption such as electricity and gas was basically the same as last year. Industrial output value increased by 6.8% year-on-year, and energy consumption per RMB0.01 million of output value decreased by 4.5% year-on-year. On May 9, 2020, completed the filing and registration of Drainage Permit. On May 11, 2020, changed the Drainage Permit, which is valid until May 10, 2025. Drainage Permit number: 91310114741645404X001Z.

4-3 Company name: Shanghai SPH Xingling Sci. & Tech. Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of odor emitted (kg)
6.67	8.4	0.11	91.26	0.82	565.82	2526.47	0
Greenhouse gas emissions (tonne)	**Direct greenhouse gas emissions (tonne)**	**Indirect greenhouse gas emissions (tonne)**	**Amount of general solid waste produced (tonne)**	**Amount of general solid waste disposed (tonne)**	**Amount of general solid waste utilized (tonne)**	**Amount of hazardous waste produced (tonne)**	**Amount of hazardous waste disposed of (tonne)**
5518.77	3085.06	2433.71	643.5	643.5	0	5.2	5.2

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
7.4	2562.08	345.92	132.53	0	0	2.45	31.4	16.4

Overall description: the total cost of environmental protection operation, maintenance and various pollutants treatment was about RMB2 million in 2020. The total consumption of water, electricity, gas and other items for the whole year decreased by more than 2 percentage points compared with 2019. In 2020, low-nitrogen burners were replaced for boilers with significant improvement in nitrogen removal effect , greatly reducing nitrogen oxide emissions. On August 19, 2020, the company obtained the Drainage Permit, which is valid until August 18, 2023. Drainage Permit number: 91310000631243797W001Q.

4-4 Company name: Shanghai Dehua Traditional Chinese Medicines Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
0.99	2.55	0.2	0	0.19	145.30	30.1	0
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
1059.39	77.5	981.89	62	62	0	1.5	1.5

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
1.1	791.48	55.81	0	5313.4	0	2.8	9.43	12.89

Overall description: In 2020 the company invested over RMB0.65 million in environmental protection. In 2020, water consumption was saved by 5,500 tonnes year-on-year; diesel oil was saved by 13.7 tonnes year-on-year; the heat consumption of outsourcing decreased by 170.1 million kJ year-on-year, and the comprehensive energy consumption decreased by 34.96 tonnes of standard coal year-on-year. On March 31, 2020, completed the registration and filing of Drainage Permit. On September 11, 2020, changed the Drainage Permit. On September 11, 2020, changed the Drainage Permit, which is valid until October 20, 2025. Drainage Permit number: 91310120607223032300 1Y.

4-5 Company name: Shanghai Yutiancheng Chinese Herbal Medicine Company Limited

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
0.48	0.34	0.006	0	0.18	233.68	136.09	0
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
863.32	272.09	591.22	20	20	0	1.22	1.22

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
0.53	229.47	83.7	0	0	0	0	8.8	78

Overall description: In 2020, the company invested about RMB0.8305 million in environmental protection, which was mainly used to increase sewage treatment equipment to reduce the risk of excessive sewage discharge. Compared with 2019, the amount of diesel used in 2020 decreased by 4.44 tonnes, and the amount of hazardous waste generated decreased by 1 tonne. On May 13, 2020, completed the registration and filing of Drainage Permit, which is valid until May 12, 2025. Drainage Permit number: 91310117134105094C001Z.

4-6 Company name: Shanghai Huapu Chinese Herbal Medicine Company Limited

Emissions							
Waste water emission (10,000 tonnes)	**Amount of COD in wastewater discharged (tonne)**	**Amount of N-NH3 in wastewater discharged (tonne)**	**Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)**	**Amount of sulfur dioxide in exhaust gas emitted (kg)**	**Amount of nitrogen oxide in exhaust gas emitted (kg)**	**Amount of particulate matter in exhaust gas emitted (kg)**	**Amount of others in exhaust gas emitted (kg)**
0.8	1.23	0.12	19.7	0.22	112.86	11.72	0
Greenhouse gas emissions (tonne)	**Direct greenhouse gas emissions (tonne)**	**Indirect greenhouse gas emissions (tonne)**	**Amount of general solid waste produced (tonne)**	**Amount of general solid waste disposed (tonne)**	**Amount of general solid waste utilized (tonne)**	**Amount of hazardous waste produced (tonne)**	**Amount of hazardous waste disposed of (tonne)**
595.26	208.95	386.31	46	46	0	1.41	0.91

Energy use								
Water consumption (10,000 tonnes)	**Comprehensive energy consumption (tonne of standard coal)**	**Electricity consumption (10,000 kWh)**	**Natural Gas Consumption (10,000 cubic meter)**	**Purchased thermal power consumption (million kJ)**	**Coal consumption (tonne)**	**Liquefied petroleum gas consumption (tonne)**	**Gasoline consumption (tonne)**	**Diesel fuel consumption (tonne)**
0.89	165.91	53.48	0	0	0	0	38.38	30

Overall description: In 2020, 1.3 million was invested in environmental protection, including RMB0.85 million for new sewage treatment facilities, RMB0.25 million for new laboratory waste gas treatment facilities, and RMB0.2 million for adding boiler exhaust gas treatment facilities. In 2020, laboratory exhaust gas was collected and treated, and non-methane total hydrocarbons began to be monitored regularly. In 2020, the total water consumption decreased by 3,100 tonnes compared with the same period in 2019; the diesel consumption decreased by 15 tonnes. On January 2, 2020, obtained the national Drainage Permit, which is Certificate valid until January 1, 2023. Drainage Permit number: 91310115133971097G001U.

4-7 Company name: Shanghai Huaying Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	**Amount of COD in wastewater discharged (tonne)**	**Amount of N-NH3 in wastewater discharged (tonne)**	**Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)**	**Amount of sulfur dioxide in exhaust gas emitted (kg)**	**Amount of nitrogen oxide in exhaust gas emitted (kg)**	**Amount of particulate matter in exhaust gas emitted (kg)**	**Amount of others in exhaust gas emitted (kg)**
0.33	0.12	0.01	0	1.09	5.16	4.93	0
Greenhouse gas emissions (tonne)	**Direct greenhouse gas emissions (tonne)**	**Indirect greenhouse gas emissions (tonne)**	**Amount of general solid waste produced (tonne)**	**Amount of general solid waste disposed (tonne)**	**Amount of general solid waste utilized (tonne)**	**Amount of hazardous waste produced (tonne)**	**Amount of hazardous waste disposed of (tonne)**
140.71	65.1	75.61	20	20	0	0.5	0.5

Energy use								
Water consumption (10,000 tonnes)	**Comprehensive energy consumption (tonne of standard coal)**	**Electricity consumption (10,000 kWh)**	**Natural Gas Consumption (10,000 cubic meter)**	**Purchased thermal power consumption (million kJ)**	**Coal consumption (tonne)**	**Liquefied petroleum gas consumption (tonne)**	**Gasoline consumption (tonne)**	**Diesel fuel consumption (tonne)**
0.41	43.51	10.68	0	0	0	0	4.31	16.5

Overall description: In 2020, the company invested about RMB0.078 million in environmental protection, of RMB0.05 million was invested in the renovation of waste gas treatment facilities, RMB0.003 million was invested in general solid waste treatment, RMB0.33 million was invested in hazardous waste treatment, RMB0.02 million was invested in environmental monitoring, and RMB0.005 million was invested in online monitoring. In June 2020, the company began to stop production due to adjustments in operations. On November 12, 2019, obtained the national Drainage Permit. On December 23, 2019, submitted additional application for the Drainage Permit, which is valid until August 20, 2023. Drainage Permit number: 91310116134205837 1001V.

4-8 Company name: Shanghai SPH Shenxiang Health Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
0.23	1.31	0.08	0	0	0	0	0
Greenhouse gas emissions (tonne)	**Direct greenhouse gas emissions (tonne)**	**Indirect greenhouse gas emissions (tonne)**	**Amount of general solid waste produced (tonne)**	**Amount of general solid waste disposed (tonne)**	**Amount of general solid waste utilized (tonne)**	**Amount of hazardous waste produced (tonne)**	**Amount of hazardous waste disposed of (tonne)**
461.57	0.18	461.39	8	8	0	0.36	0.36

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
0.25	187.76	65.19	0	0	0	0	0	0.14

Overall description: In 2020, the company invested about RMB100,000/year in environmental protection. On April 20, 2020, completed the registration and filing of Drainage Permit, which is valid until April 19, 2025. Drainage Permit number: 91310107MA1G0DLC0L001W.

4-9 Company name: Hongqing Huiyuan Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
0.78	0.26	0.002		60.01	904.56	91.3	0
Greenhouse gas emissions (tonne)	**Direct greenhouse gas emissions (tonne)**	**Indirect greenhouse gas emissions (tonne)**	**Amount of general solid waste produced (tonne)**	**Amount of general solid waste disposed (tonne)**	**Amount of general solid waste utilized (tonne)**	**Amount of hazardous waste produced (tonne)**	**Amount of hazardous waste disposed of (tonne)**
3231.51	2602.45	596.7	12	8.5	3.5	1.4	1

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
0.98	158.33	88.6	9.7	0	0	0	2.6	12

Overall description: In 2020, RMB0.1706 million was invested in environmental protection, of which RMB0.096 million was invested in the sewage treatment station, RMB0.04 million was invested in hazardous waste treatment, RMB0.013 million was invested in general waste treatment, RMB0.016 million was invested in environmental protection equipment maintenance, and environmental protection testing fees, RMB0.0056 million was invested in environmental protection inspection fee. Compared with 2019, the output value decreased by 0.89%, the output increased by 0.87%, the water increased by 1.87%, the electricity decreased by 5.27%, and the natural gas decreased by 9.94% in 2020. On May 9, 2020, completed the registration and filing of Drainage Permit. On May 11, 2020, changed the Drainage Permit, which is valid until May 10, 2025. Drainage Permit number: 91500106203062156L001W.

4-10 Company name: Sichuan SPH Shendu Traditional Chinese Medicine Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
0.17	0.085	0.0007	0	0	0	132	0
Greenhouse gas emissions (tonne)	**Direct greenhouse gas emissions (tonne)**	**Indirect greenhouse gas emissions (tonne)**	**Amount of general solid waste produced (tonne)**	**Amount of general solid waste disposed (tonne)**	**Amount of general solid waste utilized (tonne)**	**Amount of hazardous waste produced (tonne)**	**Amount of hazardous waste disposed of (tonne)**
65.89	0	65.89	0.6	0.35	0.25	0.22	0

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
0.21	35.63	8.82	0	0	0	0	0	0

Overall description: In 2020, the company invested about RMB0.1006 million in environmental protection. Compared with 2019, the annual output value in 2020 increased by 1.81% and the energy consumption decreased by 2.16%. On April 22, 2020, completed the registration and filing of Drainage Permit, which is valid until April 21, 2025. Drainage Permit number: 91510181684553908B001Y.

5-1 Company name: Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of ammonia in exhaust gas emitted (kg)
5.88	2.23	0.43	7684.34	0.15	2259.05	23.59	56.92
Greenhouse gas emissions (tonne)	**Direct greenhouse gas emissions (tonne)**	**Indirect greenhouse gas emissions (tonne)**	**Amount of general solid waste produced (tonne)**	**Amount of general solid waste disposed (tonne)**	**Amount of general solid waste utilized (tonne)**	**Amount of hazardous waste produced (tonne)**	**Amount of hazardous waste disposed of (tonne)**
8835.22	1489.38	7345.89	37.68	37.68	3.84	271.71	271.71

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
6.54	1569.93	685.69	0	22816.55	0	5.53	7.08	69.70

Overall description: In 2020, the company invested RMB12 million in environmental protection, including RMB4.52 million for the commissioned operation of the sewage treatment station, RMB0.3 million for the operation and maintenance of the waste gas treatment facility, RMB2.31 million for the disposal of hazardous waste, incinerators and sewage treatment stations, RMB1.82 million for the cost of operating and materials for the environmental protection facilities of the incinerator and sewage treatment station, RMB0.762 million for the environmental protection self-monitoring and online monitoring operation and maintenance cost, RMB0.6 million for the environmental protection consulting fee, and RMB1.3 million for other environmental protection costs. Compared with 2019, the amount of pollutants generated decreased by 20%. In 2020, the operation of incinerators was longer than in 2019, and the emissions of nitrogen oxides were relatively high. On January 1, 2018, obtained the national Drainage Permit. In April 2019, completed renewal of the Pollutant Discharge Permit . In the end of December 2020, completed the change and extension of the Drainage Permit, which is valid until December 31, 2025. Drainage Permit number: 91310120607349938600g1P.

5-2 Company name: Shanghai SPH Zhongxi Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
9.52	3.49	0.26	240.99	0.12	1125.82	297.38	0
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
10095.55	3382.65	6712.90	118	103	15	551.45	551.45

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
11.74	3244.07	949.82	154.74	0	0	0	5.87	0

Comprehensive description: In 2020, the company invested RMB3.51 million in environmental protection, including RMB0.8345 million for creation of green factory, RMB0.8445 million for sewage commissioned operation, RMB0.27 million for hazardous waste disposal, RMB0.7 million for environmental impact assessment, and RMB0.34 million for environmental testing. On October 16, 2020, it won the title of national green. In May 2020, it won the title of Shanghai Water-saving Enterprise. On August 21, 2020, obtained the national Drainage Permit, which is valid until August 20, 2023. Drainage Permit number: 9131011413362209XY001V.

5-3 Company name: Shanghai Jinhe Bio-Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of ammonia in exhaust gas emitted (kg)
1.59	1.96	0.14	12384	0	305.6	55.87	10.08
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
6178.33	991.22	5187.11	17.86	17.86	0	204.30	204.30

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
3.18	2933.01	736.68	40.89	0	0	0	14.99	3.85

Overall description: In 2020, the company expense invested a total of about RMB8.5 million in environmental protection (including daily management expenses). In 2020, due to the increase in production, the overall energy consumption increased significantly. The clean production review work carried out has passed expert evaluation. On July 23, 2020, obtained the national Drainage Permit, which is valid until July 23, 2022. Drainage Permit number: 91310118736688258F001V.

6-1 Company name: Shanghai Zhonghua Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
5.34	2.59	0.02	310.18	0.12	50.79	118.82	0
Greenhouse gas emissions (tonne)	**Direct greenhouse gas emissions (tonne)**	**Indirect greenhouse gas emissions (tonne)**	**Amount of general solid waste produced (tonne)**	**Amount of general solid waste disposed (tonne)**	**Amount of general solid waste utilized (tonne)**	**Amount of hazardous waste produced (tonne)**	**Amount of hazardous waste disposed of (tonne)**
4418.9	64.71	4354.19	62.52	54.38	8.14	53.2	53.2

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
5.93	1733.61	496.3	1	7779.4	0	0	3.66	2.69

Overall description: In 2020, the company invested a total of RMB1.28457 in environmental protection, including RMB0.59 million for the renovation of the sewage station and the replacement of waste gas treatment equipment in the second workshop. Hazardous waste, general solid waste, waste water and waste gas detection, management, publicity and other expenses were RMB0.69457 million. On September 1, 2020, obtained the national Drainage Permit, which is valid until August 31, 2023. Drainage Permit number: 91310105685497805C001P.

6-2 Company name: Shanghai Zhonghua Nantong Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
0.48	0.36	0.07	0	0.08	2.99	0.22	0
Greenhouse gas emissions (tonne)	**Direct greenhouse gas emissions (tonne)**	**Indirect greenhouse gas emissions (tonne)**	**Amount of general solid waste produced (tonne)**	**Amount of general solid waste disposed (tonne)**	**Amount of general solid waste utilized (tonne)**	**Amount of hazardous waste produced (tonne)**	**Amount of hazardous waste disposed of (tonne)**
3597.94	1227.46	2370.48	53	33	20	7.52	7.52

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
2.7	195.95	149.27	0	0	0	0.06	4.06	4.41

Overall description: In 2020, RMB0.5 million was invested to completely divert and transform the three types of pipe network channels for production wastewater, domestic sewage, and rainwater in the plant area. At the same time, 6 grease traps were installed. The annual sewage discharge decreased reduced by 22,000 tonnes compared with 2019. On March 25, 2020, it completed the filing and registration of Drainage Permit. On March 26, changed the Drainage Permit, which is valid until March 25, 2025. Drainage Permit number: 91320623608305953C001X.

7-1 Company name: Shanghai Sunway Biotech Co., LTD.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
0.56	0.06	0.005	14.06	0.23	4.37	0.42	0
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
1402.16	38.14	1364.02	3.4	3.4	0	0.099	0.099

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
0.63	580.04	130.98	0	4006	0	0	1.45	10.74

Overall description: In 2020, the company invested about RMB0.2 million in environmental protection, of which RMB0.064 million was used for obtaining the Drainage Permit, RMB0.068 million was used to transform the exhaust gas ducts of Ankerui workshop to meet environmental protection requirements, install an activated carbon treatment facility in the laboratory, and treat the experimental exhaust gas in an organized manner, and RMB0.059 million was used for newly added sewage flow meter, RMB0.008 million was used to dispose of hazardous waste. Compared with 2019, wastewater emissions decreased by 0.09 tonnes, COD in wastewater discharged decreased by 1.64 tonnes, N-NH3 in wastewater discharged decreased by 0.035 tonnes, and greenhouse gas emissions decreased by 509.34 tonnes in 2020. Compared with 2019, the water consumption decreased by 0.09 million tonnes, the electricity consumption decreased by 195,500 kWh, and the consumption of purchased heat decreased by 3577 million kJ in 2020. Starting in 2020, it monitored the concentration of non-methane total hydrocarbons in accordance with the requirements of the Drainage Permit. On July 24, 2020, obtained the national Drainage Permit, which is valid until July 23, 2023. Drainage Permit number: 913101156306061620001V.

8-1 Company name: Changzhou Pharmaceutical Factory Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of methanol in exhaust gas emitted (kg)
15.78	27.94	0.25	136.87	0.20	73.95	419.84	297.22
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
10886.13	320.34	10565.79	238.15	238.25	0	295.36	293.3

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
13.97	2743.71	996.57	1.08	31908.73	0	0.46	7.51	2.69

Overall description: In 2020, about 12 million yuan was invested in environmental protection, mainly for the operation, maintenance and technical improvement of pollutant treatment facilities. The enterprise added two diaphragm plate and frame filter presses, reducing the moisture content of the treated sludge to about 60%, and the average annual sludge reduction was 25%, reducing the sludge disposal fee by RMB0.15 million/year. In 2020, amount of COD in wastewater decreased by 10.94 tonnes and 0.09 tonnes year-on-year. On September 4, 2020, it obtained the ISO50001 energy management system certification. In 2020, it won the title of "Changzhou Environmental Protection Demonstration Enterprise and Institution in 2020". In December 2017, obtained the national Drainage Permit. In December 2020, completed the change and renewal of Drainage Permit, which is valid until December 7, 2025. Drainage Permit number: 91320400137158490L001P

8-2 Company name: Nantong Changyou Pharmaceutical Technology Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of ammonia emitted (kg)
11.27	22.54	0.34	2245.56	0.86	463.93	140.97	56.44
Greenhouse gas emissions (tonne)	**Direct greenhouse gas emissions (tonne)**	**Indirect greenhouse gas emissions (tonne)**	**Amount of general solid waste produced (tonne)**	**Amount of general solid waste disposed (tonne)**	**Amount of general solid waste utilized (tonne)**	**Amount of hazardous waste produced (tonne)**	**Amount of hazardous waste disposed of (tonne)**
12949.34	487.66	12417.05	150	150	0	1313.57	1354.99

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
10.93	7852.02	1012.99	10.97	47791.5	0	0	10.24	35.36

Overall description: In 2020, the company invested about RMB10.99 million in environmental protection, including investment of RMB1.7 million to build an EGSB reactor, which improved the efficiency of sewage treatment; investment of RMB0.25 million for packing repair of the original hydrolysis tank no. 1; investment of RMB0.4 million to add a magnetic suspension fan to replace the original Roots fan as aeration fan, saving 460,000 kWh of electricity every year; investment of RMB8.64 million in hazardous waste disposal fees, wastewater treatment and management fees and operating expenses. The annual production of sludge and hazardous waste was reduced by 110 tonnes. 100 tonnes of tetrahydrofuran was recovered. Due to the completion and the commencement of formal production of the construction of the second phase of the project, the amount of hazardous waste rose sharply. Completed renewal of the National Pollutant Discharge Permit in November 2017. On October 30, 2020, completed the change and renewal of the Drainage Permit, which is valid until November 13, 2025. The discharge permit number is 91320623575376 48XH001P.

8-3 Company name: Chifeng Arker Pharmaceutical Technology Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
3.46	3.16	0.24	18949	0.16	4.57	0.34	0
Greenhouse gas emissions (tonne)	**Direct greenhouse gas emissions (tonne)**	**Indirect greenhouse gas emissions (tonne)**	**Amount of general solid waste produced (tonne)**	**Amount of general solid waste disposed (tonne)**	**Amount of general solid waste utilized (tonne)**	**Amount of hazardous waste produced (tonne)**	**Amount of hazardous waste disposed of (tonne)**
7700.78	111.49	7589.29	107.42	0	104.22	12.21	10.05

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
4.16	6583.16	364.44	0	45666.72	0	0	6.7	1.03

Overall description: In 2020, the enterprise invested RMB1.286 million in environmental protection, including RMB1.044 million for operation of pollution prevention facilities, RMB0.04 million for treatment of solid wastes, RMB0.06 million for detest fees, RMB0.122 million for association, newspapers, books, publicity, etc. On December 29, 2017, it obtained the national Drainage Permit. After that, it underwent a second change. On December 9, 2020, it completed the renewal application for Drainage Permit. The new Drainage Permit is valid until December 28, 2025. Drainage Permit number: 91150400720172660N001P. In 2021, it will monitor pollution factors such as benzene series and hydrogen chloride in accordance with the requirements of the Drainage Permit.

8-4 Company name: Chifeng Mysun Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
4	11.39	0.37	0	2.5	16.45	583.68	0
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
3538.71	424.95	3113.77	1.6	1.6	0	0	0

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
5	1958.51	301.53	0	8988.89	0	0	31.45	103.42

Overall description: In 2020, the enterprise invested RMB0.554 million in environmental protection, including RMB0.383 million for operation of pollution prevention facilities, RMB0.106 million for equipment and facilities investment cost, RMB0.055 million for detest fees, RMB0.01 million for association, newspapers, books, publicity, etc. On July 10, 2020, obtained the national Drainage Permit. On August 24, 2020, changed the Drainage Permit, which is valid until July 9, 2023. Drainage Permit number: 91150402114795518Q001V.

9-1 Company name: SPH Qingdao Growful Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
8.76	9.98	0.19	0	2.16	374.22	1995.42	0
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
19680.98	1321.94	18359.04	689	87	602	8.85	8.3

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
11.68	4460.05	958	1.16	96266	0	0	40.75	69.83

Overall description: In 2020, the company invest about RMB2.361 million in environmental protection, including RMB1.759 million for the operation and maintenance of pollutant treatment facilities, RMB0.2 million for the technical transformation of waste gas treatment facilities, RMB0.03 million for the cost of obtaining pollutant discharge permit and handling the emergency response plan filing, RMB0.11 million for self-monitoring cost, about RMB0.182 million for solid waste disposal cost, and about RMB0.08 million for the environmental assessment cost. In 2020, water consumption decreased by 11.98% year-on-year, and the consumption of purchased heat decreased by 18.29% year-on-year. The conversion coefficient of wastewater discharge was 0.75. On July 29, 2020, obtained the national Drainage Permit, which is valid until July 28, 2023. Drainage Permit number: 91370200264584097H001V.

10-1 Company name: Xiamen Traditional Chinese Medicine Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
8.06	2.58	0.03	0	0.65	67.67	5.66	0
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
9680.70	94.98	9585.72	849.10	823.50	25.60	4.61	4.61

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
11.57	1987.45	586.35	0	36486.8	0	0	25.57	4.96

Overall description: In 2020, a total of RMB1.32 million was invested in environmental protection, including the maintenance of various environmental protection facilities, annual waste water, exhaust gas, noise pollutant inspection costs, and solid waste disposal fees. In 2020, the consumption of purchased heat decreased by 18% year-on-year, comprehensive energy consumption decreased by 16.79% year-on-year, and electricity consumption decreased by 7.8% year-on-year. On August 12, 2020, obtained the national Drainage Permit, which is valid until August 12, 2023. Drainage Permit number: 91350200155021172500 1U.

11-1 Company name: Chiatai Qingchunbao Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
20.28	7.10	0.04	0	98.17	3700.41	679.75	0
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
14446.45	6036.84	8409.61	3787	587	3200	70.57	70.57

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
27.57	4393.85	1113.52	235.38	0	0	0	71.98	37.58

Overall description: In 2020, the company invested RMB2.83 million in environmental protection, including the major revision of the company's rain and sewage pipe network and the company's soil survey. In 2020, wastewater discharge will be reduced by 73,500 tonnes year-on-year, amount of COD in wastewater discharged decreased by 15.83 tonnes year-on-year, the amount of hazardous waste generated decreased by 13.61 tonnes year-on-year, greenhouse gas emissions decreased by 7,266.44 tonnes year-on-year, and the comprehensive energy consumption decreased by 2,805.22 tonnes of standard coal year-on-year. Completed the annual review and certification of the new version of the environmental management system GB/T24001-2016 standard. On August 18, 2020, obtained the national Drainage Permit, which is valid until August 17, 2023. Drainage Permit number: 91330100609120766P001U.

12-1 Company name: Hangzhou Huqingyutang Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
15.32	4.14	0.47	0	0.74	1456.73	486.42	0
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
12826.24	128.48	12697.76	4542.1	121	4421.1	6.55	6.4

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
15.3	3252.48	801.24	0	64093.23	0	5.2	37.54	18.31

Overall description: In 2020, the total investment in environmental protection was RMB2.25 million (RMB1.68 million for the first phase of the sewage treatment station, RMB0.03 million for renovation for exhaust gas from the cooking room, RMB0.04 million for renovation for exhaust gas from laboratory, and RMB0.5 million for other costs). Despite an 11.62% increase in production capacity, electricity consumption dropped by 3.17% year-on-year; tap water consumption decreased by 1.61% year-on-year; the amount of sewage generated decreased by 21.96% year-on-year; energy consumption per RMB0.01 million output value decreased by 9.02% year-on-year; total cost decreased by 10.73% compared with last year; on December 29, 2020, the company established a new energy management system. The certificate is valid until December 28, 2023. Certificate number: 074417En. On July 30, 2020, obtained the national Drainage Permit. On September 30, 2020, changed the Drainage Permit, which is valid until July 31, 2023. Drainage Permit number: 91330100716100250300 1Q.

13-1 Company name: Liaoning SPH Herbapex Pharmaceutical (Group) Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
9.4	10.72	0.069	0	969.7	6679.01	2279.14	0
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
29553.65	20209.76	9343.89	5387	0	5387	0.06	0.06

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
11.71	6219.96	817.73	0	29225.92	9720	4	23.86	14.39

Overall description: In 2020, the company invested RMB0.2415 million in environmental monitoring and exhaust gas treatment. Completed the renovation of environmental protection facilities for boiler. Through the renovation , the boilers' sulfur dioxide, nitrogen oxide, and particulate pollutant emission concentration kg/h decreased from the original 26.085, 5.402, 2.405 to 0.135, 0.7, 0.82, and the discharge of pollutants dropped significantly. Installed boiler online monitoring. In 2020, sulfur dioxide emissions decreased by 117,978.47 kilograms and nitrogen oxide emissions decreased by 18,366.53 kilograms. The entire plant's particulate matter emissions decreased by 9,817.47 kg. At the same time, the company planted more than 6,198 trees, an increase of 538 trees compared to last year, reducing 142.55 tonnes of carbon dioxide emissions. At present, the company does not have organized VOCs, so the total non-methane hydrocarbon emissions are not calculated. On July 9, 2020, it obtained ISO14001 Environmental Management System certification. On June 23, 2020, obtained the national Drainage Permit, which is valid until June 23, 2022. Drainage Permit number: 91210000701855714F001V.

14-1 Company name: SPH Dong Ying (Jiangsu) Pharmaceutical Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of others in exhaust gas emitted (kg)
0.43	0.06	0.007	0	0.36	235.59	20.25	0
Greenhouse gas emissions (tonne)	**Direct greenhouse gas emissions (tonne)**	**Indirect greenhouse gas emissions (tonne)**	**Amount of general solid waste produced (tonne)**	**Amount of general solid waste disposed (tonne)**	**Amount of general solid waste utilized (tonne)**	**Amount of hazardous waste produced (tonne)**	**Amount of hazardous waste disposed of (tonne)**
1696.47	347.16	1349.3	7.8	5.8	2.0	1.48	1.48

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
1.84	299.27	124.66	0.53	4237.09	0	0	4.96	13.44

Overall description: In 2020, the company invested RMB0.1513 million in environmental protection, which was mainly used for the operation of daily pollution facilities. In 2020, COD emissions decreased by 62.63% compared with 2019. On August 20, 2020 it obtained ISO14001 environmental management system certification certificate. On March 23, 2020, completed the registration and filing of Drainage Permit, which is valid until March 22, 2025. Drainage Permit number: 91320691138738649100 1W.

14-2 Company name: SPH Changzhou Kony Pharmaceutical Co., Ltd

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of methanol in exhaust gas emitted (kg)
4.99	2.05	0.021	173.7	0.2	411.02	30.35	69.47
Greenhouse gas emissions (tonne)	**Direct greenhouse gas emissions (tonne)**	**Indirect greenhouse gas emissions (tonne)**	**Amount of general solid waste produced (tonne)**	**Amount of general solid waste disposed (tonne)**	**Amount of general solid waste utilized (tonne)**	**Amount of hazardous waste produced (tonne)**	**Amount of hazardous waste disposed of (tonne)**
6401.34	2036.07	4365.27	117.1	115	2.1	298.45	298.45

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
5.07	1627.84	619	76.06	0	0	0	2.12	10.32

Overall description: In 2020, the company invested RMB2.7 million in environmental protection, mainly used in the homogenization tank and secondary sedimentation tank of the wastewater treatment station, the upgrade and transformation of the sludge pressure filter, the low-nitrogen upgrade and transformation of the gas boiler, the addition of online total nitrogen monitoring facilities and portable non-methane total hydrocarbon monitor, etc. Compared with 2019, COD emissions decreased by 2.55 tonnes in 2020. After the low-nitrogen upgrade and renovation of the boilers, the exhaust nitrogen oxide emissions decreased by 1,258.1 kg, the exhaust particulate matter emissions decreased by 63.67 kg, and the indirect greenhouse gas emissions decreased by 268.22 tonnes and general solid waste decreased by 16.9 tonnes. Compared with 2019, water consumption decreased by 0.11 million tonnes and electricity consumption decreased by 380,000 kWh in 2020. On May 25, 2020， it obtained ISO14001 environmental management system certification certificate (renewal upon expiry). On December 4, 2018, obtained the national Drainage Permit, which is valid until December 3, 2021. Drainage Permit number: 9132041271689963X2001P.

15-1 Company name: Shanghai Pharmaceutical Group (Benxi) Northern Pharma Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of sulfuric acid mist in exhaust gas emitted (kg)
3.48	1.65	0.31	407.45	478.78	3485.83	250.37	2.33
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
6488.72	3765.44	2723.28	42.65	40	2.65	70.24	69.04

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
6.39	3262.13	809.60	166.66	0	0	0	21.18	9.86

Overall description: In 2020, environmental protection investment will be about RMB2.4047 million, of which about RMB1.59 million was invested in environmental protection equipment and facilities, and about RMB0.8147 million was invested in daily management. In May 2018, obtained the Drainage Permit issued by the Ministry of Environmental Protection; in 2019, changed the Drainage Permit, and in May 2019, obtained the change approval for the Drainage Permit, which is valid until May 28, 2021. Drainage Permit number: 91210500318644906M001P.

16-1 Company name: Techpool Bio-pharma Co., Ltd.

Emissions							
Waste water emission (10,000 tonnes)	Amount of COD in wastewater discharged (tonne)	Amount of N-NH3 in wastewater discharged (tonne)	Total amount of non-methane hydrocarbon in exhaust gas emitted (kg)	Amount of sulfur dioxide in exhaust gas emitted (kg)	Amount of nitrogen oxide in exhaust gas emitted (kg)	Amount of particulate matter in exhaust gas emitted (kg)	Amount of ethanol in exhaust gas emitted (kg)
4.45	8.56	0.06	16.68	219	1489.2	24.33	70.55
Greenhouse gas emissions (tonne)	Direct greenhouse gas emissions (tonne)	Indirect greenhouse gas emissions (tonne)	Amount of general solid waste produced (tonne)	Amount of general solid waste disposed (tonne)	Amount of general solid waste utilized (tonne)	Amount of hazardous waste produced (tonne)	Amount of hazardous waste disposed of (tonne)
7476.93	2547.74	4929.19	842.57	808.18	34.39	555.28	554.05

Energy use								
Water consumption (10,000 tonnes)	Comprehensive energy consumption (tonne of standard coal)	Electricity consumption (10,000 kWh)	Natural Gas Consumption (10,000 cubic meter)	Purchased thermal power consumption (million kJ)	Coal consumption (tonne)	Liquefied petroleum gas consumption (tonne)	Gasoline consumption (tonne)	Diesel fuel consumption (tonne)
6.79	1374.86	695.72	39.08	0	0	0	0	0

Overall description: In 2020, the enterprise invested a total of RMB2.732 million in environmental protection, including RMB0.0588 million for waste water facility operating costs, RMB2.1126 million for waste treatment, RMB0.072 million for environmental protection monitoring, RMB0.4604 million for plant greening, and RMB0.028 million for other environmental protection investment. For the whole year of 2020, the consumption of tap water decreased by 25.91% compared with the previous year. In 2020, the amount of hazardous waste generated was 555.28 tonnes, representing a significant decrease from the 1,037.55 tonnes in 2019. Due to the change in product categories in 2020, the output of Ulinastatin, which mainly produced waste alcohol, decreased, resulting in a decrease in the amount of waste alcohol produced. December 18, 2017, obtained the national Drainage Permit.
On December 16, 2020, completed the renewal of the Drainage Permit, which is valid until December 18, 2025. Drainage Permit number: 91440101190490505C001P.

VI | Packaging for finished products

Name of company	Category of materials	Name of materials	Amount of materials purchased (kg)	Material usage (kg)	Recycling amount (kg)	Recycling rate (%)
Shanghai SPH Sine Pharmaceutical Laboratories Co., Ltd., General Factory	Raw material	Metformin Hydrochloride	57825	54551.22	/	/
	Raw material	Methotrexate	195.47	246.61	/	/
	Raw material	Digoxin	43.521	44.086	/	/
	Raw material	Spironolactone	9.68	682.6	/	/
	Raw material	Salbutamol Sulfate	2	31.82	/	/
	Auxiliary materials	Corn starch	47000	45825	/	/
	Auxiliary materials	White sugar	0	900	/	/
	Auxiliary materials	Pregelatinized starch	51099.95	48749.95	/	/
	Auxiliary materials	Magnesium stearate	2979.06	2288.2	/	/
	Auxiliary materials	White dextrin	1700	1800	/	/
	Auxiliary materials	Talcum powder	2000	1480.64	/	/
	Auxiliary materials	Magnesium oxide	1280	1585.68	/	/
	Auxiliary materials	Mannitol (Imported)	1500	1404.64	/	/
	Auxiliary materials	Polyvinylpyrrolidone k29/32	199.6	119.48	/	/
	Auxiliary materials	Film coating premix HEY5403747	500	375.96	/	/
	Auxiliary materials	Titanium dioxide	50	69.86	/	/
	Auxiliary materials	Hypromellose / E5-LV	4975	4250	/	/
	Auxiliary materials	Calcium carbonate	100	117	/	/
	Auxiliary materials	Cross-linked PVPxl	1098.3	860.64	/	/
	Auxiliary materials	95% Ethanol	30690	31302	/	/
	Auxiliary materials	Carmellose sodium (SH-SJJ-4000) 7000	7000	4276	/	/
	Auxiliary materials	Hypromellose K100M	40250	34000	/	/
	Auxiliary materials	Microcrystalline cellulose PH302 Asahi Kasei	16825	10325.5	/	/
	Auxiliary materials	99.5% Ethanol	3296.568	3386.568	/	/
	Auxiliary materials	HFA-134a	18620.64	18640.84	/	/

Name of company	Category of materials	Name of materials	Amount of materials purchased (kg)	Material usage (kg)	Recycling amount (kg)	Recycling rate (%)
	Auxiliary materials	Maltodextrin	12400	8100	/	/
	Auxiliary materials	Skim milk powder	59663	59213	/	/
	Auxiliary materials	Oligofructose P95	6150	5525	/	/
	Auxiliary materials	Fresh milk essence (powder)	260.08	180.08	/	/
	Auxiliary materials	Glucose (water free)	6475	5150	/	/
	Auxiliary materials	Yeast extract	8003	6694	/	/
	Auxiliary materials	Trypticase soy agar	10484	8272	/	/
	Auxiliary materials	Soy peptone	2000	2056.5	/	/
	Auxiliary materials	Dipotassium phosphate	524	538.9	/	/
	Auxiliary materials	Ammonium sulphate	800	800.5	/	/
	Auxiliary materials	Ammonium sulphate	10000	8733	/	/
	Auxiliary materials	Vitamin C Sodium	300	275	/	/
	Packaging materials	Medicinal high density polyethylene bottle for oral solid	6311.58	6048.92	/	/
	Packaging materials	Medicinal high density polyethylene bottle for oral solid	10777.6	10487.6	/	/
	Packaging materials	Medicinal aluminum platinum for Digoxin 30 tablets	827.1	1091.1	/	/
	Packaging materials	Polyvinyl chloride solid medicinal hard patch (digoxin)	5362.8	8632.8	/	/
	Packaging materials	Medicinal high density polyethylene bottle for oral solid	370.46	439.46	/	/
	Packaging materials	Medicinal high density polyethylene bottle for oral solid dosage 50ml/01B	12826.7	12822.5	/	/
	Packaging materials	Bidobacterium triple active bacteria powder composite film			/	/
Shanghai Sine Tianping Pharmaceutical Co., Ltd.	Raw material	Sulfasalazine	72860.97	65939.09	/	/
	Auxiliary materials	Pregelatinized starch	24072	22340	/	/
	Auxiliary materials	Starch	50160	47961	/	/
	Auxiliary materials	Magnesium stearate	6671	7049	/	/
	Auxiliary materials	Carboxymethyl starch sodium	12715	13271	/	/
	Packaging materials	Aluminum foil for 60 tablets/box of salazide	3659	3652	/	/
	Packaging materials	PVC for 60 tablets/box of salazide	22621	22299	/	/
	Packaging materials	Single box for 60 tablets/box of salazide	2399930	2268270	/	/
	Packaging materials	Medicinal high density polyethylene bottle for 60 tablets of salazide	1809590	1916799	/	/

Name of company	Category of materials	Name of materials	Amount of materials purchased (kg)	Material usage (kg)	Recycling amount (kg)	Recycling rate (%)
	Packaging materials	Single box for 60 tablets/bottle of salazide	1411180	1381280	/	/
	Packaging materials	Medicinal high density polyethylene bottle for 100 tablets of salazide	0	0	/	/
	Packaging materials	Single box for 100 tablets/bottle of salazide	485250	470225	/	/
Shanghai SPH Sine Pharmaceutical Laboratories Co., Ltd., No. 2 Subsidiary	Raw material	Warfarin sodium	827	877.141	/	/
	Raw material	Amiodarone hydrochloride	7075	8031.67	/	/
	Auxiliary materials	Dextrin	4914	4914	/	/
	Auxiliary materials	Pregelatinized starch	4947	4947	/	/
	Auxiliary materials	Microcrystalline cellulose	11473	11473	/	/
	Auxiliary materials	Corn starch	5767.5	5767.5	/	/
	Auxiliary materials	Magnesium stearate	349.76	349.76	/	/
	Packaging materials	Medicinal high density polyethylene bottle	5088500 pieces	5082000 pieces	/	/
	Packaging materials	Medicinal PVC	6083.6	6195.3	/	/
	Packaging materials	Medicinal aluminum foil	1039.6	1016.2	/	/
Shanghai Sine Jinzhu Pharmaceutical Co., Ltd.	Raw material	Salbutamol Sulfate	200	140	/	/
	Auxiliary materials	Sodium chloride	1000	101	/	/
	Packaging materials	Low borosilicate glass ampoule	46,947,552 pieces	46,947,552 pieces	/	/
	Packaging materials	Single box	10,272,100 pieces	10,272,100 pieces	/	/
Shandong Sine Pharmaceutical Co., Ltd.	Raw material	Amiodarone	8600	2280	/	/
	Raw material	Lorazepam	236.33	157.5	/	/
	Auxiliary materials	Lactose	30000	7605	/	/
	Auxiliary materials	PH302	16000	12474	/	/
	Auxiliary materials	Magnesium stearate	1500	253.6	/	/
	Auxiliary materials	Starch	53000	315	/	/
	Auxiliary materials	Pregelatinized starch	9000	1672	/	/
	Auxiliary materials	Microcrystalline cellulose	2000	1140	/	/
	Packaging materials	PVC	20000	20038.3	/	/

Name of company	Category of materials	Name of materials	Amount of materials purchased (kg)	Material usage (kg)	Recycling amount (kg)	Recycling rate (%)
	Packaging materials	Aluminum foil	3796	3695.1	/	/
	Packaging materials	Manual	7078000	7077924	/	/
	Packaging materials	Xiaohe	7078000	7077924	/	/
	Packaging materials	Cardboard box	31800	31777	/	/
	Packaging materials	Composite film	10000	8636	/	/
Shanghai Fuda Pharmaceutical Co., Ltd.	Raw material	Sulfasalazine	14700	14700	/	/
	Raw material	Spironolactone	1500	1500	/	/
	Auxiliary materials	Corn starch	8870	8870	/	/
	Auxiliary materials	Dextrin	480	480	/	/
	Auxiliary materials	Low-substituted hydroxypropyl cellulose	1150	1150	/	/
	Auxiliary materials	Magnesium stearate	288	288	/	/
	Auxiliary materials	Carboxymethyl starch sodium	148	148	/	/
	Auxiliary materials	Coated powder	2450	2450	/	/
	Auxiliary materials	Calcium hydrogen phosphate	2241	2241	/	/
	Packaging materials	Medicinal PVC	10780	10780	/	/
	Packaging materials	Medicinal high density polyethylene bottle	750,000 pieces	750,000 pieces	/	/
	Packaging materials	Medicinal aluminum foil	1568	1568	/	/
SPH No. 1 Biochemical & Pharmaceutical Co., Ltd.	Raw material	Tanshinone IIA	2304	2256	/	/
	Raw material	Pericarpium trichosanthis	132000	116850	/	/
	Raw material	Chymotrypsinogen	15.64	145.219	/	/
	Raw material	Dibutyl cyclic phosphate adenosine calcium	786.391	702.463	/	/
	Auxiliary materials	Glucose (for injection)	4000	5849.775	/	/
	Auxiliary materials	Dichloromethane (industrial)	73800	74475	/	/
	Auxiliary materials	Hydrochloric acid (CP)	28800	28520	/	/
	Auxiliary materials	Ethanol (food grade)	772870	772870	/	/
	Auxiliary materials	Mannitol injection (250ml: 50g)	400	1328	/	/
	Auxiliary materials	Dextran 20	250	161.12374	/	/
	Packaging materials	Low borosilicate glass ampoule（2ml）	113,492,000 pieces	105,124,600 pieces	/	/

Name of company	Category of materials	Name of materials	Amount of materials purchased (kg)	Material usage (kg)	Recycling amount (kg)	Recycling rate (%)
	Packaging materials	Low borosilicate glass ampoule（5ml）	7,202,184 pieces	6,577,808 pieces	/	/
	Packaging materials	Low borosilicate glass control injection bottle (2ml)	33,804,750 pieces	28,909,230 pieces	/	/
	Packaging materials	Freeze-dried halogenated butyl rubber plug for injection (Φ13)	38,407,500 pieces	37,690,000 pieces	/	/
	Packaging materials	Small box for tanshinone IIA sodium sulfonate injection (2ml: 10mg)	14,109,700 pieces	14,486,200 pieces	/	/
	Packaging materials	Small box for dibutyl cyclic phosphate adenosine calcium for injection (20mg)	12,978,400 pieces	12,172,700 pieces	/	/
	Packaging materials	Small box for chymotrypsinogen for injection (4000u)	1,486,000 pieces	1,122,700 pieces	/	/
	Packaging materials	Small box for pericarpium trichosanthis injection (4ml)	4,448,300 pieces	4,518,800 pieces	/	/
Shanghai Leiyunshang Pharmaceutical Co., Ltd.	Raw material	Salvia miltiorrhiza	864900	943635.25	/	/
	Raw material	Patchouli oil	320	153.28	/	/
	Auxiliary materials	Corn starch	48000	51909.33	/	/
	Auxiliary materials	Salvia miltiorrhiza tablet coating premix	12000	11567.6	/	/
	Auxiliary materials	Polyethylene glycol 6000	2060	1334	/	/
	Packaging materials	1*1 color box for 100 salvia miltiorrhiza tablets	1560000(pieces)	1380000(pieces)	/	/
	Packaging materials	60mlMedicinal high density polyethylene bottle	1630000(pieces)	1340000(pieces)	/	/
	Packaging materials	1*1 color box for 60 tablets of Huodan Diwan	1189919(pieces)	509100(pieces)	/	/
	Packaging materials	Bottle with cover for 60 tablets of Huodan Diwa	1005000(pieces)	508400(pieces)	/	/
	Packaging materials	Color box for 10 tablets*6 tubes/box of Liushenwan (artificial)	2560800(pieces)	2718686(pieces)	/	/
	Packaging materials	Bottle with cover for 10 tablets/tube of Liushenwan	22230000(pieces)	22987560(pieces)	/	/
Shanghai Leiyunshang Fengbang Pharmaceutical Co., Ltd.	Raw material	Hypoglaucous Collett Yam Rhizome	6240	7200	/	/
	Raw material	Liquorice Root	3120	3600	/	/
	Raw material	Combined Spicebush Root	1560	1800	/	/
	Auxiliary materials	Talcum powder	7000	6591	/	/
	Auxiliary materials	Sucrose	1800	1450	/	/
	Packaging materials	Medicinal high density polyethylene bottle	2475000	3141437	/	/
	Packaging materials	Color box	200298	339625	/	/
Shanghai SPH Xingling Sci. & Tech. Pharmaceutical Co., Ltd.	Raw material	Ginkgo leaf	663030	643200	/	/
	Raw material	Ginkgo ketoester	604.8	604.8	/	/

Name of company	Category of materials	Name of materials	Amount of materials purchased (kg)	Material usage (kg)	Recycling amount (kg)	Recycling rate (%)
	Auxiliary materials	Ethanol	376430	371935	/	/
	Auxiliary materials	Macroporous resin	9600	9600	/	/
	Auxiliary materials	Polyamide resin	4800	4800	/	/
	Auxiliary materials	Cyclohexane	18300	18750	/	/
	Auxiliary materials	Corn starch	1600	1267.2	/	/
	Auxiliary materials	Microcrystalline cellulose	175	252	/	/
	Auxiliary materials	Carboxymethyl starch sodium	125	180	/	/
	Auxiliary materials	Film coating premix	200	216	/	/
	Packaging materials	Ginkgo ketone ester paper bucket	1492	1693	/	/
	Packaging materials	20mlMedicinal high density polyethylene bottle	1005400	1098788	/	/
	Packaging materials	Small box of ginkgo ketone ester tablets (12 tablets)	1400800	1008803	/	/
	Packaging materials	Medium box of ginkgo ketone ester tablets (12 tablets)	174960	100883	/	/
Changzhou Pharmaceutical Factory Co., Ltd.	Raw material	Reserpine	33kg	18.437kg	/	/
	Raw material	Dihydrazide sulphate	5875kg	4782.59kg	/	/
	Auxiliary materials	Starch	70000kg	69832.95kg	/	/
	Packaging materials	30mlMedicinal high density polyethylene bottle	3504400	3440000	/	/
	Packaging materials	15mlMedicinal high density polyethylene bottle	16151900	15680000	/	/
	Packaging materials	Small box	29813530 pieces	28520932 pieces	/	/
Nantong Changyou Pharmaceutical, Ltd.	Raw material	(3R)-3-(3R)-3-tertbutyldimethylglyoxylglutarateRmandelate	33610	31511.2	/	/
	Auxiliary materials	Methanol	311720	311720	202618	65.00%
	Auxiliary materials	Triethylamine	23380	26040	19530	75.00%
	Auxiliary materials	Toluene	98340	98340	88506	90.00%
	Packaging materials	Medicinal transparent polyethylene bags	82000 pieces	82600 pieces	/	/
SPH New Asia Pharmaceutical Co., Ltd.	Raw material	Ceftriaxone	37,981.81	38,289.80	/	/
	Raw material	Meropenem	703.39	665.18	/	/
	Raw material	Cefotiam Hydrochloride	9,349.31	8,800.10	/	/
	Raw material	Ceftazidime	3,390.00	1,268.00	/	/
	Raw material	Praxilene Sodium Sulbactam	2,408.63	2,410.00	/	/

Name of company	Category of materials	Name of materials	Amount of materials purchased (kg)	Material usage (kg)	Recycling amount (kg)	Recycling rate (%)
	Raw material	Cefamandole Nafate	2,070.90	1,908.71	/	/
	Raw material	Amphotericin B	1.35	11.29	/	/
	Auxiliary materials	Anhydrous sodium carbonate	3,230.00	2,878.14	/	/
	Auxiliary materials	Sodium deoxycholate	40	30	/	/
	Auxiliary materials	Lecithin	/	48.7	/	/
	Auxiliary materials	Pregelatinized starch	/	/	/	/
	Packaging materials	10ml molded bottles	87,570,672 pieces	78,021,500 pieces	/	/
	Packaging materials	25ml molded bottles	10,561,600 pieces	11,006,000 pieces	/	/
	Packaging materials	30ml molded bottles	4,057,200 pieces	4,047,300 pieces	/	/
	Packaging materials	25ml glass vials	792,000 pieces	791,800 pieces	/	/
	Packaging materials	Coated butyl rubber plug	22,563,000 pieces	20,783,900 pieces	/	/
	Packaging materials	Butyl rubber plug	53,430,000 pieces	63,606,200 pieces	/	/
	Packaging materials	Freeze-dried butyl rubber plug	/	2,336,000 pieces	/	/
Shanghai New Asiatic Pharmaceutical Minhang Co., Ltd.	Raw material	Benazepril hydrochloride	1,318.49	1,283.93	/	/
	Raw material	Amoxicillin potassium clavulanate (7:1)	4,228.68	4,332.01	/	/
	Raw material	Cefixime	2,870.06	2,960.57	/	/
	Auxiliary materials	Microcrystalline cellulose（import PH102）	10,013.07	11,098.48	/	/
	Auxiliary materials	Lactose(import 200M)	22,809.22	25,738.09	/	/
	Auxiliary materials	Low-substituted hydroxypropyl cellulose	1,937.88	2,048.50	/	/
	Auxiliary materials	Hypromellose	1,600.00	1,558.36	/	/
	Auxiliary materials	Ethanol (water free)	6,048.00	6,135.84	/	/
	Auxiliary materials	Ethanol	47,647.90	47,853.78	/	/
	Auxiliary materials	Coated powder（OY-22967）	1,169.70	1,151.71	/	/
	Auxiliary materials	Carboxymethyl starch sodium	9,781.31	10,074.40	/	/
	Auxiliary materials	Magnesium stearate	3,246.21	3,154.56	/	/
	Auxiliary materials	Croscarmellose sodium	1,213.70	929.7	/	/
	Auxiliary materials	Silicon dioxide (solid phase)	540.26	765.76	/	/

Name of company	Category of materials	Name of materials	Amount of materials purchased (kg)	Material usage (kg)	Recycling amount (kg)	Recycling rate (%)
	Auxiliary materials	Talcum powder	525	765.76	/	/
	Packaging materials	Molding material 250	41673.63	40285.13	/	/
	Packaging materials	Benazepril hydrochloride 片 Medicinal aluminum foil	5193.7	5669.6	/	/
	Packaging materials	Medicinal composite film for amoxicillin potassium clavulanate dispersible tablets (0.5g)	4229.08	4407.9	/	/
	Packaging materials	Medicinal composite film for amoxicillin potassium clavulanate dispersible tablets (0.5g)	690.645	801.216	/	/
Shanghai SPH Zhongxi Pharmaceutical Co., Ltd.	Raw material	Hydroxychloroquine Sulfate	63887.76	73802.371	/	/
	Raw material	Hydroxychloroquine sulphate	332.094	320.95	/	/
	Raw material	Diloxetine hydrochloride	2039.94	2824.845	/	/
	Auxiliary materials	Corn starch	37000	34277.581	/	/
	Auxiliary materials	Magnesium stearate	2330	2184.664	/	/
	Auxiliary materials	Talcum powder	10000	10076.856	/	/
	Auxiliary materials	Lactose	11000	16915.22	/	/
	Packaging materials	Hydroxychloroquine Sulfate	50071850 pieces	49845805 pieces	/	/
	Packaging materials	Hydroxychloroquine Sulfate Tablets Medicinal Aluminum Foil (0.1g)	20572	19519.24	/	/
	Packaging materials	Polyester/aluminum/polyethylene medicinal composite film and bag (Aripiprazole tablets) 3774.8	3774.8	5779.6	/	/
	Packaging materials	Aripiprazole tablets small box	2663100 pieces	3045728 pieces	/	/
	Packaging materials	Duloxetine hydrochloride enteric-coated tablets medicinal aluminum foil (20mg)	3390.9	3834.7	/	/
	Packaging materials	Duloxetine hydrochloride enteric-coated tablets small box	5486500 pieces	5189201 pieces	/	/
Techpool Bio-pharma Co., Ltd.	Raw material	Ulinastatin solution	5591.478154	6477.293265	/	/
	Raw material	Urinary Kallidinogenas	113.334	106.038	/	/
	Auxiliary materials	Mannitol injection	1342.5	1047.75	/	/
	Auxiliary materials	Sodium hydroxide	1350	1573.775	/	/
	Auxiliary materials	Acetic acid	2230	2506.76	/	/
	Auxiliary materials	Sodium acetate	1493.5	1410.852	/	/
	Auxiliary materials	Ammonium sulphate	45000	45297.138	/	/

Name of company	Category of materials	Name of materials	Amount of materials purchased (kg)	Material usage (kg)	Recycling amount (kg)	Recycling rate (%)
	Auxiliary materials	Phosphoric acid	200	346.629	/	/
	Auxiliary materials	Sodium hydroxide	1350	1573.775	/	/
	Auxiliary materials	Phosphoric acid	200	346.629	/	/
	Auxiliary materials	Phosphoric acid	200	346.629	/	/
	Auxiliary materials	Acetic acid	2230	2506.76	/	/
	Auxiliary materials	Sodium acetate	1493.5	1410.852	/	/
	Auxiliary materials	Polysorbate 20	300	454.5	/	/
	Auxiliary materials	Mannitol	800	532.228	/	/
	Auxiliary materials	Disodium ethylenediaminetetraacetate	300	409.708	/	/
	Auxiliary materials	95% Ethanol	445.236	445.271	/	/
	Auxiliary materials	Zinc chloride solution	4250	3991.774	/	/
	Packaging materials	Aluminum-plastic combination cover (unit: piece)	6500000	6824200	/	/
	Packaging materials	Aluminum-plastic combination cover (unit: piece)	300000	194399	/	/
	Packaging materials	Aluminum-plastic combination cover (unit: piece)	8200000	6705824	/	/
	Packaging materials	Rubber stopper (unit: piece)	4121600	6758900	/	/
	Packaging materials	Rubber stopper (unit: piece)	8112681	6581432	/	/
	Packaging materials	Control injection bottle (unit: piece)	8473140	6640842	/	/
	Packaging materials	Control injection bottle (unit: piece)	6854003	6707021	/	/
	Packaging materials	Liquid medicinal polypropylene bottle (unit: piece)	0	6903	/	/
	Packaging materials	Carton for Ulinastatin for Injection (unit: piece)	18000	20993	/	/
	Packaging materials	Carton for Ulinastatin for Injection (unit: piece)	687400	632716	/	/
	Packaging materials	Cardboard box for Ulinastatin for Injection (unit: piece)	1800	2261	/	/
	Packaging materials	Cardboard box Ulinastatin for Injection (unit: piece)	59080	62307	/	/
	Packaging materials	Small box for Urinary Kallidinogenas for Injection (unit: piece)	1288829	1390077	/	/
	Packaging materials	Medium box for Urinary Kallidinogenas for Injection (unit: piece)	117593	133593	/	/
	Packaging materials	Cardboard box for Urinary Kallidinogenas for Injection (unit: piece)	12998	13590	/	/
	Packaging materials	Carton for Urinary Kallidinogenas for Injection (unit: piece)	704075	539717	/	/

Name of company	Category of materials	Name of materials	Amount of materials purchased (kg)	Material usage (kg)	Recycling amount (kg)	Recycling rate (%)
Chiatai Qingchunbao Pharmaceutical Co., Ltd.	Raw material	Red ginseng	30000	28800	/	/
	Raw material	Radix Ophiopogonis (from Zhejiang)	30000	28800	/	/
	Raw material	Salvia miltiorrhiza	241000	205200	/	/
	Auxiliary materials	Activated carbon	1500	1360	/	/
	Auxiliary materials	Polysorbate 80	1500	1440	/	/
	Auxiliary materials	Sodium chloride	2000	1928	/	/
	Packaging materials	50ml Infusion bottle (Type B) (piece)	5240000	5760000	/	/
	Packaging materials	10ml Ampoule bottle (piece)	14000000	13680000	/	/
	Packaging materials	Small box for Shenmai injection (50) (piece)	5500000	5760000	/	/
	Packaging materials	Small box for Salvia miltiorrhiza injection (10ml*6) (piece) 2180000	2180000	2280000	/	/
SPH Qingdao Growful Pharmaceutical Co., Ltd.	Raw material	Common Bletilla Tuber	8000	7859	/	/
	Raw material	Cuttlebone Sepium	26832	22433	/	/
	Raw material	Yanhusuo Tuber	36776	48514	/	/
	Raw material	Pilose Asiabell Root	63159	53537	/	/
	Raw material	Chinese goldthread rhizome	41656	31356	/	/
	Raw material	Ginseng	13000	12735	/	/
	Raw material	Ferric chloride	225916	229125	/	/
	Raw material	Syrup	250000	241110	/	/
	Raw material	Sodium hydroxide	150000	138885	/	/
	Auxiliary materials	Coating agent (Kuaiwei Tablets)	2000	1840	/	/
	Auxiliary materials	Starch	5000	6297	/	/
	Auxiliary materials	Opadry 80W	6000	5798	/	/
	Auxiliary materials	Magnesium stearate	2000	1226	/	/
	Auxiliary materials	Talcum powder	2275	2175	/	/
	Auxiliary materials	Ethanol (Polyferose Capsules)	487660	236880	2244720	90.45%
	Packaging materials	Small box (90 pieces of Kuaiwei Tablets) (piece)	1175687	1291605	/	/
	Packaging materials	Medicinal high density polyethylene bottle(pieces)	3067200	3114577	/	/
	Packaging materials	Small box (90 pieces of Yangxinshi Tablets) (piece)	998270	816180	/	/

Name of company	Category of materials	Name of materials	Amount of materials purchased (kg)	Material usage (kg)	Recycling amount (kg)	Recycling rate (%)
	Packaging materials	Medicinal PVC (175 Transparent) (piece)	47833	44288	/	/
	Packaging materials	Medicinal composite film (Yangxinshi Tablets)	18580	17622	/	/
	Packaging materials	Small box (Polyferose Capsules) (piece)	19478055	19085836	/	/
	Packaging materials	Medicinal PVC (180 Orange yellow)	0	0	/	/
	Packaging materials	Medicinal PVC (280 Orange yellow)	35121	38628	/	/
	Packaging materials	Medicinal composite film(up to)	31038	25380	/	/
Liaoning SPH Herbapex Pharmaceutical (Group) Co., Ltd.	Raw material	Figwort Root	80229	80229	/	/
	Raw material	Sanchi	31196	69450	/	/
	Raw material	Safflower	126924	143258	/	/
	Raw material	Rehmannia root	150376	146160	/	/
	Raw material	Asper-like Teasel Root	108052	107947	/	/
	Raw material	Common Swisscentaury Root	51314	46584	/	/
	Raw material	Chinese Angelica	52672	52595	/	/
	Raw material	Milkvetch Root	21445	19424	/	/
	Raw material	Malaytea Scurfpea Fruit	15176	14196	/	/
	Raw material	Indian Buead Tuckahoe	27166	29806	/	/
	Raw material	Common Yam Rhizome	34035	32918	/	/
	Raw material	Prepared Milkvetch Root	63915	57620	/	/
	Auxiliary materials	Sucrose	272000	253942.3	/	/
	Auxiliary materials	Talcum powder	15000	132346.6	/	/
	Auxiliary materials	Coated powder	8593	10162	/	/
	Auxiliary materials	Dextrin	30000	29799.4	/	/
	Auxiliary materials	Blood stasis capsule shells	23140	23412.67	/	/
	Packaging materials	Medicinal PVC	171230	160545	/	/
	Packaging materials	Medicinal aluminum foil	24736.9	25427	/	/
	Packaging materials	Medicinal high density polyethylene bottle(pieces)	7761400	8075690	/	/
	Packaging materials	Composite film	13531.5	15642.7	/	/
	Packaging materials	Small box for Rupixiao Tablet (piece)	9289020	9838058	/	/

Name of company	Category of materials	Name of materials	Amount of materials purchased (kg)	Material usage (kg)	Recycling amount (kg)	Recycling rate (%)
	Packaging materials	Small box for Qiangshen Tablet (piece)	1626190	1498533	/	/
	Packaging materials	Small box for Tongru Granule (piece)	937770	1010590	/	/
	Packaging materials	Small box for Blood Stasis Capsule (piece)	4820450	4661690	/	/
	Packaging materials	Small box for Wangbi Tablet (piece)	10372900	8662686	/	/
Hangzhou Huqingyutang Pharmaceutical Co., Ltd.	Raw material	Red ginseng	110000	100644.68	/	/
	Raw material	Isodon amethystoides	2000000	1920700	/	/
	Raw material	Submature bitter orange	200000	192070	/	/
	Raw material	Loquat leaf	60000	54234	/	/
	Raw material	Stemona root	13000	11790	/	/
	Raw material	Chinese goldthread rhizome	300	180	/	/
	Raw material	Baikal skullcap root	300	180	/	/
	Auxiliary materials	Starch	30000	27849	/	/
	Auxiliary materials	Magnesium stearate	1300	1237	/	/
	Auxiliary materials	Sucrose	430050	471600	/	/
	Auxiliary materials	Citrate	750	393	/	/
	Auxiliary materials	Refining honey	2000	1862	/	/
	Packaging materials	Small box (piece)	12500000	12103900	/	/
	Packaging materials	Medicinal high density polyethylene bottle(pieces)	2500000	2402400	/	/
	Packaging materials	Medicinal polyester bottle (piece)	6000000	5490000	/	/
Shanghai Zhonghua Pharmaceutical Co., Ltd.	Raw material	Menthol	28000	27638.84	/	/
	Raw material	Camphor (synthetic)	20470	22931.94	/	/
	Raw material	Peppermint oil	10800	13523.41	/	/
	Raw material	Camphorated	6125	2842.76	/	/
	Raw material	Eucalyptus	16200	13943.4	/	/
	Auxiliary materials	Yellow Vaseline	19840	18962.74	/	/
	Auxiliary materials	White Vaseline	18720	17526.75	/	/
	Auxiliary materials	Eugenol	300	312.74	/	/
	Auxiliary materials	Methyl salicylate	1000	2718.48	/	/

Name of company	Category of materials	Name of materials	Amount of materials purchased (kg)	Material usage (kg)	Recycling amount (kg)	Recycling rate (%)
	Packaging material	3 g OTC cooling oil tin box	24116400 (pieces)	22150714 (pieces)	/	/
	Packaging material	3 g cool oil plastic tape	1508 (roll)	1610.46 (roll)	/	/
	Packaging material	3 g plastic bag cooling oil medium box	195350 (pieces)	219456 (pieces)	/	/
	Packaging material	3 grams plastic bag of cooling oil cardboard box	7442 (pieces)	7336 (pieces)	/	/
	Packaging material	10 g OTC cooling oil (white) tin box	1466250 (pieces)	1465561 (pieces)	/	/
	Packaging material	10 g domestically sold cooling oil (white) small box	687600 (pieces)	1464182 (pieces)	/	/
	Packaging material	10 g domestically sold cooling oil (white) cardboard box	2010 (pieces)	3043 (pieces)	/	/
	Packaging material	6ml essential balm small box 2018	768000 (pieces)	848417 (pieces)	/	/
	Packaging material	6ml essential balm cylindrical glass bottle	755334 (pieces)	856134 (pieces)	/	/
	Packaging material	Essential balm bottle cap 2018	2224000 (pieces)	2320753 (pieces)	/	/
	Packaging material	6ml ball essential balm cardboard box	2802 (pieces)	1761 (pieces)	/	/
Xiamen TCM Factory Co., Ltd.	Raw material	Sanchi	38452	30576.8	/	/
	Raw material	Arti_cial Bezoar	3128.5	4094.8	/	/
	Raw material	Artificial Forest Musk Abelmosk	154	188.99	/	/
	Auxiliary materials	Corn starch	11900	11488.44	/	/
	Auxiliary materials	Magnesium stearate	3050	3862	/	/
	Packaging materials	Medicinal aluminium foil for Xin Huang Tablet (234mm)	7995.5	7928.5	/	/
	Packaging materials	Composite film for Xin Huang Tablet [145*150mm (36 pieces)]	6778.7	8749.15	/	/
	Packaging materials	Medicinal aluminium foil for Pill of Eight Treasures capsules (170mm)	3067.8	2310.9	/	/
SPH Dong Ying (Jiangsu) Pharmaceutical Co., Ltd.	Raw material	Cisatracurium Besilate	50.0015	51.01986	/	/
	Raw material	Perindopril tert-butylamine	42.429	73.2932	/	/
	Auxiliary materials	Mannitol	500	569.27486	/	/
	Auxiliary materials	Medicinal charcoal	10	10.31059	/	/
	Auxiliary materials	Lactose	675	531.35096	/	/
	Auxiliary materials	Magnesium stearate	75	42.037816	/	/
	Packaging materials	Freeze-dried sterile powder for injection with chlorinated butyl rubber plug	7,209,400 pieces	5,944,469 pieces	/	/

Name of company	Category of materials	Name of materials	Amount of materials purchased (kg)	Material usage (kg)	Recycling amount (kg)	Recycling rate (%)
	Packaging materials	Aluminium composite cover for antibiotic bottle	5,549,820 pieces	5,996,307 pieces	/	/
	Packaging materials	Polyvinyl chloride solid medicinal PVC sheet	5953	6391.66778	/	/
	Packaging materials	Perindopril tert-butylamine tablets	1064	1452.89948	/	/
SPH Changzhou Kony Pharmaceutical Co., Ltd.	Raw material	Acyclovir crude	8,175.00	12,487.00	/	/
	Raw material	N-benzyloxycarbonyl-L-valine	30,017.80	33,520.00	/	/
	Raw material	Dicyclohexylcarbodiimide	34,000.00	28,225.00	/	/
	Raw material	N, N-dimethylformamide N	209,210.00	313200	269665	86.1
	Raw material	Methanol	1,434,680.00	445440	223542	50.2
	Packaging materials	Medicinal low tensity polyethylene bags	18,240.00	18,500.00	/	/
	Packaging materials	40*50 cardboard barrel	3,958.00	4,088.00	/	/

VII | Significant benefits brought by normalized green offices

Video conference

From January to December of 2020, the Company held 382 video conferences in total. The total duration of the video conferences was 776 hours and the average duration of the video conferences was 2.03 hours. Supposing that an average traveling expense of RMB0.003 million/ time is provided for eight attendees outside Shanghai, the Company saved travel costs of more than RMB9.16 million in one year.

Collaborative office management OA

Up to now, the Company's OA has over 40,000 users, initiated over 5.59 million processes, and uploaded more than 4.78 million files. If each file has 10 pages on average and each electronic file is printed twice for distribution, it is equivalent to cumulative savings of more than 95 million pieces of paper.

Our Responsibilities Commitment (2020)

OUR RESPONSIBILITIES COMMITMENT (2020)

Let people take medicine of high quality and make the medicine affordable

Shanghai Pharmaceuticals is patient-oriented, adheres to innovation, efficacy, safety and compliance, closely integrates medical development and clinical needs, and is open to cooperation and works together with partners. We continue to seek new ways and methods for the diagnosis and treatment of major diseases and chronic diseases, provide safe and effective branded therapeutic drugs, continue to increase investment in R&D, pave the way for innovative development in the pharmaceutical industry, and accelerate the development of major innovative drugs, gene therapy and cell therapy products, and micro-ecological products. We will continue to strive for excellence and continuously improve the energy level of production technology and equipment, production management and quality management with world leading standards to ensure the quality and safety of drugs.

Let people take medicine with ease

Shanghai Pharmaceuticals has basically established the nation's third drug and medical device distribution service platform and innovation platform, and has a modern drug distribution system that covers 31 provinces and cities in China and has a high level of intensification and informatization. In the future, through (1) the innovative drug distribution approach, we will continue to provide services for the reform of medical institutions, and simplify the process of drug purchase by patients and improve service experience by means of leading supply chain management, information technology, and logistics technology. (2) upgrading global resource allocation, we will build a new structure of integrated services with large channels, expand international perspectives, and enhance the overall capabilities of one-stop service, integrated cooperation, and seamless management through cooperation in technology and services, and continue to introduce the world's most valuable innovative therapeutic drugs with optimal efficiency through the establishment of an internationally competitive import variety operating platform; (3) accelerating the development of new online and offiine retail models, and building a "backtracking cloud" service platform, focusing on the data of the whole process of production, distribution and use, we establish an electronic traceability and regulatory public platform covering drugs, equipment and other goods covering multiple regions to ensure the safe use of drugs of patients, striving to build a modern healthcare service provider driven by services and technology.

Ensure that special needs of special groups are met

Shanghai Pharmaceuticals, as the group- based industrial company with the most abundant pharmaceutical approvals in China, will continue to ensure the normal supply of low-cost drugs in shortage, and continue to bring good news to special groups and patients with rare diseases.

Care for the community and help build a healthy China

Shanghai Pharmaceuticals actively responded to the Party Central Committee's call for the entire party and society to participate in poverty alleviation. Subsidiaries have engaged in targeted poverty alleviation activities such as "A Hundred Enterprises Help A Hundred Villages" and "Ten Thousand Enterprises Help Ten Thousand Villages", achieving village-enterprise paired assistance in Yunnan and Hebei through financial support, materials donations, improvement of infrastructure construction in the village, provision of information assistance and technical training for project management and industrial development, and education funding. Relying on its own industrial resources, Shanghai Pharmaceuticals promoted industrial poverty alleviation. It promoted the development of the traditional Chinese medicine industry in poverty-stricken areas such as Yunnan and Hunan through the construction of traditional Chinese medicinal materials planting bases and the purchase of medicinal materials, and helped more poor households to escape poverty.

Sound governance and operations ensure the interests of investors

Shanghai Pharmaceuticals is an A+H listed company. It also takes into account the requirements of laws and regulations in mainland China and Hong Kong and maintains sound governance and operations. The management of the Company performs its duties diligently and takes the initiative to create more values for shareholders.

Respect the value of employees and create opportunities and platforms for employee development

Shanghai Pharmaceuticals constantly integrates internal and external recruitment channels and resources, enhances market allocation, and attracts various types of talents; pays high attention to the growth and development of employees, and provides employees with systematic learning development paths and training courses to empower employees; adheres to the concept of remuneration based on position, ability, performance and market, improves employee remuneration system, performance assessment system and benefit system, so that employees can share the development results.

This report is printed on recycled paper

Your comments and suggestion on this report will be appreciated

Century-Old Shanghai Pharma
Trustworthy Medicine We Provide

T: 021-63730908
Shanghai headquarters:
200 Taicang Road, Huangpu District, Shanghai, China

T : 852. 31515901
Hong Kong headquarters:
26F Henley Building, 5 Queen's Road, Central,Hong Kong

www.sphchina.com

Official Wechat

Official Weibo